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Abstract 
Aims and Background: The current research aims to explore the role of 
epigenetic processes in mediating the action of adverse antenatal exposures and 
sex in the development of psychotic symptoms at ages 12 and 18 years. This 
thesis consists of several background and review chapters followed by three 
empirical Studies and a discussion of each. Using prospective data from the Avon 
Longitudinal Study of Parents and Children (ALSPAC) and linked DNA 
methylation (DNAm) data from the Accessible Resource for Integrated 
Epigenomics Studies (ARIES), the thesis will initially explore the role of global 
DNA methylation, measured in umbilical cord blood, in the development of 
psychotic symptoms at age 18 years. It will then explore differences in global 
DNAm between participants with and without psychotic symptoms across specific 
CpG site regions (islands, north shores, north shelves, south shores and south 
shelves).  Next, the thesis will investigate the role of epigenome-wide DNAm as a 
predictor of psychotic symptoms at ages 12 and 18 years. Finally, an analysis will 
be made of the role of epigenome-wide DNAm as a mediator of the relationship 
between both sex and exposure to influenza and diabetes/glycosuria in utero and 
psychotic symptoms at ages 12 and 18 years.  
 
Methods: The current thesis uses longitudinal data from 831 (393 males and 438 
females) and 735 (329 males and 406 females) child participants who took part in 
the Psychotic-Like Symptom Interview (PLIKSi) at ages 12 and 18 years 
respectively, and who also had available cord blood DNAm data from the ARIES 
subsample. All participants were medication-naïve at the time of data collection. 
xxiii 
 
 
 
Information regarding participants’ exposure to maternal influenza and diabetes 
and/or glycosuria (i.e., the presence of abnormal amounts of glucose in the urine) 
in utero was obtained from self-report postal questionnaires that were completed 
by mothers at various time-points during pregnancy and from their antenatal 
medical records. Epigenetic data from ARIES were derived from umbilical cord 
blood, taken at birth, using the HM450 arrayarray. For Study 1, binary logistic 
regression was used to investigate the role of global DNA methylation in 
psychotic symptoms at age 18 years and differences in global DNAm between 
participants with and without psychotic symptoms across specific CpG site 
regions. Study 2 employed the R function CpGassoc to explore differential 
methylation at an epigenome level in the umbilical cord blood of participants with 
psychotic symptoms at ages 12 and 18 years. Finally, for Study 3, an SPSS 
function for path-based mediation analysis called PROCESS was used to explore 
the role of epigenome-wide DNA methylation as a potential mediator of the 
relationship between psychotic symptoms at ages 12 and 18 years and both sex 
and exposure to influenza and diabetes/glycosuria in utero. 
 
Results: Overall, the results show that higher global DNAm at birth strongly 
predicts psychotic symptoms at age 18 years. Moreover, the likelihood of 
psychotic symptoms at this time-point is even greater for female participants with 
higher global DNAm at birth than for female participants with lower global 
DNAm. Additionally, participants with psychotic symptoms at both ages 12 and 
18 years showed differential methylation of individual CpG sites, linked to genes 
RAS-like, estrogen-regulated, growth inhibitor (RERG), Cytochrome c oxidase 
subunit VIb polypeptide 2 (COX6B2), Crystallin, beta A2 (CRYBA2), Zinc 
xxiv 
 
 
 
finger, NFX1-type containing 1 (ZNFX1), ATPase, H+ transporting, lysosomal 
56/58kDa, V1 subunit B1 (ATP6VIB1), Transmembrane protein 163 
(TMEM163), WD repeat domain 16 (WDR16) and Syntaxin 8 (STX8). Finally, 
the results of a series of mediation models suggest that the results of a series of 
mediation models suggest that DNA methylation of specific CpG sites may 
mediate the relationship between sex and prenatal exposures of maternal influenza 
and diabetes/glycosuria during pregnancy and psychotic symptoms at ages 12 and 
18 years. 
Conclusions: These findings are broadly consistent with the neurodevelopmental 
model of psychotic symptoms and schizophrenia. More specifically, they indicate 
that prenatal exposures during gestation to influenza and diabetes/glycosuria may 
predispose an individual to the later development of psychotic symptoms via a 
pathway which alters the expression of specific genes such as STX8 and WDR16 
which are involved in early brain development. Furthermore, if the identified 
epigenetic marks in umbilical cord blood identified in Studies 2 and 3 are found to 
be valid and reliable biomarkers of disease-associated abnormalities occurring in 
the cortical tissue of participants at high risk of schizophrenia, they may prove 
invaluable in the development of new clinical interventions aimed at early 
identification and psychotropic treatment of the disorder. 
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Chapter 1 
 
Nature of Schizophrenia and Psychotic Symptoms 
This chapter will first provide an overview of schizophrenia, including a brief 
description of its core clinical symptoms and current diagnostic criteria according 
to the Diagnostic Statistical Manual of Mental Disorders, 5th Edition (DSM-5). 
Next, the chapter will summarise empirical findings describing its clinical 
presentation, onset and course. While schizophrenia refers to a specific disorder 
and diagnosis, the notion that psychotic symptoms are better described as existing 
on a continuum will be discussed. Finally, studies examining the continuum 
hypothesis of psychotic symptoms will be presented.  
1.1 Nature of Schizophrenia and Psychotic Disorders 
1.1.1 Clinical signs and symptoms. 
Schizophrenia is a chronic and disabling mental disorder that affects 
approximately 1% of the general population (Jablensky, Kirkbridge, and Jones, 
2011). It presents clinically in a variety of ways. Clinical features are routinely 
grouped into three broad categories: positive symptoms (e.g., hallucinations, 
delusions and paranoia), negative symptoms (e.g., dysphoric mood, anhedonia and 
avolition) and cognitive impairment (e.g., inattention and poor executive 
functioning and working memory). Unlike symptoms in the first two domains 
which have the propensity to fluctuate and be episodic in nature, cognitive deficits 
generally occur prior to the prodromal phase and persist throughout the course of 
the illness, despite treatment (Tandon, Nasrallah, & Keshavan, 2009). Current 
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estimates indicate that cognitive impairment is central to schizophrenia in at least 
70% of affected individuals and is more closely associated with their long-term 
prognosis in terms of social and occupational outcomes than is impairment 
associated with positive psychotic symptomatology (Green, Kern, Braff, & Mintz, 
2000; Van Hooren et al., 2008; Van Winkel et al., 2007). 
1.1.2 DSM-5 criteria and diagnosis. 
In DSM-5, schizophrenia belongs to the family of schizophrenia spectrum 
and other psychotic conditions which comprises a number of psychiatric disorders 
that are all defined by the presence of one or more of the following five domains: 
(1) hallucinations; (2) delusions; (3) disorganised speech or thought; (4) 
disorganised or abnormal motor behaviour, and (5) negative symptoms. Along 
with schizophrenia, these other psychotic disorders include brief psychotic 
disorder, schizophreniform disorder, schizoaffective disorder and delusional 
disorder. DSM-5 distinguishes among the various types of psychosis according to 
the nature of the psychotic symptoms, the course of the illness, the functional 
impact of the illness and the presence of any mood disturbance during the 
psychotic episode. To receive a diagnosis of schizophrenia, at least two of the 
following five characteristic symptoms must be present: delusions, hallucinations, 
disorganised speech (e.g., frequent derailment or incoherence), grossly 
disorganised or catatonic behaviour, and negative symptoms (e.g., dysphoric 
mood, anhedonia or avolition). These symptoms need to have been present for a 
significant portion of time during a one-month period, or less if successfully 
treated, and must persist for a minimum of six months. Moreover, at least one of 
these two requisite clinical features must be delusions, hallucinations or 
disorganised speech. Finally, symptoms must result in marked impairment to the 
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person’s educational, occupational and/or social functioning. For brief psychotic 
disorder, at least one psychotic symptom (e.g., hallucinations, delusions or 
disorganised speech) must be present for less than one month. Similarly, 
schizophreniform disorder is defined by the presence of the symptoms of 
schizophrenia for between one and six months. In contrast, schizoaffective 
disorder requires the occurrence of schizophrenia symptoms for at least one 
month, accompanied by prominent mood symptoms of either mania or depression. 
For delusional disorder, patients present with delusions in the absence of other 
schizophrenia symptoms. Finally, to meet the diagnostic criteria for any psychotic 
disorder, an individual’s symptoms must not be attributable to the effects of a 
general medical condition or due to substance/medication intoxication or 
withdrawal.  
 Due to the considerable overlap in core symptoms across psychotic 
conditions, DSM-5 adopts a continuum approach to its conceptualisation of 
schizophrenia spectrum disorders. People are diagnosed on the spectrum 
according to the number and severity of their deficits, ranging from a few 
psychotic symptoms of short duration (in brief psychotic disorder) to more 
enduring breaks from reality (in schizophrenia). The current research will focus 
predominantly on psychotic symptoms as a marker for the later development of 
schizophrenia. 
1.1.3 Heterogeneity of schizophrenia.  
The DSM-5 diagnostic criteria for schizophrenia employs a classificatory 
system where each disorder is a categorical entity, suggesting that a psychological 
disorder represents a definable shift from psychological health to a state of illness. 
Though useful in clinical practice in facilitating communication between 
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practitioners and serving as a basis for treatment planning (American Psychiatric 
Association, 2013; Kraemer, Noda, & O’Hara, 2004), many researchers argue that 
conceptualising schizophrenia as a categorical phenomenon fails to adequately 
capture the considerable heterogeneity associated with all aspects of the disorder, 
including its clinical expression, aetiology and pathophysiology (Craddock & 
Owen, 2010; Keshavan, Nasrallah, & Tandon, 2011). Attesting to the diverse 
nature of the disorder are wide variations in a number of characteristics of the 
illness, including the age of onset, rate of onset, early morbid or pre-morbid 
functioning, nature and duration of the prodromal period, symptomatology, 
interepisode residual disturbance (e.g., episodic or unremitting impairment), long-
term prognosis and treatment response (Tandon et al., 2009). For example, despite 
disorder onset typically occurring between the ages of 15 and 45 (American 
Psychiatric Association, 2000), individuals who meet the diagnostic criteria for 
the disorder during adolescence (i.e., < 20 years) have been found to manifest 
poorer premorbid functioning in terms of neurocognitive and social performance 
and to exhibit more severe negative and disorganised symptoms than their later-
onset counterparts (Häfner & an der Heiden, 1999; Luoma, Hakko, Ollinen, 
Järvelin, & Lindeman, 2008). Additionally, a recent meta-analysis investigated 
empirical data from 30 studies (involving 25,684 males and 16,802 females) 
examining sex differences in age at onset of schizophrenia and found that males 
tended to experience initial signs of the illness 1.49 years earlier than females and 
were on average hospitalised for a first episode of schizophrenia 1.37 years earlier 
than their female counterparts (Eranti, MacCabe, Bundy, & Murray, 2013).  
Considerable heterogeneity has also been observed in the development of 
schizophrenia. For example, Watt and colleagues (1983) followed 121 affected 
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individuals (61 males and 60 females) over a five-year period and found 
differences in the course of the disorder. These included 16% of participants 
experiencing one episode followed by full remission from the illness, 32% 
experiencing several episodes followed by full remission from the illness or only 
mild residual symptoms, 9% manifesting residual symptoms following their initial 
psychotic episode and 43% showing increasing negative symptoms following 
each of their multiple episodes. Finally, marked variation has also been observed 
in both the symptom profiles of affected individuals (Strauss et al., 2013; Tsuang, 
Stone, & Faraone, 2001) and the aetiological factors implicated in the 
manifestation of the illness (Tandon et al., 2009, Tsang & Faraone, 1995).  
Given the substantial heterogeneity associated with all aspects of the 
illness, many researchers have suggested that schizophrenia should be re-
conceptualised as existing on a continuum with normal experience and behaviour 
(Johns & van Os, 2001; Keshavan et al., 2011; Nelson, Seal, Pantelis, & Phillips, 
2013 Tandon et al., 2009; van Os, Linscott, Myin-Germeys, Delespaul, & 
Krabbendam, 2009).  
1.2 Dimensional Approach to Schizophrenia 
The notion that schizophrenia exists on a continuum, often referred to as 
the dimensional approach, is considered by its proponents to have a number of 
advantages over the current categorical diagnostic system (e.g., in the DSM-5) in 
its capacity to more reliably and validly describe the disorder. Unlike the DSM-5, 
the dimensional approach states that schizophrenia represents an endpoint on a 
continuum with psychological health at the other end. Psychotic experiences and 
psychotic symptoms are more common and located at a midway point on the 
continuum between these two extremes. Psychotic experiences are defined in the 
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literature as strange, unusual or out-of-the-ordinary occurrences which may 
include auditory and visual hallucinations and/or delusions. As depicted in Figure 
1, psychotic experiences differ from psychotic symptoms in that they tend to be 
transitory in nature and to not cause people untoward distress (Hanseen, Bak, 
Vollebergh, & van Os, 2005; Linscott and van Os, 2013; van Os et al., 2009).  
 
Phenotypic level Behavioural expression Time frame perspective 
Psychotic experiences Subtle flucutuating alterations 
in cerebral representations of 
environment in daily life 
 
 
 
 
 
 
Momentary and fluctuating 
feelings of paranoia, negative 
affect etc in daily life 
Psychotic symptoms Noticeable expression of 
reality distortion 
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dysregulation, 
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Need for care 
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Figure 1. Distinctions between psychotic experiences, psychotic symptoms and 
psychotic disorders in terms of their behavioural expression and persistance over 
time. 
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1.2.1 Prevalence of psychotic experiences in non-clinical populations. 
The dimensional approach to schizophrenia is supported by research 
which examines the prevalence of positive psychotic symptoms (e.g., 
hallucinations, delusions, thought disorder) within non-clinical populations. Such 
studies have found that positive symptoms observed in individuals with psychotic 
disorders were also observed and measured in those without psychotic disorders. 
For example, Barrett and Etheridge (1992) tested 585 healthy university students 
(198 males and 387 females) using the basic verbal hallucination questionnaire 
(see Posey & Losch, 1983, for full details) and found that 30-40% of participants 
had experienced auditory hallucinations. Additionally, approximately 50% of 
participants who reported verbal hallucinations indicated that these experiences 
occurred at least once a month. However, it should be noted that questionnaires 
may have a limited capacity to clinically investigate whether these reported 
experiences are psychotic in a clinical sense. 
Using formal diagnostic measures, including the Diagnostic Interview 
Schedule for Schizophrenia, Eaton, Romanoski, Anthony, & Nestadt (1991) 
explored the presence of thought disturbance in 810 healthy individuals from 
Eastern Baltimore. The researchers found that around 2% of participants had 
experienced delusions of a bizarre or odd nature, while delusions of paranoia and 
grandeur occurred in 4% and 8% of the population, respectively.  
In a more recent and larger-scale study, Nuevo et al. (2010) investigated 
the prevalence of individual psychotic phenomena in 256,445 participants 
(102,578 males and 153,867 females), selected from nationally representative 
samples of 52 countries which were taking part in the World Health 
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Organisation’s World Healthy Survey. Overall prevalence rates were reported for 
the following specific psychotic experiences: 7.80% for delusional mood, 8.37% 
for delusions of reference and persecution, 4.80% for delusions of control, and 
5.81% for hallucinations. The prevalence rate for specific psychotic experiences 
varied widely across countries, with .8% of Vietnamese participants reporting 
auditory hallucinations compared to 31.4% of Nepalese participants, which 
suggests that either cultural norms play a role in the reporting of such experiences 
or that there are major differences in the occurrence of these experiences.  
Linscott and van Os (2013) conducted a systematic review and meta-
analysis of 95 articles, with publication dates from 1950 to 2010, which had 
explored prevalence and incidence rates of psychotic experiences within general 
populations. To reduce the risk of overestimation of psychotic experiences (a 
criticism of a previous review by van Os et al., 2009), Linscott and van Os (2013) 
only included articles that measured psychotic phenomena using diagnostic or 
screening tools administered in an interview format or items from psychometric 
measures which referred to specific, personally relevant psychotic events that 
were unlikely to be socially or culturally based or to be associated with more 
realistic interpretations. Based on 61 studies, reviewing 56 participant cohorts, the 
overall estimated median prevalence of psychotic experiences was 7.20%, which 
is significantly higher than the comparable prevalence of diagnosed schizophrenia 
which is .87% (Perälä et al., 2007). 
 
Complementing empirical outcomes on the occurrence of individual 
psychotic phenomena in non-psychotic individuals and providing further support 
for the dimensional approach to schizophrenia is research on schizotypy. 
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Schizotypy refers to a cluster of personality traits which include psychotic 
symptoms, odd or bizarre behaviour, speech anomalies and social anhedonia 
(Kwapil et al., 2014; Meehl, 1962). Findings from factor-analytical studies 
indicate that schizotypy is a multidimensional construct comprising three factors 
(perceptual, interpersonal and disorganised), which largely correspond to the 
positive, negative and disorganised dimensions (i.e., cognitive deficits) of 
schizophrenia (Fonesca-Pedero, Paino, Lemos-Giraldez, Sierra-Biagrie, & Muniz, 
2011; Vollema & van den Bosch, 1995; Wuthrich & Bates, 2006). Further, 
empirical data from neuropsychological and environmental research indicate that, 
as with schizophrenia, schizotypy personality traits in psychologically healthy 
individuals exist on a continuum, ranging from few traits and minimal impairment 
to multiple traits and impairment in the form of psychosis and disorganised speech 
and behaviour (Gooding, Matts, & Rollmann, 2006; Linscott, Marie, Arnott, & 
Clarke, 2006; Lovatt et al., 2010; Schmidt-Hansen & Honey, 2009; Zammit et al., 
2009).  
1.2.2 Prospective studies of psychotic experiences  
Further support for the dimensional approach to schizophrenia can be 
gleaned from the prospective outcome studies which have explored psychotic 
experiences over time. In a landmark study in the field, Poulton et al. (2000) 
analysed data from a prospective birth-cohort study (Dunedin Multidisciplinary 
Health and Development Study) comprising 761 children who were assessed for 
the presence of psychotic symptoms at 11 and 26 years using the Diagnostic 
Interview Schedule for Children for DSM-III and the Diagnostic Interview 
Schedule for DSM-IV, respectively. The authors found that psychotic experiences 
at age 11 strongly predicted a high risk of developing a schizophreniform disorder 
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at age 26 (OR = 16.4; [95% CI = 3.9, 67.8]). Importantly, psychotic experiences at 
age 11 did not predict affective conditions of mania or depression at age 26, 
suggesting that subclinical psychotic experiences confer a specific risk for the 
later development of psychotic disorders like schizophrenia rather than a 
generalised risk for affective and non-affective conditions.  
 Similar findings were described by Hanssen et al. (2005) who 
prospectively followed 7076 Dutch participants enrolled in The Netherlands 
Mental Health Survey and Incidence Study and aged between 18 and 64 years. 
The aim of the study was to explore the incidence, stability and outcome of 
subclinical psychotic experiences in a non-clinical population. The presence of 
psychotic experiences was assessed at three time-points, namely 1996 (baseline), 
1997 (T1) and 1999 (T2), using the composite international diagnostic interview 
version 1.1 (Smeets & Dingemans, 1993). Data from 4,042 participants who had 
valid interview data across all three time-points and who did not have an affective 
or non-affective psychotic disorder at baseline and T1, were included in the final 
analysis. Of these, 79 participants reported psychotic experiences at T1, reflecting 
an incidence rate of 2% over a 12-month period, which is higher than the 
incidence rate of schizophrenia in the general population (.02%; McGrath et al., 
2004). At T2, a total of 25 individuals were evaluated as presenting with 
subclinical psychotic symptoms and 11 with symptoms that met the DSM-III-R 
criteria for a non-affective psychotic disorder. Hanssen et al. (2005) observed 
some continuity in subclinical experience from T1 to T2, with those who reported 
a psychotic incident at time-point one 18.6 times (95% CI 7.20, 48.0) more likely 
to present with a comparable subclinical outcome at T2 than were those without 
psychotic experiences. In terms of relative risk, participants with an incident 
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psychotic experiences at T1 were 65 times (95% CI 19.4, 218.1) more likely to 
present with a clinical psychotic disorder two years later than were those without 
subclinical experiences at this time-point. Other predictors of a clinical psychotic 
diagnosis at T2 included a familial history of hallucinations and/or delusions as 
reported by the participant (OR = 5.3, 95% CI 2.0, 14.6), the use of mental health 
services by the participant at some point across their life span (OR = 5.2, 95% CI 
2.3, 11.8), and an interviewer CIDI rating of observed emotional blunting (OR = 
31.1, 95% CI 6.6, 145.5). Demographic factors associated with a clinical outcome 
at this time-point were participant unemployment (OR = 5.6, 95% CI 2.2, 14.2) 
and being single or divorced (OR = 3.0, 95% CI 1.3, 6.6; Hanseen et al., 2005).  
 A recent systematic review (Fusar-Poli et al., 2013) analysed data from 23 
studies comprising participants at clinical high risk for psychosis (HRP) and 
published between 2001 and 2011. Participants were considered at HRP if they 
presented with one of following: Attenuated Psychotic Symptoms (APS), full-
blown psychotic symptoms that were brief and self-limiting (Brief Limited 
Intermittent Psychotic Episode), a significant decrease in functioning in the 
context of a genetic risk for schizophrenia (Genetic Risk and Deterioration 
Syndrome) or basic psychotic symptoms (e.g., hallucinations, delusions). Fusar-
Poli et al. (2013) analysed data on 2182 HRP participants aged between 15 and 29 
years and found that of these, 560 (26%, 95% CI 23%, 36%) developed an acute 
psychotic episode over an average duration of 2.35 years. In terms of transition 
risks to specific DSM-IV psychotic disorders, the authors observed a transition 
risk of 15.7% to schizophrenia. Further, Fusar-Poli and colleagues (2013) found 
that HRP participants who later transitioned to psychosis, were 5.43 times (95% 
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CI 3.35, 8.83) more likely to develop a schizophrenia psychosis (73%) than an 
affective psychosis (11%). 
Finally, Polanczyk et al. (2010) explored psychotic symptoms and their 
risk factors in a nationally representative birth cohort of 2232 12-year-old twins, 
prospectively followed from the age of five years as part of the Environmental 
Risk (ERisk) Longitudinal Twin Study. The prevalence of psychotic symptoms at 
age 12-years was 5.9% which is comparable to the reported prevalence of 
childhood psychotic symptoms in a number of other studies using community 
samples of adolescents between ages 11 and 17 years (Dhossche et al., 2002; 
Scott et al., 2009) and suggests that the continuum model of psychosis may apply 
to children as well as to adults. Moreover, Polanczyk et al. (2010) found that, as 
with adult schizophrenia, childhood psychotic symptoms were familial and 
heritable, associated with early impairments in cognitive functioning, and linked 
to premorbid behavioural, emotional, and educational problems.    
Conclusions: 
In summary, research on psychotic experiences and schizotypy in non-clinical 
populations provides compelling evidence in favour of the dimensional approach 
to schizophrenia. Additionally, it suggests that the aetiological factors 
contributing to the development of these phenotypes (genetic, biological, 
neuroanatomical, neuropsychological and environmental factors) may also exist 
on a continuum. This, in turn, underscores the potential value of using psychotic 
experiences to investigate the aetiology of schizophrenia. One of the clear 
advantages of investigating psychotic symptoms in cohorts from the general 
population is that there are not the same confounding influences of anti-psychotic 
medication or disease-associated effects. Additionally, psychotic symptoms are 
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more prevalent in the general population than schizophrenia and, therefore, 
provide a sufficient number of diseased participants in order to conduct a range of 
statistical analyses.  
This chapter has described the construct of schizophrenia in terms of its 
core clinical characteristics, diagnostic criteria and clinical heterogeneity as it has 
been observed in all aspects of the illness. It has also reviewed empirical data in 
support of the notion that schizophrenia is not a discrete, categorical entity but 
rather exists on a continuum with psychological health and wellbeing.  
The next chapter will introduce various aetiological perspectives of 
schizophrenia, including the neurodevelopmental and epigenetic models, and will 
report research findings relevant to these aetiological standpoints. In addition, the 
nature of epigenetic research will be discussed, along with the potential 
contributions that epigenetic epidemiology may make to the current understanding 
of the causes of and treatment for this debilitating disorder.  
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Chapter 2 
 
The Aetiology of Schizophrenia 
 
This chapter will explore various theoretical perspectives regarding the aetiology 
of schizophrenia, with an emphasis on the neurodevelopmental and epigenetic 
models which underpin the current research. Previous empirical studies 
undertaken on each theory of psychotic disorders will also be examined. Recent 
advances in the broader field of genetics which provide important accounts of the 
processes controlling gene expression have now reached a point of wider 
application to many health conditions. This chapter will, therefore, discuss an 
emerging field of research known as epigenetic epidemiology as it bears upon 
older neurodevelopmental models of the pathway to psychotic disorder. This 
approach is central to the current research and may lead to a better understanding 
of the interaction of putative genetic and environmental risk factors in the 
development of psychotic disorders. 
2.1 Heritability of Schizophrenia: Genetic Model 
 2.1.1 Family studies. 
Family studies provide robust evidence for the presence of a strong genetic 
component to the aetiology of schizophrenia. For example, the risk of developing 
the disorder for children and siblings of an affected family member is 9 and 13 
times greater than the risk of schizophrenia in the general population (Kendler & 
Diehl, 1993; McGue, & Gottesman, 1991). The risk for children increases to 46% 
when both parents express the illness (Faraone, Taylor, & Tsuang, 2002). 
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Furthermore, the chance of manifesting the disorder increases the more closely 
related a family member is to the affected proband (Owen, Williams, & 
O’Donovan, 2004). Twin studies (Cardno & Gottesman, 2000; Gottesman, 1991; 
McGuffin, Asherson, Owen, & Farmer, 1994; Tsuang, 2000) show that 
concordance rates for schizophrenia are higher for monozygotic twins (MZ; 
between 41 and 65%) than they are for dizygotic twins (DZ; approximately 15%). 
And finally, a meta-analytic review of 12 published twin studies (Sullivan, 
Kendler, & Neale, 2003) found the point estimate of heritability in liability to 
schizophrenia to be 81% (95% CI 73%, 90%).  
 2.1.2 Genome-wide association studies. 
In light of empirical findings from family and twin studies, which suggest 
that much of the risk of schizophrenia is genetically inherited, a considerable 
amount of research has been directed toward identifying potential disease-
associated genes. For example, numerous genome-wide linkage studies have been 
conducted with the aim of exploring potential relationships between various copy 
number variants (CNVs) and schizophrenia. CNVs refer to structural changes in 
the DNA sequence of a genome which result in certain genes having an abnormal 
number of copies of one or more sections of the deoxyribonucleic acid (DNA; 
Millan, 2013). Typically, the term CNV is used to describe DNA changes 
covering several hundred or more base pairs and these changes include insertions, 
deletions and repeated sequences. In order to follow convention, single nucleotide 
polymorphisms (SNPs) which involve alteration to only one base pair will be 
discussed separately from research findings on CNVs.  
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Studies on CNVs in schizophrenia have revealed several rare copy variants 
of strong effect, with relative risk values ranging between four and 20 (e.g., 
Sullivan, Daly & O’Donovan, 2012). Levinson et al. (2011), for example, 
conducted a comprehensive meta-analytic review of 15 studies on schizophrenia-
associated CNVs, along with new data derived from their genome-wide analysis 
of 3,945 participants with schizophrenia/schizoaffective disorder and 3,611 
healthy controls, all of whom were enrolled in the Molecular Genetics of 
Schizophrenia Study. The authors reported evidence for strong associations 
between deletions in chromosomes 1q21.1 (OR = 9.5, 95% C.I. = 3.0 – 33.4), 
15q13.3 (OR = 12.1, 95% C.I. = 3.8 – 42.0) and 22q11.21 (OR = 20.3, 95% C.I. = 
15.6 – ∞) and duplications in chromosome 16p11.2 (OR = 9.5, 95% C.I. = 3.6 – 
28.4) and schizophrenia.  
 With respect to SNPs, numerous genome-wide associations studies 
(GWAS) have been conducted in an effort to identify variants in candidate genes 
which may confer risk of the disorder. GWAS studies employ microarray 
technology to identify variations in SNPs across the genome which occur more 
frequently in individuals with a specific disease or disorder, like schizophrenia, 
than in unaffected individuals. Specifically, by recording the frequency of SNPs 
that occur in conjunction with symptoms of the disorder, researchers can calculate 
a statistical estimate regarding the level of increased risk associated with each 
SNP (Paria et al., 2014). A positive association between an SNP and disorder of 
interest identifies a genomic region (rather than a complete gene), not a specific 
causative mechanism that may be involved in the development of the disorder 
(Paria et al., 2014). GWAS studies in schizophrenia have produced highly varied 
and inconsistent results. In an effort to address these discrepant findings, Allen et 
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al. (2008) reviewed all genetic-association studies published on schizophrenia and 
ran meta-analyses for all SNPs which had been shown to be associated with the 
illness in at least four independent case-control studies. Data from 118 
polymorphisms (in 52 genes) met the inclusion criteria set by Allen and 
colleagues (2008) and warranted a meta-analysis (n = 3,589). A total of 24 
polymorphisms within 16 genes (listed in Table 1) were found to be significantly 
associated with a risk of manifesting the disorder (p < .05).   
Table 1. SNPS found to be nominally significantly associated with schizophrenia 
Gene SNP Odds Ratio (95% CI)a P value 
APOE APOE (Ɛ2/3/4) E4 vs. E3 1.16  (1.00-1.34) .043 
COMT rs165599 1.11 (1.02-1.21) .019 
COMT rs737865 1.13 (1.01-1.28) .039 
DAO rs4623951 .88 (.79-.98) .026 
DRD1 rs4532 (DRD1_48A/G) 1.18 (1.01-1.38) .037 
DRD2 rs1801028 (S311C) 1.52 (1.09-2.12) .013 
DRD2 rs6277 (P319P) 1.45 (1.21-1.73) < .001 
DRD4 rs1800955 (521T/C) 1.15 (1.05-1.26) .003 
DRD4 120-bp TR .81 (.70-.94) .005 
DTNBP1 rs1011313 (P1325) 1.23 (1.07-1.40) .003 
GABRB2 rs1816072 .82 (.72-.93) .002 
GABRB2 rs1816071 .82 (.72-.93) .002 
GABRB2 rs194072 .83 (.69-1.00) .048 
GABRB2 rs6556547 .70 (.52-.95) .022 
GRIN2B rs7301328 (366G/C) 1.16 (1.01-1.33) .034 
GRIN2B rs1019385 (200T/G) 1.45 (1.14-1.85) .003 
HP Hp1/2 .88 (.80-.98) .016 
IL1B rs16944 (C511T) .78 (.65-.93) .006 
MTHFR rs1801133 (C677T) 1.16 (1.05-1.30) .005 
MTHFR rs1801131 (A1298C) 1.19 (1.07-1.34) .002 
PLXNA2 rs752016 .82 (.69-.99) .037 
SCL6A4 5-HTTVNTR .86 (.74-.99) .036 
TP53 rs1042522 1.13 (1.01-1.26) .029 
TPH1 rs1800532 (218A/C) 1.31 (1.15-1.51) < .001 
aSummary odds ratios are based upon random-effects allelic contrasts comparing minor and major alleles (based upon 
frequencies in the control samples). 
Note: SNPs in bold were found to be associated with a decreased risk of developing schizophrenia. 
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Of these, 14 polymorphisms were associated with an increased risk of 
schizophrenia, while 10 polymorphisms were associated with a decreased risk of 
the disorder (see Abbreviations list for full gene details). Attesting to the 
considerable variability in genome-wide research findings, seven of these 
aforementioned polymorphisms had not been explored in meta-analytic syntheses 
prior to April 2007.  
 This variability is further highlighted by a more recent meta-analytic 
review by Ripke et al. (2013) which was conducted in three stages, beginning 
with an exploration of candidate genes in a Swedish national sample (5,001 
affected individuals and 6,243 healthy controls), followed by a meta-analysis of 
existing findings from published GWAS studies in schizophrenia (8,832 affected 
individuals and 12,067 healthy controls) and concluded by way of replication of 
SNPs in 168 genomic regions in independent cohorts (7,413 affected individuals, 
19,762 healthy controls and 581 parent-offspring trios). From this, 22 SNPs were 
found by Ripke and colleagues (2013) to be significantly associated with 
schizophrenia at a genome-wide significance level of p < 5 × 10-8. Of these, five 
(rs114002140, rs7085104, rs1198588, rs1538774 and rs11995572) had previously 
met genome-wide significance alone (Hamshere et al., 2013; Schizophrenia 
Psychiatric Genome-Wide Association Study Consortium, 2011; Stefansson et al., 
2009), three (rs107504622, rs1006737 and rs17691888) had been reported to be 
associated with a combined phenotype, including schizophrenia and bipolar 
affective disorder (Ferreira et al., 2008; Purcell et al., 2009), and 14 (rs6461049, 
rs4129585, rs10789369, rs7940866, rs107504622, rs2905424, rs2373000, 
rs6878284,  rs12991836, rs2949006, rs4801131, rs778371, rs11532322 and 
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rs171748) were novel disease-associated SNPs which had not previously been 
linked to schizophrenia.  
 Research derived from GWAS studies continues to be plagued by the so-
called ‘problem of missing heritability’ in which heritability estimates derived 
from molecular studies account for considerably less variance in phenotype than 
do estimates derived from family and twin studies drawing on behavioural genetic 
approaches (Manolio et al., 2009). Potential sources of "missing" heritability, 
include gene-environment interactions, epigenetic variation, and rare genetic 
variation (van Dongen & Boomsma, 2013). In addition to fluctuations in the 
number and nature of SNPs identified by GWAS studies, a further limitation to 
genetic research is that individually, these alleles have very small effects on 
schizophrenia risk with odds ratios accounting for less than 1.2% of the variance 
(Purcell et al., 2014). Moreover, collectively, schizophrenia-candidate SNPs only 
explain a small amount of the latent liability for the disorder (Manolio et al., 2009; 
Visscher, Goddard, Derks, & Wray, 2012). Lee et al. (2012) explored the role of 
915,354 SNP’s imputed from the Schizophrenia Psychiatric Genome-Wide 
Association Study Consortium in a sample of 9,087 affected individuals and 12, 
171 healthy controls and found that together, these genetic variants captured 23% 
(SE = 1%) of the variation in heritability for schizophrenia.  
The substantial genetic heterogeneity associated with the disorder, the very 
small effect sizes of disease-associated alleles and the fact that not all MZ twins 
are concordant for the onset of the schizophrenia suggest that non-genomic factors 
must also contribute considerably to the expression of the illness. Increasingly, 
researchers are coming to the realisation that a focus only on genetic variants, 
although extremely important, is unlikely to reveal the full aetiological picture of 
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schizophrenia. Such a view is consistent with the vast amount of research which 
also shows well-replicated associations for certain environmental predictors of 
schizophrenia. 
2.2 Environmental Risk Factors 
 
Epidemiological, case control and prospective cohort studies have reported 
associations between a number of environmental events, occurring during both 
early and late development, and schizophrenia (Brown & Derkitis, 2009). These 
include maternal diabetes and influenza during pregnancy (Brown, 2006; Brown 
& Derkits, 2009), obstetric complications (Clarke, Harley & Cannon, 2006; 
Geddes, Verdoux, Takie, Lawrie, & Murray, 1999; Rosso et al., 2014), prenatal 
maternal nutrition (Brown & Susser, 2008; Kirkbride et al., 2012; Susser et al., 
1996) and body mass index (Kawai et al., 2004; Khandaker, Dibben, & Jones, 
2012), urban birth and residence (Kelly et al., 2010; McGrath et al., 2004), 
immigrant status (Cantor-Graae, & Selten, 2014; Tortelli et al., 2015) and 
cannabis misuse (Henquet, Murray, Linszen, & van Os, 2005). 
The current thesis will first focus on the antenatal period, specifically on adverse 
exposures to maternal influenza and diabetes during pregnancy. The reason for 
this focus is the accumulating evidence suggesting that schizophrenia may have 
its origins in early life in the form of aberrant brain development (Khandaker, et 
al., 2012).  Empirical findings from research that specifically focuses on the 
contributions of these environmental risk factors during pregnancy to the 
subsequent development of schizophrenia are described in the following section.  
2.2.1 Maternal diabetes or uncontrolled blood sugar during 
pregnancy. 
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Few studies have focused on the contribution of prenatal maternal diabetes 
to liability for the later development of schizophrenia. A meta-analytic review by 
Cannon, Jones and Murray (2003) reported a seven-fold increase in schizophrenia 
risk associated with exposure to diabetes in utero. This observation was based 
upon the synthesis of two prospective population-based studies. Since 2003, only 
one other prospective study has explored an association between maternal 
diabetes during pregnancy and psychotic outcomes.  Zammit et al. (2009) 
investigated the role of adverse prenatal and perinatal events, including maternal 
diabetes or glycosuria (i.e., the presence of abnormal amounts of glucose in the 
urine), in the development of non-clinical psychotic symptoms at age 12 years. 
From this, the researchers found that the presence of maternal diabetes was 
significantly associated with an increased risk of any suspected or definite 
psychotic symptoms in adolescents at age 12 years (OR = 2.68, 95% CI 1.08, 
6.64; p = 0.034), after adjustment for potential covariates and confounders, 
including child intelligence quotient and birth weight. 
2.2.2 Maternal influenza during pregnancy. 
Evidence of a relationship between pre-natal exposure to influenza and 
schizophrenia first emerged from epidemiological research that used ecological 
data, namely influenza pandemics in non-clinical populations, to define exposure 
state. Initial investigations by Barr, Mednick and Munk-Jorgensen (1990), 
Kendell and Kemp (1989) and Mednick, Machon, Huttunen and Bonett (1988) all 
reported associations between second-trimester exposure to influenza outbreaks 
and the later expression of schizophrenia. However, subsequent studies, many of 
which employed larger samples and clearer definitions of schizophrenia, failed to 
replicate the aforementioned significant findings (Selten & Slaets, 1994; Takei, 
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Murray, Sham, & O'Callaghan, 1995). Rather than being indicative of a null 
relationship between pre-natal exposure to influenza during gestation and the later 
development of schizophrenia, these discrepant findings may be due to 
methodological limitations associated with the aforementioned epidemiological 
research, limitations which included a high rate of misclassification of pre-natal 
exposure to influenza, broad and varied definitions of schizophrenia diagnosis and 
the absence of documentation on whether pregnancies were carried to full-term.  
The methodological shortcomings associated with epidemiological 
influenza research saw empiricists initiate prospective birth-cohort studies in 
order to further explore the influenza-schizophrenia hypothesis but with more 
statistical rigor and precision. This involved prospective documentation of 
prenatal exposure to influenza during gestation, including the use of archived 
serological samples from both mothers and their infants. These samples allow for 
reliable and accurate measurement of infection exposure. An example of research 
which explored the association between maternal influenza and schizophrenia 
during pregnancy, using a prospective birth-cohort sample and serologically 
documented viral exposure, is the Prenatal Determinants of Schizophrenia (PDS) 
study. This study was based on a cohort of approximately 20,000 pregnant women 
who were enrolled in the Child Health and Development Study and whose 
offspring were followed up for schizophrenia and other schizophrenia spectrum 
disorders (SDD) in adulthood. In a nested case-control design, which analysed 
data from 64 cohort participants with a schizophrenia spectrum disorder and 125 
healthy control participants enrolled in the PDS study, Brown et al. (2004) found 
that serologically documented fetal exposure to influenza during the first trimester 
was associated with a seven-fold increased risk of the later expression of a SDD. 
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The authors observed no association between maternal influenza during the 
second or third trimester and the later development of a SSD, indicating that 
exposure to influenza is most harmful during the early stages of fetal 
development.  
A more recent study by Elleman et al. (2009) investigated the relationship 
between influenza B exposure in utero and schizophrenia in 111 affected 
individuals (70 with schizophrenia and 41 with affective psychoses) and 333 
unaffected controls, who were enrolled in the Collaborative Perinatal Project, a 
prospective birth-cohort study aimed at exploring antenatal and postnatal 
contributors to adverse infant and child development. The researchers observed a 
70% increase in the expression of schizophrenia in participants exposed to 
influenza B in utero. This association approached statistical significance (OR = 
1.70; 95% CI .92, 3.14; p = .089). Elleman and colleagues (2009) observed no 
significant relationship between influenza B exposure and affective psychosis 
status (χ2 = .127, df = 1, p = .722; 95% CI .51, 2.60). 
The increased risk of schizophrenia following exposure to maternal 
influenza during pregnancy observed by Ellerman et al. (2009) is considerably 
lower than the 7-fold increased risk reported by Brown et al. (2004). However, 
this may be due to the fact that Ellerman and colleagues explored the risk of 
exposure to a specific strain of influenza, namely influenza B, which may have 
different effects from other forms of the virus; Brown et al. (2004) did not specify 
the specific strains of influenza that they investigated in their study.   
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2.3 Neurodevelopmental Model of Schizophrenia 
There are a number of different aetiological models of schizophrenia, 
ranging from genetic (e.g., heritability model) to environmental theoretical 
approaches (e.g., environmental exposure model; Mitchell et al., 2013). Between 
these two extremes, lie the neuroanatomical and neurochemistry models (e.g., 
dopamine dysregulation hypothesis) as well as the neurodevelopmental model 
which considers that schizophrenia risk evolves from an integration of both 
biological and environmental factors (Allin, & Murray 2002; Mitchell et al., 2013; 
Murray & Lewis, 1987). This section will discuss, in detail, the 
neurodevelopmental model of schizophrenia. 
Empirical findings which highlight associations between fetal exposures like 
maternal influenza and diabetes/glycosuria and schizophrenia have led researchers 
to hypothesise that these non-genetic factors occurring early in life may play a 
role in the later manifestation of the illness (Matheson, Shepherd, & Carr, 2014). 
The idea of an initial vulnerability to the disorder, preceding the onset of the 
phenotype, is the primary premise of the neurodevelopmental model of 
schizophrenia.  More specifically, this model asserts that the expression of 
schizophrenia is a consequence of impaired and/or delayed central nervous system 
development during gestation. It is argued by Millan (2012) and Rapoport, Giedd 
and Gogtay (2012) and Fatemi and Folsom (2009) that the disruption to normal 
brain development is caused by a combination of genes which control 
neurodevelopment  and account for the developmental unfolding of features of 
fetal development such as neuronal migration and synaptic plasticity. Primary 
neurodevelopmental aberrations in the disorder may also involve alterations in the 
normal expression of genes involved in early migration of neurons and glia, 
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axonal development, cell propagation, synaptogenesis and apoptosis (Fatemi & 
Folsom, 2009).    
Environmental insults such as exposure to influenza or diabetes in utero 
may disrupt these developmental processes with the result being a gradual path of 
aberrant brain maturation which subsequently renders an individual vulnerable to 
schizophrenia at a later point in adolescent or early adult development (Harrison, 
2007).  
Given the comparatively late onset of perceptual, mood, cognitive and 
social disturbances in affected individuals, schizophrenia is considered an atypical 
neurodevelopmental disorder (Millan, 2013). Unlike other neurodevelopmental 
disorders such as Rett’s Syndrome or Autism Spectrum Disorders, a 2-hit model 
was proposed by Keshavan and Hogarty (1999) to describe the 
neurodevelopmental course of schizophrenia. The 2-hit model highlights two 
critical periods in human brain development, namely early fetal cortical growth in 
utero and late maturational processes in adolescence, which, the authors claim, 
interact with adverse neurophysiological, hormonal and psychosocial factors 
during adolescence to produce the symptoms of the disorder. The first hit is 
presumed by Keshavan and Hogarty (1999) to be characterised by disruption to 
specific neuronal processes that are required for normative brain development, 
including neurulation, neuronal proliferation and neuronal migration. This cortical 
impairment, arising from early developmental insults, may explain the premorbid 
congenital abnormalities and neurological soft signs observed in children who 
later develop the disorder (Hammed and Lewis, in press). During adolescence, the 
second hit occurs, whereby early structural and functional brain anomalies interact 
with changes in neuroendocrine function, new phrases of brain maturation and 
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specific environmental exposures to cause excessive elimination of synapses and 
loss of plasticity. Hence, this second hit is presumed to account for the transition 
from early neurodevelopmental dysfunction to overt psychosis in vulnerable 
individuals (Rapoport, Giedd, & Gogtay, 2012).  
Several lines of evidence support the neurodevelopmental model of 
schizophrenia (Keshavan, Kennedy, Murray, & Murray, 2004; Rapoport et al., 
2012). Findings from longitudinal research which prospectively followed cohorts 
presumed to be at high familial risk of developing the disorder (e.g., first-degree 
relatives and children of affected probands) from birth, for example, suggest that 
cognitive, social, verbal language or motor deficits commonly observed in 
individuals with schizophrenia actually occur early in development (Hammed & 
Lewis, in press; Schenkel & Silverstein, 2004). In addition, brain-imaging studies, 
which typically comprise affected individuals, their first-degree relatives and 
healthy controls, also point to neurodevelopmental origins of the disorder. The 
inclusion of non-psychotic relatives in research of this nature allows for 
inferences to be made regarding early aberrant brain maturation processes, in the 
absence of possible confounding factors associated with exposure to anti-
psychotic medication and the disease process itself. Moreover, multiple markers 
of congenital anomalies and premorbid neurological abnormalities (e.g., saccadic 
eye movement dysfunction, gait abnormalities, poor motor coordination and 
sensory perceptual difficulties), indicative of early neurodevelopmental insults, 
derived from medical records of children who later go on to develop the disorder, 
are further support for the model (Keshavan, Diwadkar, Montrose, Rajarethinam, 
& Sweeney, 2005; Rapoport, Giedd, Gogtay, 2012). As indeed are the empirical 
data showing an increased prevalence of adverse antenatal exposures and events 
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in individuals who developed schizophrenia (Cannon et al., 2003; Khandaker, 
Zimbron, Lewis, & Jones, 2013). As with children who inherit genetic 
vulnerability to the disorder, these individuals also exhibited marked cognitive, 
behavioural and social indicators during childhood that may have reflected 
aberrant brain maturation in utero. 
The following section will briefly summarise research findings that are 
consistent with the neurodevelopment model of schizophrenia. 
2.3.1 Evidence from empirical studies of individuals with a latent 
liability for schizophrenia.  
2.3.1.1 Motor, cognitive/intellectual and social deficits. 
A recent systematic review by Hameed & Lewis (in press) that integrated 
and summarised data from 46 papers exploring the neurodevelopmental features 
of children born to parents with schizophrenia (i.e., at familial high risk of 
developing the disorder [FHR]) highlighted a number of significant differences 
between FHR children and their healthy control counterparts. For example, the 
authors reported a large standardised difference between the motor and visual-
motor ability of FHR infants and their non-FHR counterparts (d = 1.25). 
According to Hameed & Lewis (in press), this difference was characterised by 
delayed motor development and coordination in FHR infants compared to healthy 
control children. Consistent with these findings, data from longitudinal birth- 
cohort studies also indicate early neuromotor abnormalities among individuals 
who develop schizophrenia in adolescence or adulthood (i.e., pre-schizophrenia 
children) (Cannon et al., 2002; Isohanni et al., 2001, Isohanni et al., 2004; Murray 
et al., 2004; Welham, Isohanni, Jones & McGrath, 2009). A meta-analytic review 
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by Dickson, Laurens, Cullen, & Hodgins (2012) quantitatively summarised data 
from prospective investigations of population-based studies which explored the 
cognitive or motor function of individuals aged 16 years or younger who later 
manifested schizophrenia or an SSD. For motor functioning, the authors 
synthesised data from four studies and observed significant deficits in motor 
proficiency (skills and coordination) in pre-schizophrenia individuals by the age 
of 16 that were of moderate magnitude compared to youth who did not develop 
these disorders (SMD = .56, [95% CI = .38, .74]). 
 Based on a review of 13 studies, Dickerson et al. (2012) observed 
significant differences between the overall cognitive ability (i.e., intelligence 
quotient [IQ]), but not general academic achievement or mathematics ability, of 
pre-schizophrenia children and that of their healthy control counterparts. More 
specifically, individuals who later developed an SSD exhibited significantly lower 
IQ scores at age 16 years than did their non-SSD counterparts (SMD = 0.51, [95% 
CI = 0.38, 0.65]).  
 Several recent meta-analytic reviews have provided robust and high-
quality evidence reflecting cognitive deficits in the unaffected siblings of 
schizophrenia probands with respect to their general intelligence (Snitz, 
Macdonald, & Carter, 2006), visual and verbal memory (Sitskoorn, Aleman, 
Ebisch, Appels, & Kahn, 2004), executive functioning (Snitz et al., 2006; Szöke et 
al., 2005), attention (Sitskoorn et al., 2004), short- and long-term episodic 
memory (Whyte, McIntosh, Johnstone, & Lawrie, 2005) and theory of mind (Bora 
& Pantelis, 2013).  
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 Social deficits are a core and pervasive feature of people with 
schizophrenia. As with deficits associated with motor and cognitive functioning in 
affected individuals, empirical findings indicate that the onset of impairment to 
their social proficiency occurs well before the onset of psychotic symptoms 
(Schenkel & Silverstein, 2004). In their review, Hameed & Lewis (in press, 2015) 
reported that several studies had shown that pre-adolescent FHR children showed 
significantly lower levels of social adjustment and competence than did pre-
adolescent offspring of unaffected parents. Namely, FHR offspring were more 
likely to experience high levels of emotional distress and demonstrate aggressive 
and avoidant patterns of behaviour than were their non-FHR counterparts. 
According to the authors, the magnitude of differences between the two groups 
across these various social domains was characterised by small to moderate effect 
sizes.  
2.3.1.2 Structural and functional brain anomalies. 
The notion of aberrant early brain development would presume that 
structural and functional brain abnormalities occur prior to the onset of 
schizophrenia. Indeed, research investigating normative brain maturation have 
observed a number of irregularities in offspring of parents with schizophrenia 
(OS). A study by Keshavan et al. (1997) used magnetic resonance imaging (MRI) 
to explore structural brain differences between OS children (n = 11) and those of 
healthy, non-affected parents (n = 12). Compared to healthy controls, OS children 
showed significant volume reductions in their left amygdala (p = .05) and 
hippocampus (p = .03), along with enlarged third ventricles (p < .001; Keshavan 
et al., 1997). A recent meta-analytic review by Palaniyappan, Balain, & Liddle 
(2012) synthesised findings from 16 voxel-based morphometry analyses, 
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involving 474 cases with schizophrenia, 733 of their unaffected siblings and 563 
healthy controls, which explored grey matter differences across the three groups. 
The researchers observed grey matter (GM) reductions in unaffected siblings 
compared to healthy controls in the following brain regions: medial prefrontal 
cortex, lentiform nucleus and amygdala and parahippocampal gyrus. 
As with research exploring brain volume and GM, investigations of 
cortical white matter (WM) in participants with a familial risk of schizophrenia 
have revealed significant reductions in WM integrity in their left prefrontal cortex 
and hippocampus compared to healthy control participants (Hao et al., 2009).  
With respect to functional brain anomalies, Macdonald, Thermenos, Barch 
and Seidman (2009) conducted a systematic review of 20 functional magnetic 
resonance imaging (fMRI) studies which had explored cortical connectivity 
patterns that were activated in first-degree relatives of individuals with 
schizophrenia and healthy controls during various cognitive tasks. Given the 
significant heterogeneity with respect to analytic methods and cognitive tasks 
across the studies, the authors reported trends in the brain activation differences 
between non-psychotic relatives and healthy controls, rather than applying meta-
analytic methods (i.e., calculating a summary statistic to represent brain activation 
differences). Irrespective of the cognitive paradigm that was used, Macdonald et 
al. (2009) found that abnormal activity, defined as significant increases or 
decreases in cortical activation in first-degree relatives compared to healthy 
controls, was apparent in approximately two-thirds of studies exploring the 
cerebellum, the thalamus and the dorsal prefrontal, lateral temporal and parietal 
cortices, with the basal ganglia and ventral prefrontal cortex showing 
abnormalities in approximately 50% of studies investigating these regions.  
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Taken together, these findings point to altered neuronal integrity in 
specific areas of the brain, such as the prefrontal cortex, hippocampus and 
thalamus, in individuals at risk of schizophrenia, suggesting potential 
neurocognitive and behavioural predictors of the later development of the 
disorder. Moreover, the observations of structural and functional anomalies in 
non-psychotic first-degree relatives and pre-schizophrenia children strongly 
indicate that the neurobiological diathesis of the disorder may have its origins 
very early in development. Finally, they point to areas of the brain which may be 
more vulnerable to abnormal brain maturation following exposure to antenatal 
events such as maternal influenza and diabetes in utero. 
2.3.1.3 Minor congenital physical anomalies.  
A further line of evidence supporting the neurodevelopmental model of 
schizophrenia is the presence of several indicators of minor physical anomalies 
(MPAs), reflective of neurodevelopmental insults in individuals with 
schizophrenia and their unaffected siblings.  A meta-analysis by Xu, Chan and 
Compton (2011) analysed 14 studies (1207 patients and 1007 healthy controls) 
that compared MPAs in individuals with schizophrenia and unaffected controls. 
MPAs scrutinised included low-set ears, larger gaps between the first and second 
toes and epicanthal eye folds, all of which are indicative of both first- and second- 
trimester abnormalities (Fatemi & Folsom, 2009). Xu et al. (2011) observed a 
large difference between groups, with affected individuals exhibiting a 
significantly greater number of MPAs than did their non-affected counterparts (d 
= 0.95, [95% CI = 0.63, 1.27]). The authors then conducted two further 
quantitative reviews comprising six studies each, one comparing patients and their 
unaffected siblings, the other first-degree relatives (n = 303) and healthy controls 
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(n = 266). They found that patients exhibited a greater number of MPAs than did 
their unaffected siblings (d = 0.45, [95% CI = 0.29, 0.62]), while the prevalence of 
MPAs was higher in unaffected relatives than in healthy controls, although this 
difference did not reach statistical significance at p < .05 (d = .32, [95% CI = -.08, 
.73]). 
2.3.2 Evidence from empirical studies of individuals exposed to 
adverse antenatal events. 
2.3.2.1 Prenatal exposure to maternal diabetes/glycosuria. 
 
As described previously (section 2.2.1), epidemiological research has 
shown that individuals exposed to diabetes in utero are seven times more likely to 
manifest schizophrenia than are their non-exposed counterparts (Cannon et al., 
2003). Presently, however, it is unclear how prenatal exposure to diabetes may 
confer risk of schizophrenia (Van Lieshout & Voruganti, 2008). Diabetes during 
the prenatal period is classified into 2 types: gestational diabetes and pre-
gestational diabetes (American Diabetes Association, 2010). Gestational diabetes 
accounts for approximately 87.5% of all cases with maternal diabetes during 
pregnancy, with 7.5% being due to pre-existing type 1 diabetes and the remaining 
5% being due to pre-existing type 2 diabetes (National Collaborating Centre for 
Women's and Children's Health, 2008). 
During pregnancy, the transfer of maternal nutrients, oxygen and growth factors 
from the mother to her developing fetus occurs via the mother’s placenta. As 
insulin from the mother cannot cross the placenta, the fetus’s pancreatic insulin 
production is regulated solely by the glucose levels in the maternal blood 
(Bernasko, 2007). High maternal serum glucose (i.e., maternal hyperglycemia) 
stimulates increases in fetal insulin output which may subsequently alter the fetal 
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metabolic environment by reducing oxygen availability and altering lipid 
metabolism and may result in non-optimal programming of neuronal proliferation 
and architecture in the brain of the developing infant (Van Lieshout & Voruganti, 
2008). In contrast, maternal hypoglycemia, characterised by low maternal serum 
glucose, may also have deleterious effects on fetal central nervous system (CNS) 
development. The human brain requires a considerable amount of glucose for 
optimal functioning (approximately 20% of the body’s metabolic consumption) 
and so, if deprived of this, even temporarily, cortical growth and development 
may be adversely affected.  
 To date, despite the high prevalence of diabetes during pregnancy, only a 
handful of studies have explored the neuropsychological and behavioural sequelae 
of children exposed to diabetes in utero. Nonetheless, the findings of this research 
suggest that children born to diabetic mothers tend to show cognitive deficits in 
the areas of memory, motor functioning, attention, language proficiency and 
generalised intellectual functioning, many of which are putative risk factors in 
children who later manifest schizophrenia (Isohanni et al., 2001; Cannon et al., 
2002). 
Using the Wechsler Intelligence Scale for Children-Revised (WISC-R), 
Silverman, Rizzo, Cho and Metzger (1998) investigated the global intellectual 
functioning of 33 children born to mothers with pre-gestational diabetes (this 
included Type I and Type II) and 8,192 healthy control children. At age 8 years, 
children exposed to diabetes in utero during the second or third trimester had 
significantly lower Full-Scale IQ scores (M = 98.7) than did their non-exposed 
counterparts (M =105.3). This difference was observed by the authors across both 
verbal and performance index scores. Moreover, Silverman et al. (1998) found 
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that exposed participants’ average scores on the WISC-R Full-Scale were 
inversely correlated with maternal glycated haemoglobin levels in the second 
trimester and with beta-hydroxybutyric acid in the third trimester; high levels of 
glycated hemoglobin and/or beta-hydroxybutyric acid indicate poor control of 
maternal blood glucose levels (Inkster et al., 2006; Stojanovic & Ihle, 2011). 
Hence, the authors concluded that lower overall cognitive ability was associated 
with poorer maternal diabetic control during pregnancy. 
 A more recent birth-cohort study investigated the effect of 
exposure to diabetes in utero on the intellectual functioning and 
neuropsychological development of children aged 7 to 10 years (Bolaños, Matute, 
de Lourdes Ramírez-Dueñas, & Zarabozo, 2015). The sample consisted of 32 
children born to mothers with gestational diabetes, whose medical records 
indicated poor adherence to treatment, and 28 children born to mothers who had 
normal glucose levels during pregnancy. Akin to the findings of Silverman et al. 
(1998), Bolaños et al. (2015) found that children exposed to diabetes in utero (M 
= 96.88, SD = 10.96) achieved significantly lower Full-Scale IQ scores on the 
Wechsler Intelligence Scale for Children-IV (WISC-IV) than did children in the 
healthy control group (M = 102., SD = 9.50; p = .038) and were more likely to 
receive an IQ score within the low average range (i.e., between 80 and 90) than 
were their non-exposed counterparts (χ2 [1] = 11.53, p = .009). Children in the 
gestational diabetes group (M = 97.25, SD = 11.10) also underperformed on the 
Working Memory index of the WISC-IV compared to those in the healthy control 
group (M = 90.88, SD = 10.30; p = .025). In relation to other domains of memory, 
infants exposed to diabetes in utero have also underperformed compared to their 
non-exposed counterparts in areas of auditory recognition at birth (Nelson, 
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Thomas, Wewerka, & Georgieff, 2000), visual recognition at 6 months (Nelson et 
al., 2000) and delayed recall at 12 months (DeBoer, Wewerka, Bauer, Georgieff, 
& Nelson, 2005).  
With respect to motor development, Bolaños et al. (2015) found that 
children exposed to diabetes during gestation performed significantly poorer at a 
manual dexterity task, namely placing pins using both hands in the Purdue 
Pegboard Dexterity test (F [1, 58] =5.50; p = .023) and demonstrated poorer 
visuo-constructional ability than did children who were not exposed to diabetes in 
utero (Bolaños et al., 2015). These findings are consistent with earlier research by 
Ornoy, Wolf, Ratzon, Greenbaum, & Dulitzky (1999) which observed 
impairments in fine and gross motor functions and in hand-eye coordination in 
young children (5-8 years) born to mothers with gestational diabetes compared to 
those born to unaffected mothers.  
 Research has also shown this population to be at risk of language deficits. 
Dionne, Boivin, Séguin, Pérusse, & Tremblay (2008) compared the performance 
of 221 infants of diabetic mothers and 2612 healthy infants, aged between 18 
months and 7 years, on various language measures which included the McArthur 
Communicative Development Inventory, the Peabody Picture Vocabulary Test 
and the Early Development Instrument. After controlling for covariates of child 
sex, economic status and perinatal factors, Dionne et al. (2008) observed that 
infants exposed to diabetes in utero scored .27 to .41 standard deviations lower 
than their non-exposed counterparts on expressive vocabulary and grammar in 
children up to 30 months in age. This equated to a 4-to-12 word difference in 
vocabulary between the two groups. Children of diabetic mothers were also found 
to be 2.2 times more at risk of a language impairment (i.e., < 15th percentile on at 
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least two measures) than were children of non-diabetic mothers (Dionne et al., 
2008).  
 Finally, the potential for attentional deficits in children of mothers 
with diabetes during pregnancy has also been investigated. Nomura et al. (2012) 
investigated the attentional control and hyperactivity of 212 pre-school children  
(21 cases exposed to diabetes in utero and 191 healthy controls) using the 
Attention Deficit Hyperactivity Disorder Rating Scale-IV (ADHD RS-IV) which 
was completed by participants’ parents and teachers. In terms of attentional 
control, Nomura et al. (2012) reported that inattention scores on the ADHD RS-IV 
were significantly higher for children exposed to gestational diabetes (M = 12.58)  
than were scores for healthy controls. (M = 11.29; p = 05). No difference was 
found between the two groups for hyperactive/impulsive symptoms. Further, 
Ornoy et al. (1998) explored the neuropsychological functioning of 57 school-
aged children born to mothers with well-controlled diabetes during pregnancy and 
48 age-matched controls. The authors found that children of diabetic mothers 
exhibited significantly lower scores on the Pollack tapper test (p < .001), 
indicating higher levels of inattention and hyperactivity, than did children born to 
non-diabetic mothers.  
Taken together, these research findings show that the offspring of diabetic 
mothers tend to exhibit many of the neurodevelopmental deficits and delay in 
attaining developmental milestones that have been observed in children who later 
develop schizophrenia, albeit to a lesser degree. However, the precise mechanisms 
by which prenatal diabetes confers risk of the disorder remain unclear. In their 
review of clinical, epidemiologic and animal studies on prenatal exposure to 
diabetes, Van Lieshout and Voruganti (2007) concluded that the mechanisms by 
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which diabetic pregnancies increase the risk of schizophrenia in their offspring are 
likely to involve an interaction between changes to the fetal metabolic 
environment, triggered by maternal hyper- and hypo-glycemia and the fetus’s 
genetic vulnerability.  
2.3.2.2 Prenatal exposure to maternal influenza 
 
Serologically determined exposure to maternal influenza during the first 
trimester of gestation has been shown to be associated with a seven-fold increase 
in the likelihood of developing a schizophrenia spectrum disorder in adulthood 
(Brown et al., 2004). 
Unlike blood glucose, the influenza virus seems to be unable to cross the placenta 
into fetal blood and so any deleterious effects to the fetus are likely to be 
associated with the maternal, fetal and/or placental antiviral response to infection, 
including the release of proinflammatory cytokines (e.g., interleukin-8 [IL-8], 
interleukin-6 [IL-6], interleukin-1beta [IL-1b], tumor necrosis factor-alpha [TNF-
α]), many of which appear to cross the placenta (Knuesel et al., 2014). Certainly, 
fetal exposure to the proinflammatory cytokine interleukin-8 (IL-8) has been 
significantly associated with the risk of schizophrenia in offspring (Brown et al., 
2014). Moreover, maternal immune activation (MIA) has been shown to increase 
cytokines in the placenta (IL-1b, IL-6, TNF-α) and amniotic fluid (IL-6, TNF-α; 
Patterson, 2009). The action of cytokines on the placenta might compromise the 
availability of maternal nutrients, oxygen and growth factors to the fetal brain, 
resulting in aberrant cortical growth development.  
A number of animal studies have attempted to characterise the effect of exposure 
to influenza in gestation on fetal brain development. Fatemi and colleagues (1999) 
found that the prenatal injection of the human influenza virus in pregnant mice 
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mid-gestation resulted in decreased thickness of the cortex and hippocampus and 
reduced forebrain expression of genes responsible for optimal growth and 
development (e.g., Reelin) in neonatal offspring. According to Fatemi et al. 
(1999), offspring exposed to influenza showed aberrant neuronal migration to 
cortical layers two and three compared to their non-exposed counterparts, a 
neuropathology which has been posited to underlie the neurodevelopmental 
dysfunction in schizophrenia (Kamiya et al., 2005).  
Using a different methodological approach, Ozawa and colleagues (2005) 
induced a maternal immune response in pregnant mice using the synthetic double-
strand RNA polyriboinosinic-polyribocytidilic acid (poly I:C) to explore whether 
their adult offspring exhibited any impairments in sensory-motor gating and 
neurocognition, in particular novel-objective recognition memory, similar to those 
witnessed in people affected by schizophrenia (Geyer, Krebs-Thomson, Braff, & 
Swerdlow, 2001; Libby, Yonelinas, Ranganath, & Ragland, 2013). The 
researchers used a Prepulse Inhibition (PPI) protocol and the Novel-Object 
Recognition Test (NORT) to assess sensory-motor proficiency and recognition 
memory, respectively. Ozawa et al. (2006) found that adult mice, exposed to the 
maternal immune response during gestation, significantly underperformed on the 
PPI (p < .001) protocol and NORT (p < .001) compared to non-exposed adult 
mice.   
 As with Ozawa et al. (2006), Wallace, Marston, McQuade and Gartside 
(2014) investigated the impact of maternal immune activation on the 
neurocognition of rat offspring using the attentional set-shifting task, a multistage 
test of executive functions. Rats that were exposed to prenatal immune activation 
in utero exhibited small deficits in discrimination learning and much larger 
39 
 
 
 
deficits in reversal learning (p < .001) compared to those born to healthy mothers. 
More specifically, exposed rats were able to prioritize certain stimuli for selection 
(i.e., form an attentional set) but were unable to shift their attention to another task 
or to learn from correct responses (i.e., reversal learning deficit). These particular 
cognitive deficits are analogous to those observed by Gastambide et al. (2012) in 
their rodent neurodevelopmental model of schizophrenia.  
 In humans, Ellman and colleagues (2010) investigated an association 
between serologically determined higher maternal IL-8 levels in the second and 
third trimesters of pregnancy, indicative of maternal immune activation during the 
later stages of gestation, and structural anomalies observed in individuals with 
schizophrenia. Participants were derived from the Developmental Insult and Brain 
Anomaly in Schizophrenia (DIBS) study and comprised 17 cases of schizophrenia 
and 8 healthy controls. Using Magnetic Resonance Imaging (MRI) technology, 
the authors found that fetal exposure to increases in maternal IL-8 levels was 
significantly associated with increases in ventricular cerebrospinal fluid (CSF) 
volume among cases with schizophrenia (p=0.045). Fetal exposure to IL-8 was 
also related to significant decreases in left entorhinal cortex volumes (p=0.037) 
and decreases that approached significance in the right superior temporal gyrus 
(p=0.079), the right caudate (p=0.051), and the putamen bilaterally (p=0.061 and 
p=0.094, right and left, respectively). These findings are especially relevant to 
schizophrenia, as increases in ventricular volumes are the most well-replicated 
brain anomaly found in schizophrenia research (Wright et al., 2014) and the other 
neuroanatomical alterations have been found in schizophrenia and prodromal 
populations, suggesting that these brain abnormalities may have 
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neurodevelopmental origins (Borgwardt et al., 2007; Pantelis et al., 2003; Wright 
et al., 2014). 
With respect to the cognitive effects of exposure to influenza during 
gestation in human offspring, research has primarily focused on the 
neurodevelopmental outcomes of individuals who developed schizophrenia in 
adulthood.   
A birth-cohort study by Ellman et al. (2009), for example, investigated the role of 
serologically determined exposure to influenza during the third trimester of 
gestation on the cognitive performance of children aged 7 years on the Wechsler 
Intelligence Scale for Children (WISC) who later developed a psychotic disorder 
in adulthood. Participants were 111 affected individuals (70 with schizophrenia 
and 41 with affective psychoses) and 333 healthy controls who were enrolled in 
the Collaborative Perinatal Project. Maternal influenza during pregnancy was 
determined by serological immunoglobulin G antibody titers that were above the 
75th percentile. Ellman and colleagues (2009) found that psychotic participants 
who were exposed to influenza in utero showed significantly lower verbal IQ 
index (Cohen’s d = .41; p = .02) and information subtest scores (Cohen’s d = .37; 
p = .04) than did their non-exposed counterparts, as well as non-significant 
reductions in Full Scale IQ, comprehension, vocabulary, digit span and picture 
arrangement scores.  
 A study by Brown et al. (2009) explored the relationship between 
serologically determined pre-natal exposure to influenza (or toxoplasmosis) and 
executive functioning in 26 cases with schizophrenia who were enrolled in the 
Prenatal Determinants of Schizophrenia study (previously described in section 
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2.2.2). Executive functioning was assessed using a variety of neuropsychological 
tests, including the Wisconsin Card Sorting Test (WCST) and Trail Making Tests 
Part B (Trails B). Cases exposed to infection in utero committed significantly 
more total errors on the WCST (p < .001) and took significantly more time to 
complete the Trails B (p = .001). 
The results of the aforementioned studies raise the possibility that fetal exposure 
to influenza may partially explain the occurrence of deficits in language 
acquisition, object-recognition memory and sensory-motor proficiency as well as 
decreased performance on verbal IQ  and executive function tasks during the 
premorbid period of schizophrenia (Bearden et al., 2000; Niendam et al., 2006). 
2.4 Role of Epigenetic Mechanisms in Schizophrenia 
The precise molecular mechanisms underpinning the neurodevelopmental 
model of schizophrenia are unknown. Recently, however, empiricists have begun 
to consider the role of epigenetic processes in schizophrenia. In particular, 
attention is currently being directed toward epigenetic modifications as a result of 
exposure to adverse prenatal events in conferring risk of the later development of 
the disorder. 
 Presently, the term epigenetics refers to mitotically heritable and 
potentially reversible changes to gene expression and function that do not involve 
alterations (mutations, deletions) to the DNA sequence itself (Fazzari & Greally, 
2010). There are several different epigenetic events, including cytosine 
methylation (i.e., DNA methylation), histone deacetylation and chromatin 
modification, ribonucleic acid (RNA) interference and RNA editing (for a review 
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of these mechanisms see Portela & Esteller, 2010). The current research will focus 
on arguably the most characterised and investigated of these, DNA methylation.  
 2.4.1 Nature and function of DNA methylation. 
In humans, DNA methylation typically occurs at the DNA sequence where 
a cytosine base is followed by a guanine base (i.e., CpG dinucleotides/sites) and is 
characterised by the addition of a methyl group at the C5 position of a cytosine 
base in the CpG site sequence (Akabarian, 2010). This action is catalysed by a 
number of different DNA methyltransferases, including DNMT1, DNMT2, 
DNMT3A and DNMT3B which are encoded on chromosomes 19p13.2, 10p.15.1, 
2p23, and 20q11.2, respectively (Grayson & Guidotti, 2013). Despite recognition 
of the enzymes that facilitate methylation at CpG dinucleotides/sites, the exact 
mechanisms that regulate this process (e.g., instruct DNA methyltransferases to 
specific sequences in different cell states) continue to be poorly understood (Roth, 
Lubin, Sodhi, & Kleinman, 2009). 
Recent profiling of CpG site methylation across the genome has revealed 
that methylation frequency is distributed bimodally (Bird, 1985; Stadler et al., 
2011). That is, a large percentage of CpG sites are methylated (high-methylated 
areas), while a smaller number are under-methylated (low-methylated areas). 
Moreover, it appears that the frequency of CpG sites is relatively low compared to 
the number of cytosine and guanine base-pairs that comprise the DNA sequence 
(Stadler et al., 2011). However, within a genomic landscape that is typically 
methylated and depleted of CpG sites, exist stretches of DNA sequence called 
CpG islands that are approximately 1-kb in length and densely populated with 
sites (Du, Han, Guo, & Zhao, 2012). Seventy percent of islands are located within 
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the promoter area of genes (i.e., regions that initiate gene transcription) and, in 
contrast to other gene regions, are thought to be primarily under-methylated. In 
addition to CpG islands, there are north and south shores and shelves, located up 
and downstream from the island, respectively, and defined according to their 
distance (in base pairs) from islands. As depicted in Figure 1, CpG shores lie up to 
2kb on either side of CpG islands, while CpG shelves lie within 2-4kb of islands 
(Sandoval et al., 2011). 
  
 
 
. 
Figure 2. Illustration of a CpG island (CGI) with surrounding CGI shores, CGI 
shelves and non-CGI regions (taken from van Dongen at al., 2014) 
 
In healthy tissue, unmethylated CpG island regions are hypothesised to 
facilitate gene expression by enabling access to transcriptional machinery required 
for optimal gene transcription (Roth et al., 2009). This process is depicted in the 
top line of Figure 2. In specific disease states (e.g., cancer), however, CpG sites in 
island regions have been observed to become aberrantly methylated, interrupting 
the regular transcriptional activity of the gene, as depicted in the bottom line of 
Figure 2.  
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Figure 3. CpG island promoter methylation as a cause of epigenetic dysregulation 
of gene transcription (taken from Fazzari & Greally, 2010) 
 
The top line in Figure 2 depicts an unmethylated state of the promoter region in 
normal tissue, resulting in normal gene transcription. The bottom line shows a 
methylated state of the promoter region, resulting in repressed gene transcription. 
Importantly, this pattern of hypermethylation may not be consistent across all 
CpG sites. Research has reliably demonstrated the role of aberrant DNA 
methylation, in particular the presence of promoter CpG island hypermethylation-
associated silencing of tumor suppressor genes (TSG), in many human cancers 
(Guzman, 2012; Lopez-Serra and Esteller 2012). TSG genes are responsible for 
repressing abnormal cell growth and so when silenced (i.e., switched off), they are 
Promoter region Gene body 
Promoter region Gene body 
- Unmethylated CpG site 
- Methylated CpG site 
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unable to prevent further replication and proliferation of the damaged tissue 
(Esteller, 2002).  
Using the Infinium Human Methylation 450k array (Illumina, Inc. CA, USA), 
Sandoval et al. (2011) explored CpG site methylation changes in colon mucosa of 
patients with colorectal cancer compared to their non-affected counterparts. Of the 
484,968 sites assayed by the researchers, between 17,884 (3%) and 29,784 (6%) 
were differentially methylated between cases and controls, with changes 
corresponding to hypermethylation accounting for between 96 and 97% of sites in 
participants with cancer. Consistent with prior cancer research, CpG site 
hypermethylation in affected cases most commonly occurred in CpG islands (66-
68%; 11,784 and 19,372 CpG sites) and proximal promoters (54-56%; 9,720 and 
15,792 CpG sites; Sandoval et al., 2011). Taken together, 69-71% (6,894 and 
10,843 CpG sites) of the sites that were observed to be differentially 
hypermethylated occurred in proximal promoters which comprised a CpG island 
(Sandoval et al., 2011). In contrast, Sandoval and colleagues (2011) found that 
differentially methylated sites which showed significantly low levels of 
methylation between cases and controls, were typically located in the body of 
genes (38-40%; 253 and 277 CpG sites) and in the Open Sea areas (isolated CpG 
sites in the genome without a specific designation) of the genome (67-70%; 448 
and 483 CpG sites). There were a small number of CpG sites that were observed 
to be significantly hypomethylated in affected cases (1-2%; 165 and 483 CpG 
sites), most of which (61%) were found in non-CpG island-associated promoter 
regions (Sandoval et al., 2011). Exploration of genes associated with the 
aforementioned differentially methylated CpG sites revealed hypermethylation of 
a number of tumor suppressor genes (e.g., SFRP2 and SFRP5) and of the 
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transcription start sites of several mircoRNAs with growth inhibitory functions 
(e.g., miR-124a and miR-34b/c; Sandoval et al., 2011).  
 Empirical findings such as those described by Sandoval et al. (2011) have 
caused researchers to focus their attention on CpG island methylation patterns in 
their attempts to identify epigenetic mechanisms which may mediate the 
relationship between environmental exposures and genetic vulnerability in 
conferring risk of complex disorders like schizophrenia (Ladd-Acosta et al., 
2007).  
 Presently, there are any many different technologies for investigating 
DNA methylation. These include Bisulfite conversion (Gu et al., 2011), 
Methylation-Sensitive Restriction Digestion Array (Bock et al., 2010), High-
performance liquid chromatography (HPLC; Bock et al., 2010) and 
Immunoprecipitation-Based Enrichment Assays (Bock et al., 2012). The current 
research uses the Infinium Human Methylation 450k array (Dedeurwaerder et al., 
2011) which will be discussed in detail in the following section. 
2.4.1.1 Measuring DNA methylation: Infinium Human Methylation 
450k array 
In the current study, epigenetic data from ARIES was produced using the 
Infinium Human Methylation 450K (Infinium Methylation 450K) array. 
Traditional DNA methylation methods, such as bisulfite genomic sequencing, 
provide highly accurate mapping of DNA methylome data at single-base pair 
resolution (Siegmund, 2011).  Bisulfite sequencing allows precise analysis of 
methylation in a certain region by converting all nonmethylated cytosines into 
thymines, while methylated cytosines remain unchanged (Li & Tollefsbol, 2011). 
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This method allows all methylated CpGs to be distinguished from unmethylated 
CpGs by presence of a cytosine "C" versus thymine "T" residue during 
epigenomic sequencing (Li & Tollefsbol, 2011). Single-base pair resolution refers 
to the methylation status of the specific nucleotide bases which form the double 
helix structure of DNA.  While such an approach can allow for a comprehensive 
assessment of a small number of samples (Dedeurwaerder et al., 2011), it is 
unsuitable for biomarker research akin to the current study that aims to investigate 
DNA methylation across the genome.  Such research requires the analysis of 
thousands of samples in a cost-effective way. For detailed information regarding 
the contents and applicability of the HM450 arrayarray, refer to papers by 
Bibikova et al. (2011) and Dedeurwaerder et al. (2011). 
The HM450 array constitutes a major extension of the previous Infinium 
HumanMethylation27 BeadChip (Infinium Methylation 27K) (Illumina, Inc. CA, 
USA). This upgraded technology is a hybrid of two different chemical assays, the 
Infinium I and Infinium II assays, allowing assessment of the methylation status 
of more than 480,000 methylated cytosines distributed over the entire genome 
(Dedeurwaerder et al., 2011). To detect the methylation status at individual CpG 
loci, the Illumina Infinium assay relies on hybridization of bisulfite-converted 
DNA fragments to bead-bound probes (Bibikova et al., 2011). Two probe types 
exist on the array, Infinium I and Infinium II. Infinium I type probes interrogate 
the methylation status of a CpG using the ratio between two probes that hybridize 
either the methylated or unmethylated DNA template flanking the CpG of interest 
(Bibikova et al., 2011). In addition, the assays can evaluate the methylation status 
of CpG-poor regions, such as CpG island shores and shelves, which are more 
prone to alter their DNA-methylation status in response to environmental 
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exposures such as maternal influenza during pregnancy (Irizarry et al., 2009). 
Furthermore, analysis of the results is relatively straightforward and, compared 
with sequencing-based DNA methylation analysis, does not require adjustment for 
CpG density or bioinformatic calculations that are costly and time-consuming 
(Dedeurwaerder et al., 2011). Finally, results produced by the HM450 arrayhave 
been found to be accurate, correlating highly with reduced representation bisulfite 
sequencing.  For example, Sandoval et al. (2011) applied the HM450 array to 
evaluate DNA methylation in normal lung tissue and tumour lung DNA samples 
and compared these results with whole-genome bisulfite sequencing (WGBS) data 
obtained for the same samples.  Extremely high correlations (average R2 = 0.95) 
were found between the methylation beta-values generated by the array and 
sequencing methods.  
2.4.2 An epigenetic framework for the neurodevelopmental model of 
schizophrenia. 
Empirical evidence points to the contributions of both genetic and 
environmental risk factors in the development of schizophrenia. Moreover, it 
seems that the aetiology of the disorder reflects a disruption, both inherited and 
acquired, of DNA sequence-independent processes controlling gene expression.  
For this reason, a number of prominent researchers, including Akbarian (2010), 
Gavin and Floreani (2014) and Milan (2013), have proposed that schizophrenia 
may, in fact, be an epigenetic disorder with neurodevelopmental origins. More 
specifically, they argue that brain anomalies observed in people with 
schizophrenia may have come about as a result of epigenetic mechanisms which 
occurred during gestation and were characterised by altered gene expression 
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following exposure to adverse environmental events (e.g., exposure to maternal 
influenza/diabetes).  
Preclinical evidence that epigenetic processes are altered in schizophrenia 
has come from a variety of research paradigms using rodents. Of particular 
interest are studies which showed that the prenatal exposure of mice offspring to 
stress during gestation resulted in significant reductions in metabotropic glutamate 
receptors (e.g., mGluR2 and mGluR3) in the offspring’s frontal cortex and 
hippocampus that were paralleled by increased expression and binding of DNMT1 
to CpG-enriched mGluR2 and mGluR3 promoters. The reduction in mGluR2 and 
mGluR3 promoters led, in turn, to down-regulation of glutamate in the 
aforementioned brain areas and subsequent anomalies in the maturation and 
proliferation of excitatory synaptic connections, as well as impaired neuronal 
connectivity (Guidotti et al., 2011; Matrisciano, Dong, Gavin, Nicoletti, & 
Guidotti, 2011).  Using a similar research paradigm, Matrisciano et al. (2013) 
observed reduced expression of the 67-kDA isoform of glutamate decarboxylase 
(GAD67), a key enzyme in gamma-aminobutyric acid (GABA) synthesis as well 
as the down-regulation of glutamate, in the cortex and hippocampus of exposed 
mice compared to their non-exposed counterparts. Further, reduced expression of 
GABA has been consistently found in animal models exploring the impact of 
prenatal exposure to viral infection on cortical development (Gonzalez-Burgos et 
al., 2010; Meyer & Feldon, 2010; Millan et al., 2012; Pratt, Winchester, Dawson, 
& Morris, 2012).  
Comparable findings have been found in the brains of people with 
schizophrenia. Volk, Austin, Pierri, Sampson and Lewis (2014) explored 
alterations in GABA transmission in post-mortem brain tissue of 10 patients with 
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schizophrenia and 10 age-matched controls. The researchers observed the mean 
density of neurons expressing the GABA membrane transporter 1 (GAT-1) to be 
significantly lower (21-33%) in the prefrontal cortex of schizophrenia patients 
than in healthy controls, a finding that was independent of the effects of anti-
psychotic medication on neurotransmitter functioning. In addition, research 
investigating altered GABA signaling in neocortical circuits in schizophrenia have 
consistently found reduced expression of GAD67 in post-mortem brain tissue of 
the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex, anterior cingulate 
cortex, primary motor cortex and primary visual cortex, in affected individuals 
compared to healthy controls (Akbarian et al., 1995; Thompson, Weickert, Wyatt, 
& Webster, 2009; Volk, Austin, Pierri, Sampson, & Lewis, 2000; Woo, Kim, & 
Viscidi, 2008). In fact, in a recent review of cortical GABA neurons and network 
oscillations in schizophrenia, authors Gonzalez-Burgos, Hashimoto and Lewis 
(2011) concluded that the reduced expression of GAD67 in cortical brain areas 
implicated in the pathophysiology of the disorder (e.g., DLPFC ) continues to 
rank as one of the most consistently and widely replicated findings in 
schizophrenia research.  
 According to Lewis, Hashimoto and Volk (2005), reductions in GABA in 
the prefrontal cortex may underlie some of the cognitive deficits, in particular 
working memory, observed in individuals with schizophrenia and, to a lesser 
degree, their non-affected siblings. Working memory belongs to a set of cognitive 
functions which involve executive control and depend on the DLPFC (Miller & 
Cohen, 2001). People with schizophrenia tend to perform poorly on working 
memory tasks and to exhibit reduced efficiency of the DLPFC when attempting to 
carry out such tasks (Potkin et al., 2009). Although other neurotransmitter systems 
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are involved, the DLPFC comprises pyramidal neurons which use GABA to 
synchronise neuronal activity during working memory processes (Lewis, Volk, & 
Hashimoto, 2004). In animal models, for example, the injection of GABA 
antagonists into the DLPFC has been shown to disrupt working memory on 
delayed response tasks (Lewis, & Gonzalez-Burgos, 2006). The fact that working 
memory deficits in people with schizophrenia tend to occur prior to the onset of 
the disorder and are observed in unaffected relatives suggests that disruption to 
GABA neurotransmitter systems may occur early in development, during 
gestation, and are not directly caused by treatment with antipsychotic medication 
or the disease process itself. 
 Finally, reduced levels of Reelin (RELN), due to epigenetic 
hypermethylation of RELN promoters, have consistently been found in the brains 
of individuals with schizophrenia, particularly in Cortical Layers I and II, regions 
of the brain where overexpression of DNA methyltransferases DNMT1 and 
DNMT3A is most pronounced (Abdolmaleky et al., 2005; Guidotti et al., 2011).  
RELN encodes a protein that is necessary for neuronal migration, axonal 
branching, synaptogenesis and cell signalling (Dong et al., 2005). Fatemi et al. 
(1999) found that mice exposed to the human influenza virus during gestation 
exhibited significant reductions in RELN in Cortical Layer 1 of the neocortex as 
well as other cortical and hippocampal layers, associated with neuronal migration 
anomalies, compared to healthy, non-exposed mice. Further, Brosda, Dietz and 
Koch (2011) investigated the cognitive performance of RELN knockdown in the 
medial prefrontal cortex of rats and found that those injected with RELN antisense 
phosphothioate oligonucleotides showed significant impairments in prepulse 
inhibition, spatial working memory and object recognition compared to healthy 
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controls. Brosda and colleagues (2011), as well as Knuesel (2010), Levenson et al. 
(2008) and Papaleo et al (2012), argue that, comparable to deficits in GABAergic 
transmission, epigenetic modifications to RELN signalling during gestation may 
be a contributing factor to cognitive deficits in schizophrenia. 
 In summary, an epigenetic perspective on the neurodevelopmental model 
of schizophrenia suggests that the disorder may result from a complex interplay of 
developmentally regulated genetic and environmental risk factors. More 
specifically, as depicted in Figure 3, exposure of the fetus to adverse 
environmental factors such as maternal diabetes and influenza may disrupt 
epigenetic control of gene expression, which is required for brain growth and 
development. The consequences of this environment-triggered epigenetic 
disruption may endure in the form of cognitive deficits and other premorbid 
indicators of schizophrenia and increase the risk of the disorder in adolescence.
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Chapter 3 
 
Review of Empirical Literature on the Role of DNA methylation 
in Schizophrenia 
The following literature review aims to synthesise previous empirical literature on 
the role of DNA methylation in schizophrenia. To date, reviews in this area have 
been broad in scope, summarising data from empirical studies exploring 
differential methylation in a variety of tissues (e.g., post-mortem, whole blood 
leukocytes) in individuals with both affective and non-affective psychoses. In 
contrast, the current synthesis will focus exclusively on studies which explore 
methylomic variation in the peripheral blood leukocytes of participants with (i.e., 
cases) and without (i.e., controls) schizophrenia.  
3.1 Search Strategy 
An electronic literature search of all potentially important articles was 
conducted via eight electronic databases (Academic Search Complete, Medline, 
PsycARTICLES, PsycINFO, Pubmed, Science Direct, Scopus and Web of 
Science) to identify empirical studies that met the predetermined selection criteria 
(see Section 3.2). These databases were searched up until November 2014, with 
no timeframe specified for date of publication. An initial search was conducted in 
each of the databases using the key identifier DNA methylation and subheadings 
epigenetics, epigenome-wide association studies, 450k array, separated by 
“AND.” The results of the initial search were then combined with the following 
identifiers using “OR”: post-mortem tissue, whole blood, umbilical cord blood, 
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peripheral leukocytes, peripheral biomarkers, psychotic symptoms, psychosis and 
schizophrenia (see Appendix C for full search details). Abstracts were reviewed 
and all full-text articles that met the predetermined selection criteria were 
retrieved.  
3.2 Selection Criteria 
Articles were included if they met the following criteria: (1) had investigated 
DNA methylation of cytosine residues in CpG dinucleotides; (2) had explored 
DNA methylation profiles in peripheral blood leukocytes; (3) had involved 
participants with a diagnosis of schizophrenia and (4) had employed either a 
global (quantifying DNA methylation of cytosine across the genome, resulting in 
the provision of an average value for a given study participant) or individual CpG 
site approach to test differences in DNA methylation between cases and controls. 
When a study investigated differential methylation of candidate genes previously 
associated with schizophrenia, it was excluded from the review. This is because 
studies which explore the role of putative risk genes in schizophrenia generally 
adopt an a priori approach when selecting specific genes to investigate and so are 
not in keeping with the agnostic stance of the current review and thesis.  
Also omitted were data on methylomic variation in post-mortem brain tissue from 
deceased individuals with schizophrenia and their non-psychotic counterparts, as 
the current review aims to summarise methylation data only from peripheral blood 
leukocyte tissue.  
3.3 Results 
Seven articles, one covering two discrete studies, fulfilled the selection 
criteria (refer to Figure 1 for specific details).  
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Figure 5. Study flow diagram for the articles included in the literature review 
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Articles were grouped according to the two approaches that were used to explore 
the methylation status of peripheral blood leukocytes in cases and controls. These 
approaches entailed the measurement of: (1) global (i.e., average) DNA 
methylation of CpG sites across the genome and (2) DNA methylation of 
individual CpG sites across the genome. A brief description of each 
methodological approach is provided prior to a review of the relevant literature. 
 Even within the two approaches, there was diversity across studies with 
respect to the assay technologies and statistical approaches used by the authors to 
quantity DNA methylation in participants’ peripheral blood tissue. Consequently, 
rather than apply meta-analytical methods to the data, the studies’ findings will be 
presented in the form of a structured narrative synthesis.  
3.3.1 Global DNA methylation in peripheral blood leukocytes. 
Three of the eight studies explored the role of global DNA methylation in 
the peripheral blood leukocytes of participants with schizophrenia (see Table 2) .  
A study by Shimabukuro et al. (2007) sought to examine whether global 
DNA methylation differences existed in the peripheral blood leukocytes of 
participants with and without schizophrenia. Study participants were Japanese and 
comprised 210 cases (124 males and 86 females) who met the Diagnostic 
Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnostic criteria 
for schizophrenia and 237 non-psychotic controls (108 males and 129 females). 
Cases were enrolled from inpatient and outpatient wards located in various 
psychiatric hospitals throughout Japan, whilst controls were recruited primarily 
via hospital staff members and included their parents, siblings and offspring. Prior 
to their enrolment, controls were assessed by hospital psychiatrists to rule out the 
presence of any existing psychiatric diagnoses. Global DNA methylation was 
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assessed by measuring the amount of methylated deoxycytidine (mC) in 
peripheral leukocytes by way of high-performance liquid chromatography 
(HPLC). Generally speaking, DNA methylation in humans occurs at CpG sites 
where DNA methyltransferase enzymes convert cytosine to mC. The HPLC 
technology provides an approximation of the average percentage of mC across a 
given genome (Armstrong et al., 2011), whereby the lower the percentage of mC, 
the lower the levels of overall global DNA methylation and vice versa.  
To evaluate the relationship between schizophrenia and global methylation 
status (i.e., % of mC in peripheral leukocytes), Shimabukuro and colleagues 
(2007) employed a multiple linear regression model with global methylation 
status as the outcome variable and clinical diagnosis and sex of the participant as 
the primary predictor variables. As global DNA methylation in human peripheral 
blood is known to decrease with age (Bollati et al., 2009; Gomes et al., 2012), this 
was also entered into the model as a control variable. Despite not reaching 
statistical significance, a trend toward global DNA hypomethylation in males with 
schizophrenia was observed (b = -.12, t [230] = -1.79 p = .075). More specifically, 
male participants with schizophrenia showed global DNA methylation levels that 
were .12% lower than their male non-psychotic counterparts. The effect of age 
was statistically significant (b = -.21 t [230] = -3.30, p = .001), with this trend 
more pronounced in younger male cases. In contrast, the authors reported no 
association between schizophrenia diagnosis and mC content in the peripheral 
leukocytes of female cases with schizophrenia. As prophylactic treatment has 
been shown to influence the epigenome (e.g., Mill et al., 2008), the results of the 
study by Shimabukuro et al. (2007) are limited by the possible confounding 
effects of participants’ use of anti-psychotic medications. 
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The second study sought to explore the presence of global DNA 
methylation differences between cases with schizophrenia and healthy controls 
using white blood leukocytes (Melas et al., 2012). Participants were 177 
individuals diagnosed with schizophrenia (87 males and 90 females) recruited 
from the Swedish Study of Metabolic Risks in Psychosis and 171 anonymous 
blood donors from the Karolinska University Hospital in Stockholm as controls. 
General characteristics of controls known to the researchers included an age range 
between 18 and 70 years and the absence of blood-borne viruses (e.g., syphilis, 
human immunodeficiency virus and hepatitis B and C), illness and intravenous 
drug use at the time of their donation. However, no identifiable data were 
available for blood donor participants and so cases and controls were not matched 
on any socio-demographic variables. Diagnoses were made by the individual’s 
treating psychiatrists during routine outpatient care and all participants met a 
clinical diagnosis of schizophrenia according to the DSM-IV criteria. Global 
DNA methylation data was measured using the luminometric methylation assay 
(LUMA) and detecting methylation differences within CCGG sites across a given 
genome and quantifying the relative amount of DNA methylation as a ratio 
between 0 and 1; the higher the ratio, the lower the amount of methylation 
(Karimi, Luttropp, & Ekström, 2011). The authors found that DNA methylation 
levels at CCGG sites in white blood leukocytes across the genome were 
significantly lower in schizophrenia cases than in their non-psychotic 
counterparts, reflecting hypomethylation (p < .001). 
To further investigate this relationship, Melas and colleagues (2012) 
performed a stepwise linear regression to explore global DNA methylation in 
individuals with schizophrenia with respect to key clinical characteristics, 
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including sex, disease onset and anti-psychotic medication. Information regarding 
these predictors was obtained from the medical records of participants. The 
inclusion of both anti-psychotic medication and disease onset explained 11% of 
the global DNA methylation variance in the patient group (R2 = .11, F = [1, 346], 
p < .001). More specifically, cases treated with haloperidol showed significantly 
higher levels of global DNA methylation compared to cases treated with other 
anti-psychotic medications (b =.03, t [127] = 3.55, p =.001). Additionally, global 
hypomethylation was significantly more pronounced in participants with early-
onset schizophrenia (i.e., ≤ 18 years of age) compared to those with late-onset 
schizophrenia (b = -.25, t [170] = -3.09, p =.002).  
Despite significant findings, the Melas et al. (2012) study is limited by the 
use of the LUMA platform, which only identifies methylation differences within 
CCGG as these sites do not cover all CpG sites (estimated to cover only 8%). 
Furthermore, these sites are not uniformly distributed within the genome 
(Iwamoto et al., 2011; Karimi, Johansson, & Ekstrm, 2006).  
  Exploring any potential association between first-episode schizophrenia 
and global DNA methylation in peripheral blood leukocytes, Nishioka et al. 
(2013) conducted a study of 17 cases of patients with schizophrenia (10 males and 
7 females) and 15 healthy age-matched controls (10 males and 5 females). 
Participants were individuals from Tokyo Hospital who met the diagnostic criteria 
for a first episode of acute psychosis and schizophrenia according to the 
Structured Interview for Prodromal Symptoms and DSM-IV, respectively. 
Individuals who had been treated with anti-psychotic medication for longer than 
six months were not eligible to participate. DNA methylation profiles for the 32 
participants were obtained using the InfiniumMethylation27 BeadChip Kit. This 
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array platform provides data on the methylation status of approximately 27,578 
individual CpG sites (Bibikova et al., 2009). Global DNA methylation status for 
each participant was represented as an average of all beta values across the 27,578 
sites.  
To test for an association between first-episode schizophrenia and global 
DNA methylation, Nishioka and colleagues (2013) showed global DNA 
methylation levels of first-episode schizophrenia to be lower than those of healthy 
controls (p < .001) by a mean difference between participants in terms of an 
average beta value, was .01. The authors also sought to test differences in global 
DNA methylation between cases and controls in terms of CpG loci located within 
and outside CpG islands. Global DNA methylation within CpG islands was 
significantly lower for cases with first-episode schizophrenia than it was for 
healthy controls (p = < .001), with an observed mean beta value difference of 
.008. In contrast, global DNA methylation values for CpG sites outside CpG 
islands were not statistically different between the two groups. While this study 
has only a small sample size may be confounded by possible effects of anti-
psychotic medication on participants’ global DNA methylation status, its 
represents an important pilot study suggesting lower global DNA methylation can 
be discerned in peripheral blood markers, at least in first-episode schizophrenia. 
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Table 2. Descriptive information and results of studies investigating the role of DNA methylation in schizophrenia 
Author (year) Number of 
participants (sex) 
Psychiatric status of 
participants 
Methodological 
approach 
Tissue 
investigated 
DNA methylation 
assay method 
Gene ontology/ 
expression method 
Main findings 
Shimabukuro 
et al. (2007) 
210 = Schizophrenia 
cases 
(124 males & 86 
females) 
237 = Non-
psychotic controls 
(108 males & 129 
females) 
Cases were 
psychiatric inpatients 
& outpatients who had 
a pre-existing 
diagnosis of 
Schizophrenia 
according to the 
DSM-IVa  
GDNAmb PBLc High-performance 
liquid 
chromatography 
(HPLC) 
Nil Trend toward lower levels of global 
DNAm (hypomethylation) in male 
cases with schizophrenia (b = -.12, t 
[230] = -1.79, p = .75) 
 
Global hypomethylation was 
significantly more pronounced in 
younger male cases  (b = -.21, t [230] 
= -3.30, p = .001) 
Melas et al. 
(2009) 
177 = Schizophrenia 
cases 
(87 males & 90 
females) 
171 = Anonymous 
blood donor controls 
Cases were recruited 
from the Swedish 
Study of Metabolic 
Risks in Psychosis 
and met the diagnostic 
criteria for 
schizophrenia 
according to the 
DSM-IV. 
GDNAm PWBLd Luminometric 
methylation assay 
(LUMA) 
Nil DNAm at CCGG sites across the 
genome were significantly lower in 
schizophrenia cases than in controls 
(Mann Whitney U, p < .001 
 
Anti-psychotic medication and disease 
onset explained 11% of the global 
DNAm variance in cases group  
(R2 =.11, F [1, 346], p < .001). 
Nishioka et 
al. (2013) 
17 = Schizophrenia 
cases 
Cases met the 
diagnostic criteria for 
a first-episode of 
GDNAm PBL InfiniumMethylati
on 27 BeadChip 
Kit 
Nil Global DNAm in cases was 
significantly lower than in healthy 
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(10 males & 7 
females) 
15 = Age-matched 
controls (108 males 
& 129 females) 
schizophrenia 
according to the 
Structured Interview 
for Prodromal 
Symptoms and DSM-
IV; cases who had 
taken anti-psychotic 
medication for > 6 
months were 
ineligible. 
controls (MD beta value = .01, p < 
.001). 
 
Global DNAm within CpG islands 
was significantly lower for cases than 
it was for healthy controls (MD beta 
value = .008, p < .001). 
Nishioka et 
al. (2013)e 
17 = Schizophrenia 
cases 
(10 males & 7 
females) 
15 = Healthy age-
matched controls 
(108 males & 129 
females) 
Cases met the 
diagnostic criteria for 
a first-episode of 
schizophrenia 
according to the 
Structured Interview 
for Prodromal 
Symptoms and DSM-
IV; cases who had 
taken anti-psychotic 
medication for > 6 
months were 
ineligible. 
IDNAmf PBL InfiniumMethylati
on 27 BeadChip 
Kit 
Nil 603 CpG sites were significantly 
hypomethylated in cases compared to 
controls at a False Discovery Rate 
(FDR)-adjusted p value of < .001. 
 
In schizophrenia cases: 
*Site cg02399449, in close proximity 
to gene CLDN12, was negatively 
correlated with the duration of 
untreated psychosis (r [30] = -.60, p < 
.05) 
*Site cg03859282, in close proximity 
to gene ANKH,  was negatively 
correlated with total positive and 
negative syndrome scale (PANSS) 
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score (r [30] = -.53, p < .05) and 
positively correlated with global 
assessment of functioning score (r [30] 
=.51, p < .05) 
*Site cg197478852, in close proximity 
to gene TRA2A was negatively 
correlated with total PANSS score (r 
[30] = -.61, p < .05) and positively 
correlated with age at disease onset (r 
[30] =.59, p < .05). 
Liu et al. 
(2013) 
98 = Schizophrenia 
cases 
(73 males & 25 
females) 
108 = Healthy 
controls (70 males 
& 38 females) 
Cases were recruited 
from the Mind 
Clinical Imagining 
Consortium and met a 
clinical diagnosis of 
schizophrenia 
according to either 
DSM-IV or the 
Comprehensive 
Assessment of 
Symptoms and 
History 
IDNAm PBL InfiniumMethylati
on 27 BeadChip 
Kit 
A public GEO data, 
GSE38484, was used for 
verification of gene 
expression changes.  
Data included gene 
expression profiles in 
PBL of 106 schizophrenia 
cases and 96 controls. 
 
 
 
 
 
 
 
Of 7562 autosomal probes, 16 CpG 
sites were differentially methylated 
between cases and controls at p < 
.0001. 
These were: cg11939496 (CD44), 
cg12022621 (LAX1), cg09039163 
(ESPNL), cg20981615 (TXK), 
cg09914304 (PRF1), cg06806711 
MS4A1, cg20018806 (TCN1), 
cg21917349 (APBA2), cg09830866 
(FAM173A), cg13745346 
(CBFA2T3), cg16003913 (MPG), 
cg02473123 (CD7), cg04988978 
(MPO), cg07845392 (SLC25A10), 
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 cg19154438 (CKM), cg07141002 
(H1F0). 
 
In schizophrenia cases: 
Gene expression analyses showed 
upregulation of genes CD244, LAX1, 
PRF1, FAM173A CBFA2T3 & CD7 
and downregulation of TCN1. 
Kinsohita et 
al. (2014) 
63 = Schizophrenia 
cases 
(50 males & 13 
females) 
42 = Healthy 
controls  
(25 males & 17 
females) 
Cases were 
psychiatric inpatients 
& outpatients who had 
a pre-existing 
diagnosis of 
Schizophrenia 
according to the 
DSM-IV. 
IDNAm PBL InfiniumMethylati
on450 array 
Gene-ontology analysis 
was performed using the 
Database for Annotation, 
Visualization and 
Integrated Discovery 
(DAVID). 
  
After adjusting for estimated cell-type 
proportions, 2,552 CpG sites were 
differentially methylated between 
cases and controls at an FDR-adjusted 
p < .05.  
Of these, 1,607 sites (63%) were 
hypermethylated and 945 sites (37%) 
were hypomethylated in cases 
compared to healthy controls. 
 
1,491 sites (58.4%) were located in 
CpG islands, 432 sites (16.9%) in CpG 
shores and 209 (8.2%) in CpG shelves. 
 
Gene-ontology analysis showed that 
the majority of the top-10 ranked 
significant CpG sites were located in 
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close proximity to genes responsible 
for gene transcription. 
Kinoshita et 
al. (2013) 
24 = Medication-
free schizophrenia 
cases 
(11 males & 13 
females) 
23 = Non-psychotic 
healthy controls  
(10 males & 13 
females) 
Cases were 
psychiatric inpatients 
& outpatients who had 
a pre-existing 
diagnosis of 
Schizophrenia 
according to the 
DSM-IV. 
IDNAm PBL InfiniumMethylati
on450 array 
 
 
 
10,747 CpG sites were differentially 
methylated between cases and 
controls. 
 
These sites were compared to the 
findings of an IDNAm epigenome-
wide analysis of three male 
monozygotic twin pairs that were 
discordant for schizophrenia. Of the 
initial 10,747 sites, 234 were found to 
be differentially-methylated in both 
samples, with 215 sites (92.4%) 
showing hypermethylation and 19 sites 
(7.6%) showing hypomethylation in 
cases. 
 
95 sites (40.6%) were located in CpG 
islands, 31 sites (3.3%) in CpG shores 
and 27 sites (11.5%) in CpG shelves. 
Aberg et al. 
(2014) 
759 = Schizophrenia 
cases (417 males & 
342 females) 
Cases were selected 
from the Swedish 
Hospital Discharge 
register. Inclusion 
IDNAm PBL MethylMiner 
(Invitrogen) 
protocol 
 
ConsensusPathDB was 
used to generate protein-
protein interaction (PPI) 
networks and perform 
139 CpG sites were differentially 
methylated between cases and control 
at an FDR-adjusted p < .01, with 112 
of the 139 sites (80.6%) found to be 
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738 = Non-
psychotic healthy 
controls  
(399 males & 399 
females) 
criteria included an 
existing diagnosis of 
schizophrenia and at 
least two instances of 
inpatient treatment. 
 
 
 
 
pathway analyses based 
on the Reactome, Kyoto 
Encyclopedia of Genes 
and Genome and Biocarta 
databases. 
 
located within close proximity of 112 
genes. 
 
Network analysis showed the 
functional significance of these 112 
genes to be associated with hypoxia 
and the human immune response. 
aDiagnostic Statistical Manual of Mental Disorders – 4th Edition 
bGlobal DNAm 
cPeripheral Blood Leukocytes 
dPeripheral White Blood Leukocytes 
eNishioka et al. (2013) conducted both global DNAm and individual CpG site DNAm analyses using the same participant sample, human tissue and assay technology 
fIndividual CpG site DNAm 
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3.3.2 Individual CpG site DNA methylation in peripheral blood 
leukocytes. 
Whilst the global DNA methylation approach used by the studies 
described in the previous section is useful for comparing average methylomic 
profiles between disease and non-disease groups, it does not provide information 
about the status of individual CpG sites which would be useful in terms of 
identifying the biological systems involved. The five studies outlined in the 
following section explore the role of differential DNA methylation of individual 
CpG loci, and associated gene expression, in schizophrenia (see Table 2). 
Using the same participant sample (i.e., 32 Japanese participants: 17 
individuals with schizophrenia and 15 healthy individuals), Nishioka et al. (2013) 
sought to explore the role of first-episode schizophrenia in the DNA methylation 
status of individual CpG sites. To analyse the methylation data, the authors used 
Significance Analysis of Microarray (SAM) software. Results showed that 603 
CpG sites had significantly different DNA methylation levels between first-
episode schizophrenia cases and healthy controls at a False Discovery Rate 
(FDR)-adjusted p value of < .001 (refer to Chapter 8 for full details regarding this 
adjustment method). Interestingly, all these CpG sites were observed to be 
hypomethylated in cases as compared to non-affected controls. This finding was 
confirmed by a cluster analysis further assessing the DNA methylation status of 
the identified 603 sites, which clearly discriminated between cases and controls. 
In terms of genomic location, 581 (96.4%) of these loci were situated within CpG 
islands and 22 (3.6%) were situated outside CpG islands. In addition, compared to 
the overall distribution of CpG sites, these differential sites were found to be 
significantly enriched within CpG islands, indicating significant hypomethylation 
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of these regions in first-episode schizophrenia cases (χ2 [1] = 169.91, p < .001). 
Further exploration revealed that these 603 differentially-methylated sites were 
located within close proximity of the transcription start sites of 589 distinct genes.  
A series of regression models was also run by Nishioka et al. (2013)  to 
explore the relationship between known clinical indicators of schizophrenia (e.g., 
duration of untreated psychosis and age at disease onset) and DNA methylation of 
the 603 SAM-identified CpG loci. A top-ranked site cg02399449, located in a 
promoter region and within close proximity of the transcription start site (TSS) of 
the Claudin12 gene, was negatively correlated with the duration of untreated 
psychosis (r [30] = -.60, p < .05). Additionally, hypomethylation of site 
cg03859282, found within a north shore region and close proximity of the TSS of 
gene ANKH Inorganic Pyrophosphate Transport Regulator (a putative 
schizophrenia candidate gene), was found to be negatively correlated with total 
positive and negative syndrome scale (PANSS) score (r [30] = -.53, p < .05) and 
positively correlated with global assessment of functioning score (r [30] = .51, p < 
.05). Finally, site cg19747852, located in a promoter-associated island region and 
near the TSS of gene Transformer-2 protein homolog alpha, was found to be 
negatively correlated with total PANSS score (r [30] = -.61, p < .05) and 
positively correlated with age at disease onset (r [30] = .59, p < .05). Even though 
these findings were statistically robust, the methylation differences between cases 
and controls across these 603 loci were relatively small (i.e., an average beta value 
difference of .06). Hence, the authors were cautious about drawing conclusions 
regarding the functional significance of their findings. Moreover, for the reported 
findings to be (thoroughly) validated studies with larger cohorts and replication 
are required.  
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In a recent study, Liu et al. (2013) sought to explore: (1) the relationship 
between schizophrenia and DNA methylation levels of individual CpG sites 
across the genome using peripheral blood leukocytes, and (2) any potential 
association between altered methylation patterns and the clinical symptoms of the 
disorder. Participants were 98 individuals diagnosed with schizophrenia (73 males 
and 25 females) and 108 non-psychotic controls (70 males and 38 females) 
recruited from the Mind Clinical Imaging Consortium (MCIC), a multi-
institutional study of first-episode and chronic schizophrenia cases. Cases met a 
clinical diagnosis of schizophrenia according to either the DSM-IV or the 
Comprehensive Assessment of Symptoms and History (CASH). The nature and 
severity of clinical symptoms were assessed using the Scale of the Assessment of 
Positive Symptoms (SAPS) and the Scale of the Assessment of Negative 
Symptoms (SANS).  Controls had been screened prior to their inclusion in the 
MCIC, to ensure that they were free from any medical, neurological or psychiatric 
illnesses, including any history of substance misuse.  
As with Nishioka et al. (2013), the authors used the Illumina Infinium 
Methylation27 platform to obtain DNA methylation data. They then selected 7562 
variable probes in autosomes (i.e., chromosomes that are not sex-chromosomes) 
to use as the dependent variable in the association analyses. Variable probes were 
defined by calculating the mean of the standard deviation (SD) of beta values for 
all probes, then selecting those with SDs larger than the mean SD value (for a 
similar method, see Dempster et al., 2011). With respect to potential confounders, 
significantly more African-Americans were enrolled as cases than as controls. As 
previous studies had identified age (Bocklandt et al., 2011; Christensen et al., 
2009), sex (Liu, Morgan, Hutchinson & Calhoun, 2010), ethnicity (Liu et al., 
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2010), alcohol consumption (Philibert, Plume, Gibbons, Brody, & Beach, 2012), 
smoking (Breitling, Yang, Korn, Burwinkel, & Brenner, 2011) and cannabis use 
(van der Knaap et al., 2014) as variables that can impact upon DNA methylation, 
they were controlled for in all analyses in this study.  
To examine the effect of Schizoprehenia on epigenome-wide DNA 
methylation, Liu et al. (2013) applied a linear regression model to each of the 
7562 chosen variable probes. After controlling for possible confounders, they 
found 20 CpG sites to be significantly associated with the disorder at a p value of 
< .0001 and an absolute DNA methylation difference of greater than .02 between 
cases and controls. While not strictly a Bonferroni correction, according to 
Dempster et al. (2011), these criteria provide a balanced control for false-positive 
and false-negative results. To test the validity of the results, the authors also 
compared their findings to DNA methylation profiles in the peripheral blood of 
325 schizophrenia cases and 394 healthy controls, measured using the same 
Illumina Infinium Methylation27 assay and stored in the public Gene Expression 
Omnibus database (GEO) for public usage. Following validation testing, 16 of the 
20 disease-associated sites were identified as reflecting true methylation 
differences between affected cases and healthy controls. 
Liu et al. (2013) also explored gene expression changes associated with 
the 16 differentially-methylated CpG loci using a second GEO database called 
GSE38484. From this, seven genes were observed to show clear expression 
changes in cases with schizophrenia at a p value of < .05, including the 
upregulation of CD244, LAX1, PRF1, FAM173A, CBA2T3 and CD7, and the 
downregulation of TCN1 (see Abbreviation list for full gene names). Of the 16 
sites, none was correlated with disorganised or negative symptoms. Conversely, 
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one hypomethylated CpG site was found to be significantly negatively correlated 
with reality distortions: cg11939496 (r [204] = -.26, p < .001) and three 
hypomethylated CpG loci were positively correlated with reality distortions: 
cg20018806 (r [204] = .22, p = 003), cg13745346 (r [204] = .27, p = 001), 
cg16003913 (r [204] = .31, p < .001). Moreover, reality distortions were also 
significantly negatively correlated with the following seven hypermethylated CpG 
loci: cg12022621 (r [204] = -.26, p = 001), cg20981615 (r [204] = -.36, p = 
<.001), cg09914304 (r [204] = -.20, p = .004), cg21917349 (r [204] = -.27, p = 
.001), cg09830866 (r [204] = -.31, p = <.001), cg02473123 (r [204] = -.22, p = 
.003) and cg19154438 (r [204] = -.21, p = .004).Finally, Liu et al. (2013) 
conducted an interactive pathway analysis of the 16 disease-associated CpG loci, 
which revealed genes involved directly in immunologic processes, including 
activation of lymphocytes (CD244, CD7, LAX1 and PRF1), activation of T cells 
(CD7, LAX1, PRF1 and TXK), activation of natural killer cells (CD244 and 
PRF1), activation of B cells (LAX1) and differentiation of granulocytes 
(CBA2T3).  
In terms of limitations, the DNA methylation values obtained from whole 
blood represent a combination of several leukocytes and this may have partially 
confounded the results.  
Taking into the account the potential confounding effects of leukocyte 
subtypes, Kinsohita et al. (2014) sought to explore associations between genome-
wide DNA methylation and schizophrenia in peripheral blood cells, after 
adjusting for different cell-type proportions. Participants were 63 cases with 
schizophrenia (50 males and 13 females) and 42 non-psychotic controls (25 males 
and 17 females) recruited from Tokushima and Kochi University hospitals. Cases 
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met the DSM-IV criteria for schizophrenia according to at least two hospital 
psychiatrists, and all were being treated with anti-psychotic medication at the time 
of their participation in the study. Non-psychotic controls were recruited from 
hospital staff and students and were documented to be free from past and present 
psychiatric diagnoses and medications.  
DNA methylation profiles were obtained using the Illumina 
InfiniumMethylation450 array, which essentially assays the methylation status of 
485,764 CpG sites distributed across the whole genome, including promoter, gene 
body and 3′-untranslated regions (UTRs). These sites also cover 96% of CpG 
island regions, along with additional coverage in both CpG shore (0-2kb from 
islands) and shelf (2-4kb from islands) regions. Cell-type proportions (CD4+T 
cell, CD8 + T cell, CD56 + NK cell, CD19 + B cell, CD14 + Monocyte and 
Granulocyte) for each of the samples were approximated using the R-statistical 
package Minfi. A series of t tests revealed that four of these six cell types (CD4+T 
cell, CD8 + T cell, CD14 + Monocyte and Granulocyte) showed significant 
differences between cases and controls (p < .05). Equally important were the 
findings of a surrogate variable analysis (SVA) which showed significant 
differences in the DNA methylation status of 16,220 CpG sites between affected 
cases and their non-affected counterparts. After adjusting for estimated cell-type 
proportions, using a multiple linear regression model, significant diagnostic 
differences were observed for 2,552 CpG sites at an FDR-adjusted p value of .05. 
Of these, 1,607 (63%) showed higher DNA methylation in individuals with 
schizophrenia than in control participants. The authors then classified the 2, 552 
SVA-identified sites in terms of their genomic location and observed that 1,491 
sites (58.4%) were located in CpG islands, 432 sites (16.9%) in CpG shores and 
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209 sites (8.2%) in CpG shelves. Moreover, 1, 607 sites (63.0%) were situated in 
promoter regions, 525 sites (20.6%) in gene bodies and 30 sites (1.2%) in 3′- 
UTRs. Upon further investigation, the authors concluded that aberrant DNA 
methylation in schizophrenia cases was significantly more likely to occur at CpG 
sites located within specific gene-promoter island regions (χ2 [1] = -22419699.64, 
p < .001).  
Finally, Kinoshita et al. (2014) performed a gene-ontology analysis of the 
genes covered by the 2,552 differentially-methylated CpG sites using DAVID 
Bioinformatics Resources. The majority of the top-10 ranked significant gene-
ontology terms included the functions associated with gene transcription, 
including “regulation of transcription, transcription regulator activity, and 
regulation from RNA polymerase II promoter” (Kinoshita et al., 2014, p. 700). 
Attempts to adjust for blood cell heterogeneity were a significant strength 
of the Kinoshita et al. (2014) study.  
 In a similar study, Kinoshita et al. (2013) sought to explore the 
relationship between DNA methylation of individual CpG loci and schizophrenia 
using peripheral blood leukocytes. Participants were 24 medication-free cases 
with schizophrenia (11 males and 13 females) and 23 non-psychotic controls (10 
males and 13 females).  Participant recruitment methods, eligibility criteria and 
clinical measurement of schizophrenia were identical to those outlined in the 
study by Kinoshita et al. (2014). In terms of exposure to anti-psychotic 
medication, 16 cases with schizophrenia had no recorded history of treatment with 
anti-psychotic medication and seven had not taken any anti-psychotics for at least 
the previous two months.  
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DNA methylation profiles for the 47 study participants were obtained 
using the Illumina Infinium Methylation450 array and SVA was employed to test 
the relationship between clinical diagnosis and participants’ methylomic profiles 
across the genome. This analysis revealed 10,747 CpG sites that were 
differentially-methylated between participants with schizophrenia and their non-
psychotic counterparts at an FDR-adjusted p value of below .05.  
Using the same Illumina HM450 arrayarray, the authors attempted to 
replicate these findings in three male monozygotic (MZ) twin pairs that were 
discordant for schizophrenia. Recruited form Nagasaki University Hospital, the 
affected cases were taking various psycho-tropic medications. Significant 
diagnostic differences in DNA methylation were found at 15,872 CpG sites at an 
FDR-adjusted p value and beta value difference of below .01. 
Finally, Kinoshita and colleagues (2013) compared the results from the 
two independent participant cohorts and identified 234 differentially-methylated 
sites that were common to both. In terms of methylation status, 215 (92.4%) of 
these sites showed higher DNA methylation in participants with schizophrenia 
than in control participants. Moreover, following classification of the 234 sites 
into specific CpG regions, 95 sites (40.6%) were located in CpG islands, 31 sites 
(13.3%) in CpG shores and 27 sites (11.5%) in CpG shelves. The authors also 
classified them into four categories according to their genomic locations and 
observed that 109 sites (46.6%) were situated in promoter regions, 64 sites 
(27.4%) in gene bodies and 6 (2.6%) sites in 3′-UTRs. This epigenetic profiling of 
MZ twins discordant for schizophrenia is a useful strategy for exploring DNA 
methylation differences between affected and non-affected individuals without the 
influence of genetic discordance.  
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  Using a large case-control sample (i.e., discovery sample), Aberg et al. 
(2014) undertook research to explore DNA methylation biomarkers of 
schizophrenia in peripheral whole blood by way of a methylome-wide association 
study. The participant sample consisted of 759 schizophrenia cases (417 males 
and 342 females) and 738 healthy controls (399 males and 339 females). All 
participants were born in Sweden and cases were selected from the Swedish 
Hospital Discharge register, which contains information regarding all individuals 
hospitalised in Sweden since 1973. The inclusion criteria for cases were an 
established diagnosis of schizophrenia, determined by a hospital physician, and at 
least two instances of inpatient treatment for the disorder. Control participants 
were also selected from national population registers and were matched to cases 
according to age, sex and county of residence. Controls were excluded from the 
study if they had been hospitalised due to a psychiatric illness.  
To obtain whole-methylome DNA methylation profiles, Aberg et al. 
(2014) used the MethylMiner (Invitrogen) protocol, which employs methyl-CpG-
binding domain (MBD) protein-based enrichment of methylated CpG sites across 
the genome, followed by single-end sequencing (50 base-pair reads) on the 
SOLiD platform, during which a DNA fragment is sequenced from only one end 
(Sengupta et al., 2011). The degree of methylation of individual CpGs was 
quantified by estimating how many fragments covered each site. In addition, the 
authors used several different statistical methods, including principal components 
analysis and regression models, to control for potential confounders. These 
confounders included age, sex, cell-type heterogeneity and assay-related technical 
artefacts (e.g., quantity of genomic DNA starting material). Findings revealed 139 
sites that were differentially-methylated between cases and controls at an FDR-
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adjusted p value of below .01. After applying a highly conservative Bonferroni 
correction (p < 1.15E-8), only 25 of these sites remained statistically robust. In 
terms of genomic location, 112 of the 139 (80.6%) sites were found to be located 
within close proximity of the transcription start site of 112 genes. In addition, the 
authors performed network analyses to determine the functional significance of 
these genes and observed themes associated with hypoxia and the human immune 
response.  
 Researchers, Aberg et al. (2014) also sought to replicate their key 
empirical findings in two independent cohorts. The first replication sample (i.e., 
replication one sample) included 360 participants (178 cases and 182 controls), 
while the second sample (i.e., replication two sample) was compromised of 561 
cases and 582 controls. However, the number of investigated participants in each 
of the replication samples varied following stringent quality control analyses. 
Interestingly, replicated findings, obtained from a different assay technology and 
using these two additional cohorts, were also associated with hypoxia and immune 
system dysfunction. For example, a CpG site (whose probe ID was not specified 
by the authors) that covers the Family with Sequence Similarity 63, Member B 
gene, showed differential methylation between cases and controls in the discovery 
sample (n = 759 p < .001), and also in the second replication sample (n = 1075, p 
< .001; the n refers to the number of investigated participants following quality 
control procedures). A Cohen’s d value of -4.50 was observed in the second 
replication sample, indicating that this CpG site was significantly less methylated 
in schizophrenia cases than it was in non-psychotic controls. Regarding its 
functional significance, the FAM63B gene forms part of the networks regulated 
by miRNA that can be linked to dopaminergic gene expression, which in turn can 
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be altered by hypoxia (Pagida et al., 2013; Stone, Morrison, & Pilowsky, 2007). 
Strengths of this study by Aberg et al. (2014) are the use of a large case-control 
sample with replication, and technology that provided good coverage of 
methylation sites across the genome.  
3.4 Discussion 
The current review sought to explore the role of DNA methylation taken 
from peripheral blood in people with a clinical diagnosis of schizophrenia. Eight 
studies were identified that met the selection criteria. Overall, the results of these 
studies provided evidence for differential methylation profiles in individuals with 
schizophrenia. Moreover, the methylomic alterations observed in affected 
individuals were noted at both global and individual CpG site levels.  
 Of the eight studies reviewed, three sought to explore the presence of 
global DNA methylation differences between individuals with schizophrenia and 
those without the disorder. Of these three studies, two reported statistically robust 
global hypomethylation profiles in cases with the disorder. In other words, DNA 
methylation of CpG sites was significantly lower, on average, in the peripheral 
blood of schizophrenic participants than in their non-psychotic counterparts. 
While not reaching statistical significance, the third study reported a tendency for 
lower global DNA methylation in the leukocytes of Japanese male cases after 
controlling for the effects of age. This trend was most pronounced in younger 
affected males. Interestingly, no effect of age or disease status on global DNA 
methylation was observed in female participants. 
  In contrast, the remaining five studies compared the DNA methylation 
status of individual CpG sites in peripheral blood leukocytes of participants with 
and without schizophrenia. All five reported significant alterations in DNA 
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methylation of individual CpG loci and subsequent gene expression in those with 
the disorder. In addition, the findings of network pathway analyses, performed in 
two independent study cohorts, implicated genes involved in hypoxia and human 
immune processes. However, despite statistically robust findings, there was a lack 
of consistency across studies in relation to which CpG sites were found to exhibit 
differential methylation between cases and controls. This inconsistency may have 
been due to differences in sample size, the CpG sites examined and the 
demographic characteristics of participants (e.g., age, sex, ethnicity, exposure to 
anti-psychotic medication, clinical subtypes and/or illness severity). Other 
probable contributors included the varied enrichment strategies and mapping 
platforms employed by the authors to obtain and quantify DNA methylation data. 
Taken together, these factors make it difficult to reach definitive conclusions 
about the nature and strength of an associative relationship between DNA 
methylation and schizophrenia diagnosis.  
  Of particular note is the fact that all the studies included in review 
were cross-sectional in nature. This limits the capacity to draw causal inferences 
from the data regarding the direction of the observed epigenetic associations. For 
example, rather than occurring prior to illness-onset and contributing to the 
clinical phenotype, the aforementioned epimutations may, in fact, be a 
consequence of the disease process or anti-psychotic medication used to treat the 
condition. 
Future investigations in this area should employ longitudinal designs so 
that causality, important from both etiological and treatment perspectives, may be 
more clearly elucidated. As anti-psychotic medication is likely to have an effect 
on the epigenome of participants with schizophrenia, the inclusion of individuals 
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who present with psychotic symptoms (i.e., a risk factor for the later development 
of the disorder) may offer a future opportunity to study this relationship without 
the possible confounding effects of pharmacological treatment.  
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Chapter 4 
Research Rationale and Overall Aims and Hypotheses  
4.1 Rationale for Current Research 
Recent empirical findings from research exploring DNA methylation in peripheral 
blood leukocytes of individuals with schizophrenia provide preliminary evidence 
for the presence of aberrant methylation patterns in the disorder. However, to 
date, all known previous studies have been cross-sectional in nature making it 
difficult to identify the impact of environmental exposures, the effects of the 
disorder itself, and effects of treatment of the disorder. As such, researchers have 
been unable to draw inferences about the causal nature of the observed association 
between DNA methylation status and a clinical diagnosis of Schizophrenia. 
Additionally, many of the affected cases included in prior studies were receiving 
treatment with anti-psychotic medication. As pharmacological intervention has 
been shown to influence the epigenome (Boks et al., 2012), the reported findings 
may have been confounded by exposure to medication.  Finally, the varied 
methylation platforms that were used to assay and quantify DNA methylation of 
blood cells prevent direct comparison of these findings across different studies.  
The current research addresses some of these limitations. Firstly, it investigates 
DNA methylation data and phenotypic outcomes from a large-scale prenatal 
longitudinal birth-cohort study in which data was obtained prospectively using the 
same cohort at multiple time-points across its development. Specifically, the 
methylation status referred to in this study is derived from umbilical cord blood 
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and likely reflects conditions of fetal development. The fetal period is suggested 
by a number of researchers to be a critical window for epigenetic malleability of 
the kind which may predispose to later disorder. By obtaining information 
regarding participants’ exposure to antenatal events in utero, this enables the 
exploration of the influence of these factors on the epigenome and how 
subsequent epigenetic marks contribute to the later development of psychotic 
symptoms during early and late adolescence. Additionally, the current research 
design permits preliminary causal inferences about cause and effect of observed 
epigenetic associations. 
Secondly, the primary outcome variables in this thesis refer to psychotic 
symptoms in medication-naïve participants at age 12 and 18. Consequently, this 
enables exploration of the role of DNA methylation in the development of 
psychotic symptoms in the absence of possible confounding effects of anti-
psychotic medication.  
Thirdly, the current thesis employs an array platform (i.e., Infinium 
HumanMethylation450 Bead Chip array) which assesses the methylation status of 
over 480,000 cytosines distributed throughout the genome. The high sample 
throughput and coverage offered by the HM450 arraytechnology, together with 
the sizeable nature of the participant sample, increases the representativeness of 
the current findings and facilitates comparison with other studies that have 
employed comparable technology.  
Finally, unlike published studies thus far, the current thesis aims to extend its 
exploration of altered methylation patterns in participants with psychotic 
symptoms to also test whether epigenetic processes are involved in mediating the 
83 
 
 
 
relationship between known environmental risk factors (e.g., maternal influenza 
and diabetes/glycosuria) and psychotic symptoms. 
4.2 Research Aims and Hypotheses  
4.2.1 Study 1: Role of global DNAm in psychotic symptoms at age 18 
years. 
Study 1, presented in Chapter 6, aims to investigate the role of global DNAm, 
measured in cord blood (CB), as a predictor of psychotic symptoms at the age of 
18 years. The specific hypotheses to be tested are: 
(1) Participants who report psychotic symptoms at 18 years will exhibit 
significantly higher global DNA methylation levels in cord blood than will 
participants who do not report psychotic symptoms.  
(2) Participants who report psychotic symptoms at 18 years will exhibit 
significantly higher global DNA CB methylation levels at birth across 
specific CpG site regions (islands, north shores, north shelves, south 
shores and south shelves) than will participants who do not report 
psychotic symptoms. Specifically, it is hypothesised that CpG islands will 
show greater global DNAm in participants with psychotic symptoms at 
age 18 years, than will participants without psychotic symptoms at this 
time-point.  
4.2.2 Study 2: Association of DNAm of individual CpG sites and psychotic 
symptoms at ages 12 and 18 years. 
Study 2, presented in Chapter 7, aims to investigate the role of epigenome-
wide DNAm, measured in CB, as a predictor of psychotic symptoms at ages 12 
and 18 years, in order to identify differentially-methylated CpG sites at birth 
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between those with psychotic symptoms and those without. The specific 
hypotheses to be tested are: 
(1) Participants who report psychotic symptoms at ages 12 and 18 years will 
exhibit differentially-methylated CpG sites at birth, at an epigenome-wide 
level, compared to participants who do not report psychotic symptoms. 
(2) The specific CpG sites found to be differentially-methylated, at birth, 
between participants with and without psychotic symptoms will be similar 
across the two time-points (i.e., age 12 and 18 years).  
4.2.3 Study 3: Epigenetic processes as a mediator of sex and antenatal 
exposures and psychotic symptoms at ages 12 and 18 years. 
Study 3, presented in Chapter 8, aims to investigate the role of CpG sites most 
strongly associated with psychotic symptoms at ages 12 and 18 years (identified 
from study 2), as potential mediators of the relationship between sex, antenatal 
exposures of maternal influenza and diabetes/glycosuria and psychotic symptoms 
during adolescence.  
The specific hypotheses to be tested are: 
(1) The 50 top-ranked CpG sites, identified from study 2, will mediate the 
relationship between child sex and psychotic symptoms at ages 12 and 18 
years.  
(2) The 50 top-ranked CpG sites, identified from study 2, will mediate the 
relationship between maternal influenza and psychotic symptoms at ages 
12 and 18 years. 
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(3) The 50 top-ranked CpG sites, identified from study 2, will mediate the 
relationship between maternal diabetes and/or glycosuria and psychotic 
symptoms at age 12 and 18 years.  
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Chapter 5 
Characteristics of the ALSPAC and ARIES Cohorts and Data 
Collection Methods 
This thesis uses secondary analysis of data drawn from both the Avon 
Longitudinal Study of Parents and Children (ALSPAC) and the Accessible 
Resource for Integrated Epigenomics Studies (ARIES).  This chapter provides 
details of the original ALSPAC and ARIES cohorts, including information about 
recruitment strategies, data collection, characteristics of eligible mother and child 
pairs and study attrition. In addition, a brief description of the unique sample used 
for each empirical study will be provided at the beginning of subsequent chapters.  
The current chapter also provides information on the statistical aspects of the 
study including the measurement and quantification of participants’ methylomic 
profiles as well as the procedures used to address non-parametric and missing 
data. It should be noted that the author of this thesis did not participate in data 
collection for either the ALSPAC study or ARIES resource.  
5.1 Avon Longitudinal Study of Parents and Children (ALSPAC) 
Participants 
ALSPAC is a transgenerational prospective birth-cohort study, which 
commenced in 1991 and was designed to investigate the impact of genetic and 
environmental factors on multiple health and developmental outcomes across the 
lifespan in both children and their parents. The study is run primarily by the 
University of Bristol, Great Britain and recruitment sought to enrol all pregnant 
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mothers residing in the former Avon Health Authority area (including Southmead, 
Frenchay, Bristol and Weston). Hence, the total eligible population from which 
participants were recruited was 20,248 pregnant women. Of these, 14,541 (72%) 
women comprised the initial ALSPAC sample (see Figure 1 for details). Core 
funding for ALSPAC has been received primarily from the following three 
sources: University of Bristol, the Wellcome Trust (a global charitable 
foundation) and the Medical Research Council (a publicly-funded organisation).  
5.1.1 Recruitment. 
Recruitment to the study occurred across three phases (Phase I, II and III) 
and used a variety of methods. The first phase of the recruitment campaign 
occurred at the outset of the research (i.e., between 1990 and 1992) and aimed to 
enrol women as early in their pregnancy as possible (Boyd et al., 2013). Details of 
the study were communicated to eligible women via media sources and 
recruitment staff who visited local community areas to promote the research (see 
recruitment Phase I in Figure 5).   
In addition, information and ‘expression of interest’ cards were provided 
to women who attended antenatal and maternity health services within the Bristol 
area. By returning these cards, women were able to either request further details 
about the study or to decline to participate. ALSPAC staff reviewed completed 
cards to determine participant eligibility. Eligible women who requested further 
information were mailed a ‘study information booklet’ followed by an initial self-
report questionnaire approximately one week later (Boyd et al., 2013). 
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Note. Only data concerning participants enrolled in Recruitment Phase I (n = 14,541) will be 
included in this thesis. 
Figure 6. The ALSPAC enrolment campaign flow diagram (from Boyd et al., 
2013) 
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Within the booklet were invitation cards which advised mothers that consent for 
the study was contingent on an ‘opt out’ policy (i.e., mothers who did not actively 
refuse to participate in the study would be included in future data collection). The 
majority of women enrolled in ALSPAC (82.6%) were recruited during Phase I.   
  The current thesis focuses on the role of antenatal exposures of maternal 
influenza and diabetes/glycosuria, DNA methylation in umbilical cord blood 
collected at birth and data on psychotic symptoms collected during waves 4 
(Adolescence) and 5 (Transition to Adolescence) when children were aged 12 and 
18 years respectively.  Data on pregnancy, infancy and early childhood variables 
and outcomes were only collected for participants enrolled during Phase I of 
recruitment and are, therefore, not available for mother and child pairs enrolled 
during the subsequent Phase II and III recruitment (see Figure 5). Hence, only 
data from mother and child pairs recruited during the initial Phase of the study 
(Phase 1) will be examined in the three studies presented here.  Consequently 
details about procedures used during the latter two recruitment phases are not 
provided.  
5.1.2 Initial ALSPAC sample. 
The initial ALSPAC sample consisted of 14,541 pregnancies. This number 
represents mothers who were recruited to the ALSPAC study during Phase I and 
had either returned at least one questionnaire or attended a Children in Focus 
(CiF) clinic by the seven year data collection date.  Of the initial 14,541 
pregnancies, birth outcome data (e.g., fetal loss < 20 weeks, neonatal death < 7 
days) is available on all but 69 children. This information indicates that of the 
14,472 pregnancies with known outcomes, 195 resulted in twins, three resulted in 
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triplets and one was a quadruplet pregnancy. There were 14,676 fetuses in the 
initial ALSPAC sample, of which 14,062 were live births and 13,988 were alive at 
one year (Boyd et al., 2013).  
5.1.3 Representativeness of the ALSPAC sample. 
Fraser et al. (2013) used 1991 census data to compare the population of 
mothers with children under 12 months of age who were residing in the Avon area 
with those living in the whole of the United Kingdom on key demographic 
variables. In addition, mothers living in the Avon area were also compared with 
those enrolled in ALSPAC during Phase I of recruitment using data collected at 
approximately eight months post-natal. However, not all ALSPAC mothers 
completed the 8-month questionnaire and so this comparison was only conducted 
using socio-demographic data from approximately 80% of the maternal sample.  
 Overall, ALSPAC mothers tended to have indicators suggestive of higher 
economic status compared to non-ALSPAC mothers. For example, mothers 
enrolled in the study were more likely than non-enrolled mothers living in Avon, 
and also Britain, to reside in owner-occupied accommodation, to be married and 
to possess a vehicle in their household. Conversely, they were less likely to be of 
non-Caucasian descent than were their Avon and Britain counterparts. However, 
ALSPAC mothers were somewhat more likely to be residing in overcrowded 
conditions (i.e., a higher percentage of mothers living in households with more 
than one person per room) than either Avon or British females (Fraser et al., 
2013).  
In addition to comparisons made between ALSPAC mothers and those 
living in Avon and Britain, children enrolled in ALSPAC during recruitment 
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Phases I, II and III, were also compared to a national sample in terms of 
demographic and standard school assessment data which was typically obtained 
from ALSPAC participants when they were 16 years of age (Boyd et al., 2013). 
Children enrolled in ALSPAC were more likely to be of Caucasian descent and 
were more educated at 16 years of age than were children in the non-ALSPAC 
national sample; however ALSPAC children were more likely to be from low 
income households (i.e., a joint parental income of less than or equal to 16,000 
pounds) than the national sample (Boyd et al., 2013).  
6.1.4 Permanent attrition of the sample. 
Due to permanent attrition and wave non-response, sample sizes across 
research analyses with ALSPAC data differ according to the variables examined. 
For an overview of the attrition rates at different time-points during the study see 
Figure 6. Importantly, the number of participants eligible for follow-up refers only 
to those who had been contactable at all data collection points prior to the age of 
18 years. Participants who were temporarily lost to follow-up and the re-engaged 
in the study at a later date are not included in Figure 6; hence, this diagram may 
underrepresent attrition rates at individual time-points. According to Boyd et al. 
(2013), ALSPAC attrition rates were at their highest when children were in their 
infancy and have increased again now that participants are moving from late 
adolescence to early adulthood. Moreover, attrition rates have been highest for 
mothers who experienced greater adversity during their index pregnancy. This 
hardship refers to both health and environmental factors, including early 
pregnancy complications, inadequate housing, financial difficulties and an 
absence of social support (Fraser et al., 2013).  
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aDetails of participants omitted from ALSPAC study follow-up due to a ‘permanent 
status’ which remained in place up until study participants reached 18 years of age 
(e.g., individuals became untraceable and were not found again until after they had 
turned 18). Individuals for whom a change in status meant that they were 
temporarily excluded from follow-up are not included and, hence, this diagram 
represents only approximate attrition rates at individual data points. 
bPost-18-year age tracing and recruitment initiatives by ALSPAC researchers may 
result in some individuals being included in future follow-up. 
Figure 7. ALSPAC study attritiona flow diagram (from Boyd et al., 
2013). 
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5.2 Accessible Resource for Integrated Epigenomics Studies 
(ARIES) Participants 
ARIES is a Biotechnology and Biological Sciences Research Council 
(BBSRC) funded resource that generates epigenomic information on a range of 
human tissues at multiple time-points across the life course using biosamples 
collected form ALSPAC participants. ARIES aims to integrate epigenetic data 
with genetic and transcriptomic data and then link this information to exposure 
and phenotypic outcome measures.  
ARIES has produced epigenetic data on 1,000 mother and child pairs, 
selected at random from the ALSPAC cohort, at three child time-points (birth, 
seven years and 15-17 years) and two maternal time-points (antenatal and 17 
years post birth) (Relton et al., 2012).  Details of the epigenetic data derived from 
ARIES are provided in section 5.6. 
5.3 Thesis Participants: ALSPAC and ARIES  
This thesis uses data from participants enrolled in both ALSPAC and the 
ARIES cord blood cohort who undertook the Psychotic Like-Symptoms Interview 
(PLIKSi) at ages 12 and 18 years, as part of the ALSPAC data collection.  Of the 
1,000 mother and child pairs selected at random to be included in the ARIES cord 
blood sample, 106 children were removed from the sample following data control 
procedures due to problematic methylation data characterised by probes with 
detection p values of less than or equal to .01 in greater than 20% of the sample. 
Thus, 894 ALSPAC participants were included in ARIES.  Table 1 represents a 
comparison of socio-demographic characteristics of the entire ALSPAC sample  
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Table 3. Socio-demographic characteristics of mother and child pairs in the entire ALSPAC and ARIES cord 
blood cohorts 
 
ALSPAC sample  
(N = 15 444) 
ARIES sample  
(n = 894)a   
Child Characteristic  
Categorical  
 
N (%) N (%) F2 p 
Sex 
Male 7216 (51.7) 423 (47.20) 6.71 .01 
Ethnicity 
Non-Caucasian 585 (5.20) 28 (3.30) 6.71 .01 
Child Characteristic  
Continuous  M (SD) M (SD) t p 
Birth weight  
(grams) 3375 (586.22) 3476.83 (484.61) -5.94 <.01 
Gestation  
(weeks) 38.29 (5.66) 39.56 (1.54) -18.01 <.01 
Mother Characteristic 
Categorical  N (%) N (%) F2 p 
Marital Status 
Single 4980 (34.60) 161 (18) 103.34 <0.01 
Socio-economic classb 
Non-skilled 
work 
 
1897 (20.30) 113 (14.40) 16.23 <0.01 
Mother Characteristic 
Continuous  M (SD) M (SD) t p 
Maternal age at delivery  
(years) 
27.90 (4.98) 29.52 (4.41) -10.52 <.01 
aThe total ARIES sample was comprised of 1,000 mother-child pairs. However, after quality 
control procedures were performed on cord blood samples, data remained on only 894 mother-
child pairs. 
bMaternal socio-economic class is a derived classification, achieved by mapping mothers’ 
occupation to class categories. These categories were then transformed into a dichotomous 
variable, with two categories: ‘Non-skilled work’ representing lower socio-economic class, and 
‘Skilled work’ representing higher socio-economic class. 
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(N = 15,444) and the subset of the ARIES cord blood sample for whom DNA 
methylation data is available (n = 894). 
As shown in Table 3, children in the entire ALSPAC sample were significantly 
more likely to be of non-Caucasian descent, and born to a single mother than 
children in the ARIES cohort.  Moreover, children randomly assigned to the 
ARIES sample were significantly heavier at birth than children from the full 
ALSPAC sample. Finally, mothers in the ARIES sample were significantly older 
than mothers in the full ALSPAC sample and they gave birth to children who 
were significantly older in terms of gestational age, than mothers in the original 
ALSPAC sample. While representing statistical differences between the groups, it 
should also be noted that many of these values represent minimal practical 
differences (e.g., the ARIES sample on average were only one week older in 
gestational age than the ALSPAC sample). 
Moreover, while there were some significant differences between the 
retained ARIES sample and the original ALSPAC cohort, it is important to note 
that the full 1,000 mother-child pairs randomly selected from the ALSPAC cohort 
by ARIES researchers may be more similar to the entire ALSPAC sample than the 
remaining 894. In fact, according to Morales, Groom, Lawlor and Relton (2014), 
of the 1,000 mother-child pairs, 495 children were male (49.5%) and the average 
age of mothers upon delivery was 27 years and four months. These figures are 
more analogous to the entire ALSPAC sample, in which 51.7% were male and the 
average age of mothers upon delivery was 27 years and nine months.  
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5.4 Ethical Approval 
A multidisciplinary ethics and law committee was established specific to 
ALSPAC was established in 1990. The committee was involved in planning the 
study as a whole, in particular developing guidelines relating to participant 
consent and confidentiality, and continues to approve individual projects and 
respond to ethical issues (Mumford, 1999). Parents provided informed written 
consent and children assented after receiving a full explanation of the study. 
Ethical approval allowing access to the pre-existing data used in this study 
was obtained from the ALSPAC Law and Ethics Committee (ALSPAC ethical 
approval number B2042) at the University of Bristol and Deakin University 
Human Research Ethics Committee (Deakin University ethical approval number: 
2013-247). Access to the ALSPAC phenotype and ARIES DNA cord blood 
methylation data, was granted by the ALSPAC Law and Ethics Committee and 
the Local Research Ethics Committee. A copy of the approval email is available 
in Appendix A. In addition, a data transfer agreement between University of 
Bristol and Deakin University was established and signed on the 13th of August 
2013 to enable the transfer and use of ALSPAC and ARIES data by the writer for 
doctoral research purposes (see Appendix B). All terms and conditions for data 
use specified in this agreement have been meet in the current dissertation. 
5.5 Data Collection Procedures for ALSPAC 
Several different methods have been used to collect the data in the 
ALSPAC study used in this thesis, including self-report questionnaires, biological 
samples (e.g., umbilical cord blood), medical and obstetric records, and mother 
and child assessment clinics. Overall, from the age of four weeks until 18 years of 
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age, child participants and their caregivers have undertaken 68 independent data 
collection points. These have included child-completed questionnaires (CCQ) 
enquiring about multiple life domains (pre-pubertal development, academic 
performance and relational functioning), mother and child attendance at ALSPAC 
assessment clinics (described in more detail in the following section), and the 
completion of questionnaires by mothers or other primary caregivers about their 
child’s functioning from early childhood until late adolescence.  These different 
data collection methods are summarised below. 
5.5.1 Questionnaires. 
Mothers were sent three self-report postal surveys during their index 
pregnancy and 40 additional surveys over the 20-year period following the birth 
of their child (Fraser et al., 2013). These questionnaires asked mothers to 
comment on both their own and their child’s health and wellbeing, along with 
domains specific to their child’s development (e.g., fine and gross motor co-
ordination, puberty, speech and language). Questionnaire items also referred to 
mothers’ lifestyle and relational factors as well as their educational and 
employment attainment.  
From the age of 65 months until approximately 19 years of age, children 
of the ALSPAC cohort have completed 27 self-report questionnaires on a wide 
range of topics, including school life, growing up, leisure activities and hobbies, 
friendship, body image, puberty, gambling and their use of the internet.  
5.5.2 Obstetric and medical records. 
Information about pregnancy-related outcomes was also derived from the 
obstetric and medical records of ALSPAC mothers. Upon enrolment into the 
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study, pregnant mothers were advised that relevant data from their medical 
records would be abstracted unless a mother specifically requested for this not to 
occur. To date, information has been abstracted for 13,706 pregnancies.  
All recruited ALSPAC mothers who gave their consent (approximately 
99%) have been linked to the National Health Service (NHS) Central register, 
which provides information on deaths (including underlying causes and 
contributing factors), cancer and emigration (out of the United Kingdom) of study 
participants. In addition, information on individuals eligible to participate in 
ALSPAC is also available through linkage to the National Pupil Database 
(approximately 82% coverage of the ALSPAC sample depending on the time-
point) and the General Practice Research Database (approximately 4% coverage 
of the ALSPAC sample). 
5.5.3 Assessment clinics.  
Once the original child cohort turned seven years of age, invitations were 
extended to all eligible child participants, including those who had been enrolled 
during recruitment phase II, to attend subsequent assessment clinics. As a result, 
the frequency of attendance varied across the time-points, with 1,432 families 
partaking in at least one clinic.  
The aim of these assessment clinics was to provide validation to self-
reported data and to collect phenotypic and environmental data in a clinical 
setting. This data included direct assessment of children’s experience of psychotic 
symptoms, along with their intellectual functioning (IQ) and engagement in anti-
social activities. Refer to Table 4 for an overview of the data collected on child 
participants at the various ALSPAC assessment clinics. 
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Data Collection Time C linic n Data Collected  
Infancy     
4 months CiF1 1 023 Cognitive Functioning (Habituation), Diet, Visual Acuity, 
Anthropometry  
8 months CiF2 1 314 Diet, Parenting, Anthropometry, Tympanometry and Auditory 
Acuity 
12 months CiF3 1 241 Air Pollution Exposure, Parenting, Visual and Auditory Acuity 
18 months CiF4 1 183 Cognitive Functioning, Day Care, Diet, Anthropometry, Visual 
Acuity 
Early childhood     
25 months CiF5 1 127 Speech and Language, Day Care, Diet, Antthropometry, Visual
Acuity 
31 months CiF6 1 135 Day care, Diet, Auditory/Visual Acuity, Anthropometry  
37 months CiF7 1 081 Cognitive Functioning (Laterality), Day Care, Anthropometry ,
Dental 
43 months CiF8 1 065 Cognitive Functioning (Laterality), Tympanometry, Day Care, 
Diet 
49 months CiF9 1 032 Short-term memory, Diet, Speech and Language, 
Auditory/Visual Acuity 
61 months CiF10 994 Short-term memory, Diet, Speech and Language, 
Auditory/Visual Acuity 
Childhood     
7 years F@7 8 290 Literacy/Numeracy Skills, Nutrition, 
Co- ordination, Auditory/Visual Acuity 
Late Childhood     
8 years F@8 7 488 Lung function, Attenttion, Intellectual Functioning  (IQ) ,
F riendships  
9 years F@9 7 722 Physical Fitness, Scoliosis, Literacy/Numeracy skills, Weight  
  10 year s F@10 7 557 Physical Activity, Nutrition, Artery Function, Smell, Inhibition, 
Depression 
  11 years  F@11 7 153 Physical Health, Fine Motor Skills, Borderline Personality 
Disorder Traits 
  12 years  TF1  6 832 Psychotic Symptom sb, Antisocial Activities, Parent-Child
Interactions 
Adolescence      
  13 years  TF2  6 141 Personality Assessment, Physical Fitness/Activity, Nutrition, 
Weight 
  15 years  TF15 5 509 Inhibition, Face Shape, Lung Function, Mole Screen, Puberty, 
IQ  
Transition to Adulthood    
  17 /18   years TF17 5 196 Psychotic Symptoms b, Liver Function, Depression, Romantic 
Relationships 
aInformation was taken from Boyd et al. (2013). 
b Data used in the current thesis. 
 
 
 
Table 4.Data collected about child participants at ALSPAC assessment clinicsa 
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5.5.4 The ALSPAC biobank and genetic resource. 
In addition to information obtained from self-report postal questionnaires 
and child assessment clinics, blood and biological samples taken from mother and 
child participants at various time-points have been used to establish an ALSPAC 
bio-bank and genetic resource. More specifically, whole blood samples were 
taken from 10,000 pregnant mother participants as part of routine antenatal care 
(i.e., health checks) and from the umbilical cord blood of approximately 4,000 
child participants at birth. Blood samples were also collected from 8,000 children 
(70% of eligible child participants) who attended ALSPAC clinics at 
approximately 43 and 61 months and seven years of age. Furthermore, blood 
samples from 1,000 mother and child pairs were provided to ARIES for analysis. 
To date, epigenetic information has been generated for mothers at two points 
(antenatal and 17 years post birth) and for child participants at three time-points 
(birth, seven years and 15-17 years). The following section will describe the 
procedures undertaken to derive the DNA methylation data. 
5.6 Data Collection Procedures for ARIES Data 
5.6.1 Infinium humanmethylation450K beadchip array (HM450 
array). 
The Accessible Resource for Integrated Epigenomic Studies (ARIES) 
project used the HM450 array (see Chapter 3 for full details about this 
technology) array to generate epigenetic data examined in this thesis. 
5.6.1.1 Quality control (QC) of DNAm data: Procedures employed by 
ARIES. 
During the data generation process a wide range of batch variables were 
recorded in a purpose-built laboratory information management system (LIMS). 
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The LIMS also reported QC metrics from the standard control probes on the 450k 
BeadChip for each sample. Samples failing quality control (samples with >20% 
probes with p value > 0.01) were excluded from further analysis and scheduled for 
repeat assay. Batch variables recorded include sample batch, BeadArray, reagent 
batches, sample plates, lab equipment, personnel, and date/time of each step. As 
an additional QC step genotype probes on the HM450k were compared between 
samples from the same individual and against SNP-chip data to identify and 
remove any sample mismatches (samples quarantined). Samples without GW SNP 
data were not quarantined, but were flagged where there was a sex-mismatch 
(based on X-chromosome methylation; Jones et al., 2000).  
Methylation data were normalised in R with the wateRmelon package 
using the Touleimat and Tost algorithm to reduce the non-biological differences 
between probes.  The HM450 arrayuses two different assay probes (Infinium I 
and II) to enable the simultaneous quantitative measurement of the methylation 
status of more than 480,000 CpG sites across the whole genome (Touleimat & 
Tost, 2012). However, erroneous results can occur if the data from the two probes 
are combined together and interpreted as a uniform source of methylation 
measurement. Consequently, Touleimat and Tost (2012) have developed an 
algorithm that normalises the data and corrects for any bias, which may result 
from differences between the methylation signals of the two Infinium assay 
probes.  
As noted previously (section 5.6.1.1), 106 subjects were removed from the 
sample during quality control procedures, leaving DNA methylation data drawn 
from a total of 894 participants (Jones et al., 2000). 
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5.7 Measures 
5.7.1 Outcome variables: Psychotic symptoms at ages 12 and 18  
The outcome variable of psychotic symptoms at ages 12 and 18 years was 
obtained using the semi-structured PLIKSi. The PLIKSi is a measure that was 
constructed by ALSPAC researchers, using items from the National Institute of 
Mental Health (NIMH) Diagnostic Interview Schedule for Children-IV (DISC-IV; 
Shaffer, Fisher, Lucas, Dulcan, & Schwab-Stone, 2000) and the Schedules for 
Clinical Assessment in Neuropsychiatry, version 2.0 (SCAN 2.0; Rijnders et al., 
2000), to assess the presence and absence of psychotic phenomena in a non-
clinical population.  
The DISC-IV is a highly structured psychiatric diagnostic interview for 
children and adolescents aged between six to 18 years.  The original DISC was 
primarily developed for use in epidemiological research (i.e., to determine the 
prevalence of mental health conditions and related treatment needs for young 
people in the United States). The most recent version of the measure, DISC-IV, is 
designed to assess more than 30 clinical disorders that occur in children and 
adolescents based upon DSM-IV criteria (Shaffer, Fisher, Lucas, Dulcan & 
Schwab-Stone, 2000).  
Unlike the DISC-IV, which can be administered by lay interviewers, the 
SCAN is a semi-structured standardised clinical interview, developed by the 
World Health Organisation, which requires administration by clinically trained 
professionals. The SCAN was developed for use within clinical and research 
contexts to assess, measure and classify psychopathology and behaviour 
associated with the major psychological disorders in adults. The measure employs 
a ‘bottom-up approach’ whereby symptoms expressed by a client are assessed in 
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their own right without being conceptualised within a diagnostic grouping 
framework. Ratings related to the presence and severity of particular clinical 
features is done by matching the answers of the respondent against the definitions 
of symptoms in the SCAN Glossary. These symptoms represent the differential 
aspects of experience or behaviour that are commonly witnessed in people upon 
referral for specialist psychiatric opinion.  
 Developed from the DISC-IV and the SCAN, the PLIKSi is comprised of 
an introductory set of questions which enquire about participants’ sleep 
(nightmares, night terrors and sleep walking) and the following intra-psychic and 
unusual events: derealisation, depersonalisation, self-unfamiliarity, 
dysmorphophobia, partial objection perception and other non-specific perceptual 
disturbances (Horwood et al., 2008). These items are followed by 12 ‘core’ 
questions eliciting information about psychotic phenomena experienced since age 
12 across the three main domains of positive psychotic symptoms: (1) 
hallucinations (visual and auditory); (2) delusions (such as being spied on, 
thoughts being read, grandiose ability, delusions of persecution, reference, or 
control and other unspecified delusions); and (3) bizarre symptoms (such as 
thought broadcasting, insertion and withdrawal). Any unspecified delusions 
described by participants are also rated. For the 12 core items, seven stem 
questions were derived from the DISC-IV and five from of the SCAN 2.0 (i.e., 
hallucinations; experiences of thought disorder and replacement of will; 
delusions).   
Semi-structured PLIKSi interviews were conducted with ALSPAC 
participants at 18 years of age by psychology graduates who were skilled in 
assessment using the SCAN psychosis section and the PLIKSi and who were 
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blind to previous assessments (Fisher et al., 2013). Coding of all PLIKSi items 
was done with reference to the definitions, assessment and rating rules outlined in 
the SCAN Glossary.  Consequently, psychotic symptoms were rated by 
interviewers as being (1) not present, (2) suspected or (3) definitely psychotic. 
Any responses that remained ambiguous after prompting were “rated down” (i.e., 
considered less symptomatic). For example, if a participant reported auditory 
hallucinations, but after extensive questioning it remained unclear as to whether 
the voices were external to the child or whether they were in fact referring to 
hearing their own thought processes, a rating of “not present” would be given 
instead of a rating of “suspected.” Moreover, symptoms were only rated as 
definite after the participant provided a clear example. If a response was coded as 
suspected or definitely psychotic, assessors also enquired about the following: 
symptom frequency, age of onset, help-seeking behaviour, self/other attributions, 
and the impact of a participant’s symptoms on their relational, academic and/or 
occupational functioning.  
At frequent intervals, a psychiatrist rated samples of recorded interviews 
to ensure that the assessors were scoring participant experiences correctly. Finally, 
only psychotic symptoms which were not attributable to the effects of sleep, fever 
or substance use were analysed, consistent with diagnostic guidelines outlined in 
the Diagnostic and Statistical Manual-5 (DSM-5).   
To evaluate the inter-rater reliability of the PLIKSi at ages 12 and 18 
years, each student interviewer audio recorded interviews at three time-points 
across the clinic duration (5, 10 and 15 months after commencement of 
conducting assessments) until they had at least eight interviews containing several 
items rated positive or suspected. A second interviewer then listened to and rated 
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these tapes independently. Degree of agreement among interviewers with respect 
to psychotic symptoms was measured using Cohen’s kappa coefficient. The 
average kappa value for psychotic symptoms at age 12 was 0.72 and for psychotic 
symptoms at age 18 years was 0.83, with no evidence of differences across the 
times at which the interview was conducted (Zammit et al., 2014). According to 
Landis and Koch (1977) who developed benchmark standards for various 
reliability statistics, these inter-rater reliability kappa coefficients represent 
substantial and strong agreement between examiners.  
Test-retest reliability of the PLIKSi was initially examined for the 12 years 
of age administration, with 163 participants re-interviewed (3%) within 2 weeks 
of the initial assessment (Horwood et al., 2008).  Comparison of the two 
interviews showed a kappa coefficient of 0.48 indicating fair agreement between 
the two time-points (Landis and Koch, 1977). While moderate, this test-retest 
result is consistent with findings for other semi-structured interviews like the 
Present State Examination – 9th edition (PSE-9) (Laurens et al., 2007).  
To explore test re-test reliability for psychotic symptoms at age 18,162 
participants were re-interviewed 47 days after their initial interview. For the total 
sample, a kappa value of .76 was found, indicating substantial agreement between 
the two time-points. This kappa value was even higher (kappa = .86) for 46 
participants who were re-interviewed by the same assessor.  
Due to a small number of participants in the disorder group (i.e., those with 
psychotic symptoms) at both age 12 and 18 years, the outcome variable of 
psychotic symptoms in the current research will represent the presence of any 
definite or suspected psychotic symptoms compared with the absence of any 
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psychotic symptoms. Hence, in all studies of the thesis, psychotic symptoms were 
coded as a dichotomous variable with the following two categories: 
a) 0 = an interviewer rating of no psychotic symptoms 
b) 1 = an interviewer rating of any definite or suspected psychotic symptoms 
5.7.2 Predictor variables: DNAm in fetal cord blood. 
The current study includes DNA methylation data from 894 participants from 
whom cord blood was collected in a heparin tube at birth. These samples were 
anti-coagulated with ethylenediamine tetraacetic acid (EDTA) and the white cells 
separated and stored at -70 degrees Celsius for 5 to 8 years prior to DNA 
extraction (Jones, 2009). DNA was extracted from stored samples using applied 
standard phenol-chloroform extraction methods (Relton et al., 2012). DNA was 
re-suspended in 2mM Tris and stored at -80 degrees Celsius.  DNA samples were 
then treated with sodium bisulfite to convert unmethylated cytosine to uracil using 
the Zymo EZ DNA MethylationTM kit (Zymo, Irvine, CA). Following 
conversion, genome-wide methylation was measured using the Illumina 
HumanMethylation450 BeadChip (Infinium Methylation 450K).  
For each sample, the proportion of DNA molecules methylated at each 
CpG site is represented as a beta value, determined by the following equation: 
M/(M+U+a) [where M = Methylated signal, U = Unmethylated signal and a=100]. 
For more detailed information, refer to Jones (2009). Arrays were scanned using 
an Illumina iScan, with initial quality review using GenomeStudio.  
5.7.2.1 Bioinformatics. 
To link Illumina CpG site to its genomic location and function, an 
annotation file (Triche, 2009) was used to map the unique probe IDs, identified by 
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the HM450 arraytechnology (i.e., individual CpG sites) to their genomic location, 
specific CpG regions and gene symbols (i.e., the gene which the CpG site 
regulates). Gene regions were then determined using the National Centre for 
Biotechnology Information (NCBI). See http://www.ncbi.nlm.nih.gov/ for more 
information. 
5.7.3 Predictor variables: Maternal influenza 
The presence or absence of maternal influenza during pregnancy was 
assessed by way of three self-report postal questionnaires sent to ALSPAC 
mothers (recruited during Phase I) at 18 and 32 weeks of gestation, and two 
months post-natal. All three questionnaires were developed by ALSPAC 
researchers and were similar in item and participant response format.  
 To evaluate the presence or absence of influenza during the first three 
months of gestation, mothers completed an 11-item questionnaire that enquired 
about their experience of specific symptoms and medical conditions, including 
influenza, during this time period (Bishop, Herrick, Stowe, Golding & The 
ALSPAC Study Team, 2008). The exact wording of the 11-item questionnaire 
was as follows: 
“During this pregnancy so far have you had any of the following:” 
a) Nausea 
b) Vomiting 
c) Diarrhoea 
d) Vaginal Bleeding 
e) Jaundice 
f) Urinary Infection 
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g) Influenza 
h) Rubella (German measles) 
i) Thrush (Candida) 
j) Genital Herpes 
k) Other infection  
 
For each item, mothers were asked to provide a response that corresponded to 
the occurrence of that symptom or medical condition during the time period 
specified. The four response options available to the participants were as follows: 
a) Yes, in 1st 3 months 
b) Yes, in period 4th month to now 
c) No, not at all 
d) Don’t know 
At 32 weeks, the presence or absence of maternal influenza during months 
four to six of gestation was evaluated using a 12-item questionnaire (Bickerstaff et 
al., 2008) that was similar in style and format to the questionnaire listed above. 
The only differences between the former and the current questionnaires were the 
inclusion of “a cold” as an additional item to the medical symptoms and 
conditions listed, and a change to the wording of the response options available to 
reflect the time period specified in the questionnaire.  
Finally, to evaluate the presence or absence of maternal influenza from seven 
months of gestation until delivery, mothers completed a 16-item questionnaire 
(The ALSPAC Study Team, 2009) two months after birth that was similar in style 
and format to those already described. However, unlike the previous measures, it 
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also enquired about mothers’ experience of certain medical procedures (e.g., X-
ray and ultrasound) during the latter stages of their pregnancy. The wording of the 
response options was also modified to reflect the time period that was specific to 
the questionnaire.  
Information about the reliability and validity of these self-report 
questionnaires has not been provided by ALSPAC. However, in the absence of 
serological tests to assess maternal exposure to infections during the pre-natal 
period (i.e., the diagnostic identification of viral antibodies in bodily fluids), many 
researchers have employed retrospective methods. These include self-report 
questionnaires and structured interviews completed by mothers at different 
antenatal and post-natal time-points (see Stöber, Franzek, Beckmann, & 
Schmidtke, 2002; Wright, Takei, Rifkin & Murray, 1995; Zammit et al., 2009).  
Due to concerns about the impact of participant recall bias on the 
classification accuracy of classification of specific antenatal exposures or events, 
several studies have explored the reliability and validity of retrospective self-
report measures. Of these, two studies (Buka, Goldstein, Spartos and Tsang, 2004; 
Bryant, Visser and Love, 1989) sought to test the accuracy of mothers’ 
retrospective recall (long and short-term) with respect to contracting a viral 
infection during pregnancy, amongst other antenatal events and obstetric 
complications. Interestingly, both authors found that mothers tended to under-
report their exposure to these types of illnesses. For example, Buka et al (2004) 
found that despite clinical records indicating that 30% of women in their sample 
had been diagnosed with a viral infection during prenatal medical examinations, 
22 years later only 15% reported contracting an illness.  
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In light of the possibility that mothers in the ALSPAC sample may have 
under-reported their exposure to influenza during pregnancy, mothers’ responses 
on this item were combined across the three gestational time-points in order to 
maximise the likelihood of accurately capturing their experience of the illness 
during this period.  The implications of using a variable based upon subjective 
self-report will be discussed in detail in Chapter 9. 
5.7.3.1 Derived maternal influenza variable. 
The derived measure of maternal influenza during pregnancy in the current 
research represents the presence or absence of influenza at any time-point during 
pregnancy. This dichotomous variable was based upon mothers’ responses to the 
influenza item in the three self-report postal questionnaires (i.e., 18 and 32 weeks 
and two months post-natal questionnaires). Hence, a value of zero refers to the 
absence of influenza at all three time-points during pregnancy, and a value of one 
refers to the presence of influenza at any time-point during pregnancy.  
Mothers’ affirmative responses to the influenza item “Yes, in period 4th 
month to now” in the 18-week questionnaire were not considered when 
computing the derived variable. This is because the 4th month time period is 
accounted for by the ALSPAC 32-week self-report postal questionnaire. Hence, 
the inclusion of mothers’ who endorsed this item may have inflated the number of 
mothers exposed to influenza during pregnancy, thereby biasing the results.  
In all studies of the thesis, maternal influenza was coded as a dichotomous 
variable with the following two categories: 
a) 0 = a mother’s self-report of no influenza during pregnancy 
b) 1 = a mother’s self-report of influenza during pregnancy. 
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5.7.4 Predictors variables: Maternal diabetes and/or glycosuria. 
The measure of maternal diabetes/glycosuria in the ALSPAC sample 
includes the presence of existing diabetes (i.e., prior to pregnancy), gestational 
diabetes or glycosuria during pregnancy. Upon recruitment ALSPAC mothers 
were asked about a pre-existing condition of diabetes and/or history of gestational 
diabetes. Information on glycosuria (recorded as none, trace, +, ++, +++ or more) 
was abstracted from the records of each antenatal clinic visit made by mothers 
(median number of visits = 14 per woman). Glycosuria was defined as present 
based upon a record of at least ++ (equal to 13.9 mmol/l or 250 mg/100 ml) on a 
minimum of two occasions at any time during the pregnancy (Fraser et al., 2013).  
Hence, glycosuria was defined as not present for mothers who obtained glycosuria 
ratings of none, trace and +, or a rating of ++ on only one occasion. Mothers were 
then classified into one of four mutually exclusive categories: (1) no evidence of 
glycosuria or diabetes; (2) existing diabetes before the pregnancy; (3) gestational 
diabetes (i.e., a diagnosis in the medical records of gestational diabetes in any 
woman with no history of existing diabetes) and; (4) glycosuria (i.e., ++ 
glycosuria on two occasions in women with no evidence of existing or gestational 
diabetes).  
5.7.4.1 Derived maternal diabetes/gylcosuria variable. 
A derived measure of maternal diabetes/glycosuria during pregnancy will 
be used in the current research.  This measure represents the presence or absence 
of maternal diabetes and/or glycosuria at any time-point during pregnancy. This 
dichotomous variable was computed based upon the classifications (described 
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above) assigned to mothers by trained nurses and midwives following the 
abstraction of relevant information from their obstetric and medical records. 
Hence, in all studies of the thesis, maternal diabetes and/or glycosuria was coded 
as a dichotomous variable with the following two categories: 
a) 0 = a medical assessor’s rating of no maternal diabetes and/or glycosuria 
during pregnancy 
b) 1 = a medical assessor’s rating of maternal diabetes and/or glycosuria 
during pregnancy 
5.7.5 Covariates: Socio-demographic characteristics. 
Covariates representing socio-demographic characteristics of child 
participants were selected a priori based upon previous empirical findings which 
report their association with Schizophrenia (Cannon, Jones & Murray, 2002; 
Leung, 2000; McGrath et al., 2004). These covariates include child sex, birth 
weight and gestational age. Information relevant to these variables was retrieved 
by ALSPAC researchers from computerized obstetric records of mothers and their 
infants born in the two main maternity hospitals in the region, and provided to the 
author of this thesis upon request with the outcome, predictor and antenatal 
exposure variables. Covariates of birth weight and gestational age will be 
explored in this thesis as continuous variables, while sex will be explored as a 
dichotomous variables with a value of zero indicating a male participant, and 
values of one indicating a female participant.   
5.7.6 Confounders: Maternal marital status and socio-economic class  
Maternal marital status and socio-economic class variables were derived 
from ALSPAC researchers using data from self-report postal questionnaires, sent 
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to mothers at eight and 32 weeks of gestation, respectively. As with the 
covariates, information on mothers’ marital status and socio-economic class was 
provided to the writer upon request and both variables will be explored as 
dichotomous variables.  
With regards to marital status, a value of zero refers to a mother who 
reported being single at eight weeks gestation (i.e., endorsed a response option of 
either never married, widowed, divorced or separated), and a value of one refers 
to a mother who reported being married at this same time-point (i.e., endorsed a 
response option of either married once only, married for the second time or 
married for the third time). 
Importantly, maternal socioeconomic status was derived by ALSPAC 
researches by mapping mothers’ occupation and employment status to class 
categories using the job codes from the Office of Population Censuses and 
Surveys (OPCS). Hence, a value of zero refers to a mother who reported being 
employed in a non-skilled profession at 32 weeks of gestation (i.e., indicated that 
she was employed in either a skilled manual occupation, partly skilled occupation 
or unskilled occupation) and a value of one refers to a mother who reported being 
employed in a skilled profession at this same time-point (i.e., indicated that she 
was employed in either a professional occupation, managerial and technical 
occupation, or skilled manual occupation).  
To determine the most parsimonious way to explore the possible 
confounding effects of maternal marital status and socio-economic class, a latent 
variable was computed using principal components analysis, to represent the 
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combined variance of maternal marital status and socio-economic class (for more 
information on this data reduction technique see Giles, 2002).  
5.8 Data Analysis 
5.8.1 Missing data. 
Missing data due to participant attrition and non-wave response is a 
problem that arises in most large-scale longitudinal studies (Jeličić, Phelps & 
Lerner, 2009). The nature of missing data for all variables was explored using 
Little’s missing-completely-at-random (MCAR) test (Little & Rubin, 1989). This 
test explores whether patterns of actual missing data differ significantly from a 
random distribution of missing data; thus, a non-significant result indicates that 
the data is missing completely at random (Little & Rubin, 1989). Missing data in 
the current sample was missing completely at random, Little’s MCAR F2 = 
19.646, p = 0.237.  
 Missing data was not replaced for outcome or antenatal exposure variables 
due to the importance of preserving the integrity of these variables and concern 
that missing data replacement methods may inflate disease or non-disease 
conditions, thereby biasing the results. Where cases for psychotic symptoms at 
age 12 or 18 years were missing, these participants were excluded from all 
analyses using case wise deletion. However, missing data for the covariates of 
child sex, birth weight and gestational age were replaced so as to ensure that 
controlling for covariates did not suffer from reduced power. The expectation-
maximization (EM) method as described by Gold and Bentler (2000) was used to 
replace missing values. 
5.8.2 Testing assumptions of normality. 
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To check for outliers, Z scores were calculated for each variable and 
scores above 3.29 were converted to a value of the mean plus two standard 
deviations. Visual inspection of normal Q-Q plots, and skewness and kurtosis 
values for infant birth weight and gestational age suggest that normality is a 
reasonable assumption for these variables. The Shapiro-Wilk test of normality 
was significant for both child birth weight (S-W = .99, df = 735, p = <.001) and 
gestational age (S-W =.90, df =735, p = <.001). However, this may be an artefact 
of sample size rather than indicative of non-normal distributions, as the Shapiro-
Wilk test can be biased by large sample sizes (Garson, 2012).  
5.9 Statistical Programs 
The R statistical package, version 2.13 (R Development Core Team, 2011) 
was used to derive the global cord blood DNA methylation values. To test for an 
association between DNA cord blood methylation at individual CpG sites across 
the genome and psychotic symptoms at age 12 and 18 years, adjusting for relevant 
covariates, ‘CpGassoc’, version 2.11 was used (Barfield, Coneely & Kilaru, 
2014). CpGassoc (2.11) is a statistical program designed to be imported and 
stored in the R library and then uploaded to the R environment when required to 
run the aforementioned epigenome wide analysis. 
All other analyses were performed using IBM SPSS Statistics 22.0 (IBM, 2013). 
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Chapter 6 
Global methylation of Umbilical Cord Blood DNA in ALSPAC 
Participants with Psychotic Symptoms at age 18 years 
The first of three studies is presented in this chapter and focuses on the 
relationship between global DNA methylation (DNAm) from umbilical cord 
blood (i.e., leukocyte cells) and psychotic symptoms in ALSPAC participants 
assessed at age 18 years. Specifically, the term global in the current research 
refers to the average (or median) levels of DNA methylation for a given 
participant across all of their CpG sites, as assayed by the Illumina Infinium 
HumanMethylation 450k array.  
6.1 Study Aims and Hypotheses 
The specific hypotheses to be tested are: 
(1) Participants who report psychotic symptoms at age 18 years will exhibit 
significantly higher global DNA methylation levels in cord blood collected 
at birth than will participants who do not report psychotic symptoms. 
(2) Participants who report psychotic symptoms at age 18 years will exhibit 
significantly higher global DNA methylation levels in cord blood at birth 
across specific CpG site regions (islands, north shores, north shelves, 
south shores and south shelves) than will participants who do not report 
psychotic symptoms. Specifically, it is hypothesised that global DNAm of 
CpG sites in island regions will be significantly higher in participants who 
report psychotic symptoms at age 18 years than in participants who do not 
report symptoms at this time-point. 
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6.2 Method 
6.2.1 Participants 
  The Avon Longitudinal Study of Parents and Children (ALSPAC) and the 
Accessible Resource of Integrated Epigenomics Studies (ARIES) subsample have 
both been described in detail in Chapter Five. This study uses data from 735 
children (329 males and 406 females) who participated in the Psychotic-Like 
Symptom Interview (PLIKSi) at age 18 and also had available cord blood DNAm 
data from the ARIES subsample.  Of the 735 participants, 57 (8%) were classified 
as having definite or suspected psychotic symptoms at 18 years of age. The socio-
demographic characteristics, by psychotic symptom group, for the 735 ALSPAC 
mother-child pairs at age 18 years are described in Table 5.  
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Table 5. Socio-demographic characteristics of participants (n = 735) who completed the PLIKSi at 
age 18 years 
 
Psychotic Symptoms  age 18 
  
 
None Definite/Suspected 
  
Child Characteristic  
Categorical 
  
n (%) n (%) F2 p 
Sex 
Male 305 (45) 24 (42.1) .18 .68 
Ethnicity 
Non-Caucasian 18 (2.7) 2 (3.7) .18 .67 
Child Characteristic  
Continuous  M (SD) M (SD) t p 
Birth weight  
(grams) 3484.08 (473.02) 3443.82 (502.69) .61 .54 
Gestation  
(weeks) 39.58 (1.56) 39.47 (1.43) .52 .61 
Mother Characteristic 
Categorical  n (%) n (%) F2 p 
Diabetes/Glycosuris 
Yes       
Influenza 
Yes 95 (14.20) 11 (19.30) 1.12 .29 
Marital Status 
Single 107 (16.00) 16 (29.10) 6.18 0.01 
Socio-economic classa 
Non-skilled 
work 
 
78 (12.80) 13 (28.30) 8.50 p < 0.01 
Mother Characteristic 
Continuous  M (SD) M (SD) t p 
Maternal age at delivery  
              (years) 29.67 (4.23) 29.26 (5.78) .52 .60 
aMaternal socio-economic class is a derived classification, achieved by mapping maternal 
occupation to class categories. These categories were then transformed into a dichotomous 
variable, with two categories: ‘Non-skilled work’ representing lower socio-economic class, and 
‘Skilled work’ representing higher socio-economic class. 
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Table 5 shows that participants with psychotic symptoms at age 18 years were 
significantly more likely than their non-psychotic counterparts to have been born 
to single mothers and mothers of lower socio-economic standing (i.e., employed 
in non-skilled professions).  Accordingly, maternal marital status and socio-
economic class will be controlled for in all analyses undertaken in the current 
study. The total variance accounted for by maternal marital status and socio-
economic class was 54.13% and 45.87%, respectively, with a correlation of .74 
6.3 Measures 
6.3.1 Outcome variable 
6.3.1.1 Psychotic symptoms at age 18. 
The primary dichotomous outcome variable of psychotic symptoms at age 
18 was assessed using the semi-structured Psychotic-Like Symptoms Interview 
(PLIKSi; see Chapter Five for full details).  
6.3.2 Predictor variables. 
6.3.2.1 Global DNAm in cord blood. 
The primary predictor variable in this study is DNAm data from the 
umbilical cord blood of 735 child participants collected upon their delivery. This 
data was obtained using the HM450 arrayarray technology (Illumina, Inc. CA, 
USA), which provides information about methylation status of CpG sites as a 
beta-value (β) ranging from 0 (no methylation) to 1 (complete methylation). 
Global DNAm CB values were then derived from the Infinium 450K array data 
using R version 2.13 (R Development Core Team, 2011). All β values were 
multiplied by 100 to permit global DNAm to be described in terms of a 
percentage rather than as a proportion (a method described by Lund et al., 2014). 
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6.3.2.1.1 Testing assumptions of normality. 
The shape of the distribution of global DNAm values was examined to 
determine the extent to which the assumption of normality was met. Skewness (-
2.29, SE = .08), kurtosis (5.85, SE = .16) and the Shapiro-Wilk test of normality 
(S-W = .72, df = 894, p = < .001) suggest that global DNAm values were 
characterised by a non-normal distribution that was negatively skewed and 
leptokurtic. Consequently, a series of transformations were performed, including 
arisn, log, log10 and logit transformations, in an effort to improve the normality of 
the data. None of these computations improved the distribution, which continued 
to violate the assumption of normality even after transformation.  As such, the 
original untransformed global DNAm values were used in both non-parametric 
and parametric analyses.  
6.3.2.2 Global DNAm by specific CpG site region. 
An Illumina Human Methylation 450K annotation data file (Triche, 2014) 
was used initially to determine the unique location of each CpG site with respect 
to one of the following five regions: CpG islands, CpG north shore, CpG north 
shelf, CpG south shore, and CpG south shelf. Global DNAm β values for each 
region were then derived from the Infinium 450K array data using R version 2.13 
(R Development Core Team, 2011). In order to describe global DNAm as a 
percentage for each of the five CpG site regions, all β values were again 
multiplied by 100.  
 6.3.2.2.1 Testing assumptions of normality. 
Review of descriptive information, including the distributional shape of 
the global DNAm β values, indicated that the data for all five regions deviated 
from a normal distribution (see Table D1 of Appendix D). As with the global 
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DNAm values, a series of transformations were performed, however, none of 
these computations improved the distributions. Consequently, the original global 
DNAm β values for each of the five specific regions were used.  
6.3.3 Covariate variables. 
6.3.3.1 Maternal influenza. 
  Prenatal exposure to maternal influenza, in the current study, refers to the 
presence or absence of influenza at any time-point during pregnancy. This 
variable was measured retrospectively via three self-report postal questionnaires 
developed by ALSPAC researchers and completed by study mothers at 18 and 32 
weeks of pregnancy, and two months after birth (see Chapter 5, for full details).  
6.3.3.2 Socio-demographic characteristics. 
Covariates in the current study represent socio-demographic 
characteristics of mother-child pairs previously reported to be associated with 
schizophrenia (e.g. Cannon, Jones & Murray, 2002). These factors include the 
continuous measures of infant birth weight and gestational age as well as the 
dichotomous measure of child sex. Data on these variables was sourced from the 
computerised hospital obstetric and medical records of mother and child pairs.  
 6.3.3.2.1. Testing assumptions of normality. 
The Shapiro-Wilk test of normality was significant for both child birth 
weight and gestational age (see Chapter 5 for full details), indicating the 
distributions were not normally distributed. However, the original untransformed 
variables were used because binary logistic regression, the statistical method used 
in the current study, does not require continuous covariates to be normally 
distributed (Hosmer, Lemeshow & Sturdivant, 2013).  
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6.4 Statistical Method 
6.4.1 Role of global DNAm in psychotic symptoms at age 18 years. 
The role of global DNA CB methylation in predicting psychotic symptoms 
at age 18 years was explored with DNAm as a continuous variable. Global DNAm 
values were determined by averaging the level of DNAm of individual CpG sites 
across the genome for each participants. This methodology was utilised in the 
absence of Global LINE-1 DNAm data.  
The non-normal distribution of this variable motivated the use of non-
parametric methods when testing for an association between global DNAm and 
the presence of psychotic symptoms at age 18 years.  Hence, a Mann-Whitney U 
test was conducted, quantified by median differences between global DNAm of 
the disease and non-disease groups. In order to test the robustness of these 
findings, the role of global DNAm in psychotic symptoms will also be explored 
using parametric methods (i.e., an independent t test).  
 To further explore the relationship between global DNAm and psychotic 
symptoms at age 18, a series of univariate hierarchical binary logistic regression 
models were performed and involved the implementation of a three-stage analysis 
plan. Firstly, a univariate binary logistic regression was applied to assess the 
unadjusted association between global DNAm and psychotic symptoms. 
Secondly, covariates of child sex, birth weight, gestational age and exposure to 
influenza in utero were added independently in subsequent univariate analyses to 
assess the association between the predictor and outcome variables after adjusting 
for the effects of these covariates. Importantly, each covariate was added into the 
model during the first step of the analysis, with the variable representing global 
DNAm entered into the model in the second step of the analysis. Thirdly, the 
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association between global DNAm and psychotic symptoms was explored with 
the latent continuous variable, representing the combined variance of maternal 
marital status and socio-economic class, included in the adjusted model. 
Preliminary review of the results indicated possible interaction effects between 
global DNAm and sex, and global DNAm and maternal influenza. As such, the 
adjusted and unadjusted models were re-run with the interaction terms of ‘global 
DNAm by Sex’ and ‘global DNAm by Maternal Influenza’ included in the 
models.  To test for multicollinearity among predictors and covariates, 
correlational statistics were employed and reviewed. All tests in this study were 
two-tailed and the results were regarded as significant at below the five percent 
level of probability.  
6.4.2 Role of global DNAm in psychotic symptoms at age 18 by CpG 
site region. 
The same statistical approach as described above for evaluation of the role 
of global DNAm in psychotic symptoms at 18 years of age was then used to 
explore the role of global DNAm by specific CpG site region in psychotic 
symptoms at age 18. This included testing associations between the predictor and 
outcome variable using parametric as well as non-parametric methods in order to 
assess the robustness of the findings. 
 
6.5 Results 
6.5.1 Role of global DNAm in psychotic symptoms at age 18 years. 
In order to test the first hypothesis, that participants who reported psychotic 
symptoms at 18 years would exhibit significantly higher levels of global DNAm 
than would those who did not report symptoms, a non-parametric Mann Whitney U 
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test was conducted. The results of this analysis showed significantly higher global 
DNAm levels in participants with psychotic symptoms (Mdn=45.00) at age 18 than 
in those without symptoms (Mdn=44.97; U = 15594, p = 0.02) at this time-point. 
The median global DNAm in CB for participants who developed psychotic 
symptoms was 0.43, compared with a median global DNAm level of 0.36 for 
participants who did not develop psychotic symptoms.  
By way of a sensitivity analysis examining the choice of non-parametric 
analysis, the same test was performed as an independent t-test. Consistent with the 
non-parametric analysis, this also revealed significantly higher global DNAm in 
participants with psychotic symptoms (M = 44.94) compared to those without 
symptoms at age 18 (M = 44.83; p = .046). Consequently, the mean will be used 
from this point forward to describe the characteristics of the global DNAm variable.  
 Next, a series of univariate hierarchal binary logistic regressions were 
conducted to examine the role of covariates and confounders in the relationship 
between global DNA and psychotic symptoms at age 18. The multiplicative effects 
of both global DNAm and child sex, and global DNAm and maternal influenza on 
psychotic symptoms at this time point, were also explored.  
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Table 6. Results of binary logistic regression analyses of global DNAm in cord blood and psychotic symptoms at age 18 years 
 Unadjusted 
(Model1)a 
Adjusted for Sex 
(Model2)b 
Adjusted for Birth weight 
(Model 3)c 
Adjusted for Gestational age 
(Model 4)d 
Adjusted for Influenza 
(Model 5)e 
Adjusted for Marital status 
and Socio-economic class 
(Model 6)f 
  
OR 
 
95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Global DNAm 
 
5.54 .89-34.49 5.56 .89-34.70 5.67 .91-35.28 5.64 .90-35.19 5.77 .92-36.34 6.19 .76-50.37 
Global DNAm by 
Sexg  
(0 = male) 
 
 
1122.23* 
8.22-
153199.11 
   
1084.45* 
7.93- 
148367.97 
 
1088.22* 
7.91-
149724.40 
 
1330.36* 
9.76-
181408.61 
 
1169.64* 
3.33-
410393.56 
Global DNAm by 
Influenzah  
(0 = No influenza) 
 
 
119.20 
.07-
213285.44 
 
126.66 
.07-
218909.02 
 
119.65 
.07-
194225.63 
 
115.37 
.07-
202285.83 
   
215.70 
.06-
777118.94 
aModel 1 shows the results for the univariate hierarchical binary logistic regression analysis. 
bModel 2 shows the results after adjustment for child sex.   
cModel 3 shows the results after adjustment for child birth weight.  
dModel 4 shows the results after adjustment for child gestational age.  
eModel 5 shows the results after adjustment for exposure to influenza in utero. 
fModel 6 shows the results after controlling for maternal marital status and socio-economic class. 
gRepresents the multiplicative effects of global DNAm and sex across adjusted and unadjusted models.  
hRepresents the multiplicative effects of global DNAm and influenza across adjusted and unadjusted models.  
*p < .05 
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These are reported in Table 6 which shows that for every 1% increase in global 
DNAm at birth, participants were approximately five-and-a-half times more likely 
to report psychotic symptoms at 18 years.  
After adjusting for the effects of maternal marital status and socio-economic 
class, this odds ratio (OR) increased to 6.19. Despite high ORs, neither the 
unadjusted (p = .07) or adjusted (p = .09) univariate models for DNAm reached 
statistical significance at below the five percent level of probability.  
In contrast, the unadjusted interaction effect for global DNAm and child sex 
was statistically significant. For every 1% increase in global DNAm, female 
participants were 1122 times more likely to report psychotic symptoms at age 18 
(see Table 5). This interactive effect remained statistically robust after controlling 
for all covariate and confounding variables. Further, after controlling for maternal 
marital status and socio-economic class, the statistically significant ORs increased 
by 4% to 1169.64.  
As depicted in Figure 7, the magnitude of the interactive effect for global 
DNAm and child sex may be somewhat inflated due to the large variability in the 
global DNAm beta values of male participants who developed psychotic symptoms 
at age 18. Specifically, some very low global DNAm values of males in the disease 
group may have lowered their group’s mean beta-values quite considerably.  
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Figure 8. Interaction effect of global DNAm in cord blood and sex. 
 
Although, the unadjusted interaction effect for global DNAm and exposure to 
influenza in utero did not reach statistical significance (p = .21), the OR indicates 
that for every 1% increase in global DNAm, participants exposed to influenza in 
utero (n = 128) were 119 times more likely report psychotic symptoms at 18 years 
than were their non-exposed counterparts (n = 758). Despite still not reaching 
statistical significance, this OR increased by approximately 81% to 215.70 after 
adjusting for maternal marital status and socio-economic class.  
6.5.2 Role of global DNAm in psychotic symptoms at age 18 years 
across specific CpG site regions. 
A series of non-parametric Mann Whitney U tests were conducted to test 
the second hypothesis that global DNAm levels would significantly differ 
between participants with and without psychotic symptoms at age 18 years, across 
unique CpG site regions. The results showed that except for CpG island regions, 
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the median global DNAm values for all other regions were higher for participants 
with psychotic symptoms at age 18 years, than were those for participants without 
psychotic symptoms. However, only the differences in global DNAm values of 
CpG north shelf regions, between participants with and without psychotic 
symptoms at age 18, reached statistical significance at below the five percent level 
of probability (U =15240.00, p = .008; see Appendix C). 
By way of sensitivity analyses, several independent t-tests were conducted 
to test the aforementioned hypotheses using parametric methods. These results are 
shown in Appendix D and were consistent with the results of the non-parametric 
analyses reported above. As such, the mean will be used to describe the 
characteristics of global DNAm of specific CpG site regions. 
To further explore the relationship between global DNAm and psychotic 
symptoms at age 18 years by specific CpG site region, a series of univariate 
hierarchical binary logistic regression models were undertaken. The results of these 
logistic regression models will be presented in the following section under separate 
headings for each specific CpG site region.   
6.5.3.1 Global DNAm of CpG sites in island regions. 
Contrary to the predicted effects, the results of the univariate binary logistic 
regression analyses show that global DNAm of CpG island regions did not 
significantly differ between participants with and without psychotic symptoms, at 
age 18 years (see Table 7).  
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Table 7. Results of binary logistic regression analyses of global DNAm and psychotic symptoms at age 18 years by specific CpG site regions 
 Unadjusted 
(Model1)a 
Adjusted for Sex 
(Model2)b 
Adjusted for Birth 
weight 
(Model 3)c 
Adjusted for Gestational 
age 
(Model 4)d 
Adjusted for Influenza 
(Model 5)e 
Adjusted for Marital 
Status and SES 
(Model 6)f 
CpG Site Region 
 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Islands 
 
1.00 1.00-1.01 1.00 1.00-1.01 1.00 1.00-1.01 1.00 1.00-1.01 1.00 1.00-1.01 1.00 1.00-1.01 
Islands by 
Sexg 
(0 = Male) 
1.00 .99-1.01 1.00 .99-1.01 1.00 .99-1.01 1.00 .99-1.01 1.00 .99-1.01 1.00 .99-1.01 
Islands by 
Influenzah 
(0 = No influenza) 
1.00 .99-1.01 1.00 .99-1.01 1.00 .99-1.01 1.00 .99-1.01 1.00 .99-1.01 1.00 .99-1.01 
North Shores 
 
1.62 
 
.71-3.66 1.62 .72-3.67 1.63 .72-3.68 1.62 .72-3.66 1.64 .72-3.71 1.79 .71-4.55 
North Shores by 
Sexi 
6.63* 1.22-36.10   6.60* 1.20-35.71 6.52* 1.20-35.51 7.00* 1.28-38.37 5.54 .81-38.07 
North Shores by 
Influenzaj 
6.65 .38-117.17 6.68 .39-118.44 6.50 .39-108.34 6.40 .37-110.08   15.14 .56-409.36 
North Shelves 
 
2.98* 1.09-8.10 2.96* 1.09-8.04 2.97* 1.10-8.04 2.97* 1.09-8.05 3.05* 1.11-8.36 2.58 
 
.87-7.66 
North Shelves by 
Sexk 9.14* 1.28-65.26   9.00* 1.27-63.99 8.93* 1.25-63.79 10.23* 1.42-73.95 6.16 .71-53.65 
North Shelves by 
Influenzal 1.36 .09-20.48 1.40 .09-21.24 1.46 .10-21.95 1.37 .09-20.64   2.06 .11-38.07 
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 Unadjusted 
(Model1)a 
Adjusted for Sex 
(Model2)b 
Adjusted for Birth 
weight 
(Model 3)c 
Adjusted for Gestational 
age 
(Model 4)d 
Adjusted for Influenza 
(Model 5)e 
Adjusted for Marital 
Status and SES 
(Model 6)f 
CpG Site Region 
 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
South Shores 
 
2.69 
 
.71-10.20 2.64 .70-10.03 2.66 .71-10.03 2.70 .72-.10.21 2.74 .72-10.43 3.14 .69-14.35 
South Shores by 
Sexm 
 
13.44 
 
.90-200.60   
 
13.25 
 
.89-196.44 
 
13.40 
 
.90-199.80 
 
14.09 
 
.94-211.65 13.56 .58-316.01 
South Shores by 
Influenzan 
 
298.87 
 
.84-
106592.98 
 
282.87 
 
.83- 
.96822.41 
 
287.59 
 
.85-
97816.29 
 
287.04 
 
.81- 
101779.77   
 
458.06 
 
.86- 
244513.96 
South Shelves 
 
2.23 
 
.82-6.08 2.20 .80-6.03 2.28 .83-6.25 2.28 .83-6.24 2.24 .82-6.13 2.33 .75-7.24 
South Shelves by 
Sexo 14.13* 
1.87-
106.61   14.86* 
1.94-
113.79 14.14* 1.87-16.83 14.70* 
1.94-
111.33 10.82* 
1.13-
103.38 
South Shelves by 
Influenzap 6.95 .22-221.39 6.93 .22-216.16 6.61 .22-201.84 6.67 .21-211.36   10.55 .29-389.72 
aModel 1 shows the results for the univariate hierarchical binary logistic regression analysis. 
bModel 2 shows the results after adjustment for child sex.  
cModel 3 shows the results after adjustment for child birth weight. 
dModel 4 shows the results after adjustment for child gestational age.  
eModel 5 shows the results after adjustment for exposure to influenza in utero. 
fModel 6 shows the results after controlling for maternal marital status and socio-economic class. 
gRepresents the multiplicative effects of global DNAm in island regions and sex across adjusted and unadjusted models.  
hRepresents the multiplicative effects of global DNAm in island regions and influenza across adjusted and unadjusted models.  
iRepresents the multiplicative effects of global DNAm in north shore regions and sex across adjusted and unadjusted models. 
jRepresents the multiplicative effects of global DNAm in north shore regions and influenza across adjusted and unadjusted models. 
kRepresents the multiplicative effects of global DNAm in north shelf regions and sex across adjusted and unadjusted models. 
lRepresents the multiplicative effects of global DNAm in north shelf regions and influenza across adjusted and unadjusted models. 
mRepresents the multiplicative effects of global DNAm in south shore regions and sex across adjusted and unadjusted models. 
nRepresents the multiplicative effects of global DNAm in south shore regions and influenza across adjusted and unadjusted models. 
nRepresents the multiplicative effects of global DNAm in south shelf regions and sex across adjusted and unadjusted models. 
oRepresents the multiplicative effects of global DNAm in south shelf regions and influenza across adjusted and unadjusted models. 
*p < .05. 
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6.5.3.2 Global DNAm of CpG sites in north shore regions  
 A statistically significant interactive effect was found for child sex and 
global DNAm in north shore regions (as depicted in Figure 8). As shown in Table 
7, for every 1% increase in global DNAm of north shore regions, participants that 
were female were almost seven times more likely to report psychotic symptoms at 
age 18 (p = .03). This interactive effect remained statistically robust even after 
controlling for child sex, birth weight, gestational age and exposure to influenza in 
utero. However, upon adjusting for the contributions of maternal marital status 
and socio-economic class to the model, the OR reduced by 16% and was no 
longer statistically robust at below the five percent level of probability (p = .08). 
 
 
 
 
 
Figure 9. Interaction effect of global DNAm of north shore regions and sex. 
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6.5.3.3 Global DNAm of CpG sites in north shelf regions.  
 A significant association was found between global DNAm of north shelf 
regions and psychotic symptoms at age 18 years. As described in Table 7, for 
every 1% increase in global DNAm of north shelf areas, participants were three 
times more likely to report psychotic symptoms at 18 years (p = .03). This 
association remained statistically robust after controlling for child sex, birth 
weight, gestational age and exposure to influenza in utero. Upon adjusting for the 
contributions of maternal marital status and socio-economic class to the model, 
however, the OR reduced by 13% and was no longer statistically robust at below 
the five percent level of probability (p = .09). 
 In addition, a statistically significant interactive effect was found 
for child sex and global DNAm of north shelf regions (the interaction is depicted 
in Figure 9). As shown in Table 7, for every 1% increase in global DNAm of this 
region, female participants were nine times more likely to present with psychotic 
symptoms at this time-point (p = .03). The observed multiplicative effect 
remained statistically robust after controlling for child sex, birth weight, 
gestational age and exposure to influenza in utero. Upon adjusting for the 
contributions of maternal marital status and socio-economic class to the model, 
the OR reduced by 33% and was no longer statistically robust at or below the five 
percent level of probability (p = .10). 
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Figure 10. Interaction effect of global DNAm of north shelf regions and sex 
 
6.5.3.4 Global DNAm of CpG sites in south shore regions. 
An interactive effect was found for sex and global DNAm of south shore 
regions, whereby for every 1% increase in global DNAm of south shore areas, 
female participants were nearly 13-and-a-half times more likely to report psychotic 
symptoms at 18 (this interaction is depicted in Figure 10). As shown in Table 7, this 
OR increased by 5% after controlling for the contribution of maternal influenza to 
the model. However, neither of these models met statistical significance at below 
the five percent level of probability (i.e., unadjusted model p = .06; adjusted model 
p = .056) 
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Figure 11. Interaction effect of global DNAm in south shore regions and sex 
 
An interactive effect was also found for maternal influenza and global 
DNAm of south shore regions (this interaction is depicted in Figure 11). More 
specifically, for every 1% increase in global DNAm of this region, participants 
exposed to influenza in utero were approximately 300 times more likely to report 
psychotic symptoms at age 18. There was a 53% increase in the odds ratio after 
adjusting for the contributions of maternal marital status and socio-economic class 
to the model. However, neither the unadjusted nor adjusted models reached 
statistical significance at below the five percent level of probability (i.e., unadjusted 
model p = .057; adjusted model p =.056).  
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Figure 12. Interaction effect of global DNAm in south shore regions and maternal 
influenza 
 
6.5.3.5 Global DNAm of CpG sites in south shelf regions.  
An interactive effect was found for sex and global DNAm of south shelf 
regions (this interaction is depicted in Figure 12). More specifically, for every 1% 
increase in global DNAm of this region, female participants, were 14.13 times more 
likely to report psychotic symptoms (p = .01). This interactive effect remained 
statistically robust after controlling for child sex, birth weight, gestational age, 
exposure to influenza in utero. Further, upon adjusting for the contributions of 
maternal marital status and socio-economic class to the model, the OR reduced by 
23% but remained statistically robust at below the five percent level of probability 
(p = .04). 
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Figure 13. Interaction effect of global DNAm of south shelf regions and sex 
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6.6 Discussion/Preliminary Findings 
The current study aimed to explore the association between global DNAm 
derived from umbilical cord blood, collected at birth, and the presence of 
psychotic symptoms at age 18 years. It also sought to test whether this 
relationship held across specific CpG site regions, namely islands, north shores, 
north shelves, south shores and south shelves within the epigenome. 
 Supporting the first hypothesis, participants who reported psychotic 
symptoms at age 18 years were found to exhibit higher global DNAm levels than 
their non-psychotic counterparts and this effect was robust to control for the 
covariation of child sex, birth weight, gestational age and maternal influenza. 
Despite relatively high ORs, the association between global DNAm and psychotic 
symptoms at age 18 years did not reach statistical significance at or below the five 
percent level of probability. 
 Further exploratory analyses revealed moderating effects of sex on the 
relationship between psychotic symptoms and global DNAm which remained 
robust after adjusting for the effect of all covariate and confounding variables. 
Female participants who reported psychotic symptoms at age 18 years were 
significantly more likely to exhibit higher global DNAm at birth than were those 
who did not report symptoms at this time-point. Moreover, participants who were 
exposed to influenza in utero and reported psychotic symptoms at age 18 years 
were more likely to show higher global DNAm levels at birth than were their 
exposed, non-psychotic counterparts, although this relationship did not reach 
statistical significance.  
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 Not supporting the second hypothesis, global DNAm of island regions did 
not significantly differ between participants with and without psychotic 
symptoms, at age 18 years. Rather, the results showed that only global DNAm of 
north shelf regions was significantly higher in participants with psychotic 
symptoms than in those without symptoms.  
 Further exploratory analyses revealed moderating effects of sex on the 
relationship between psychotic symptoms, whereby female participants who 
reported psychotic symptoms at age 18 years were significantly more likely to 
show higher global DNAm of north shore, north shelf and south shelf regions at 
birth than did their non-psychotic, female counterparts. 
A non-significant interaction effect was found for maternal influenza, 
whereby participants who were exposed to the virus during gestation and who 
reported psychotic symptoms during late adolescence, were more likely to exhibit 
higher global DNAm of south shore regions at birth (Unadjusted OR = 298.87; p 
= .057). 
A common finding when exploring the role of global DNAm in psychotic 
symptoms at age 18 years, was associations between the outcome and predictor 
variables (and covariates of sex and maternal influenza) that were characterised 
by high ORs which did not reach statistical significance and/or were represented 
by extremely wide 95% confidence intervals. This may be due to the small 
number of participants in the psychotic group (n = 57) compared to the non-
psychotic group (n = 678) and the non-normal distribution of the data. 
Additionally, conducting a subgroup analysis to explore the role of global DNAm 
across CpG site regions reduced the number of participants in the psychotic group 
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even further reducing statistical precision. For this reason, caution should be taken 
in drawing definitive conclusions from the findings.  
The current study aimed to explore the association between global DNAm derived 
from umbilical cord blood, collected at birth, and the presence of psychotic 
symptoms at age 18 years. It also sought to test whether this relationship held 
across specific CpG site regions, namely islands, north shores, north shelves, 
south shores and south shelves within the epigenome. 
Taken together, these results suggest that higher global DNAm in 
umbilical cord blood (i.e., higher methylation of individual CpG sites, on average, 
at birth in these specific cell lines) may play a role in the development of 
psychotic symptoms at age 18 years. These findings obviously require replication 
but do show some promise that differences in DNAm can be explored as a 
potential biomarker for psychotic phenomena during adolescence or examined in 
relation to early neuropsychological markers for the developmental trajectory 
toward psychosis in adolescence. 
DNAm patterns have been shown to be particularly vulnerable to influence 
by environmental stimuli during fetal development (Drake et al., 2015; Godfrey et 
al., 2011; Herbstman, 2012; Lillycrop, Phillips, Jackson, Hanson, & Burdge, 
2005). Hence, the moderating roles of sex (i.e., sex-specific hormones) and 
maternal influenza on the relationship between global DNAm and psychotic 
symptoms at age 18 years examined here, provide evidence for possible 
environmental events which may have contributed to the epigenetic alterations 
(i.e., higher global DNAm) seen in participants who reported psychotic symptoms 
at this time-point.  
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In summary, this study explored the role of DNAm in psychotic symptoms 
at age 18 years at a global level. The next study seeks to identify differences in the 
DNAm of individual CpG sites using the HM450 arrayarray between participants 
with and without psychotic symptoms at ages 12 and 18 years.  
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Chapter 7 
 
Association Analyses of Individual CpG site DNAm in Umbilical 
Cord Blood and Psychotic Symptoms at ages 12 and 18 
This second of three studies focuses again on the association between DNA 
methylation (DNAm) of individual CpG loci, across the epigenome, in umbilical 
cord blood (i.e., leukocyte cells) and psychotic symptoms in ALSPAC 
participants at ages 12 and 18 years. In this study, the aim is to identify 
differences in the methylation of specific CpG sites from the 450K array and the 
gene regions which they are linked to when comparing those with and without 
psychotic symptoms.  
7.1 Study Aims and Hypotheses 
The specific hypotheses to be tested are: 
(1) Participants who report psychotic symptoms at ages 12 and 18 years will 
exhibit differentially-methylated CpG sites at birth, at an epigenome-wide 
level, compared to participants who do not report psychotic symptoms. 
(2) The specific CpG sites found to be differentially-methylated, at birth, 
between participants with and without psychotic symptoms will be similar 
across the two time-points (i.e., age 12 and 18 years).  
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7.2 Method 
7.2.1 Participants. 
The ALSPAC and ARIES subsample have both been described in detail in 
Chapter Five. This study uses data from participants who had available cord blood 
gene DNAm data from the ARIES subsampled and who had participated in the 
PLIKS at either of the two time-points of interest (at age 12 and 18 years). Thus, 
831 (393 males and 438 females) participants are included in the analyses for 
psychotic symptoms at age 12 years and 735 (329 males and 406 females) 
participants are included in analyses for psychotic symptoms at age 18 years. 
Of the 831 participants examined at 12 years of age, 83 (10%) were 
classified as having definite or suspected psychotic symptoms, while 748 (90%) 
were classified as exhibiting no psychotic symptoms. The socio-demographic 
characteristics by psychotic group, for the 831 ALSPAC mother-child pairs at age 
12 years are described in Table 8. As shown, participants with psychotic 
symptoms at age 12 were significantly more likely than their non-psychotic 
counterparts to have been born to single mothers. However, they were comparable 
on all other socio-demographic factors listed.  
 Details regarding the socio-demographic characteristics for the 735 
ALSPAC mother-child participants that had data with respect to the PLIKSi at age 
18 years are previously described in Chapter Six. In summary, of these, 57 child 
participants (7.8%) were classified as having definite or suspected psychotic 
symptoms, while 678 (92.2%) were classified as exhibiting no psychotic 
symptoms.  
 
143 
 
 
 
Table 8. Socio-demographic characteristics of participants (n = 831) who completed the PLIKSi at age 12 for 
whom DNAm is available via ARIES 
 Psychotic Symptoms at age 12   
 
None 
n=748 
Definite/Suspected 
n=83   
Child Characteristic  
Categorical  
n (%) n (%) F2 p 
Sex 
Male 
351 46.9 42 50.6 .41 .52 
Ethnicity 
Non-Caucasian 
24 3.3 2 2.5 .16 .69 
Child Characteristic  
Continuous  
M (SD) M (SD) t p 
Birth weight  
(grams) 
3477.34 482.93 3500.42 511.98 -.41 .68 
Gestation  
(weeks) 
39.55 1.54 39.75 1.63 -1.12 .27 
Mother Characteristic 
Categorical  
n (%) n (%) F2 p 
Marital Status 
Single 
117 15.8 22 27.2 6.65 .01 
Socio-economic classa 
Non-skilled work 
96 14.5 10 14.1 .01 .92 
Mother Characteristic 
Continuous  
M (SD) M (SD) t p 
Maternal age at delivery  
              (years) 
29.57 4.32 29.29 4.74 .56 .57 
aMaternal socio-economic class is a derived classification, achieved by mapping mothers’ 
occupation to class categories. These categories were then transformed into a dichotomous 
variable, with two categories: ‘Non-skilled work’ representing lower socio-economic class, and 
‘Skilled work’ representing higher socio-economic class. 
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As in Chapter Seven, maternal marital status and socio-economic class will be 
controlled for in all analyses undertaken in the current study. While the latter 
factor was not significantly different between participants with and without 
psychotic symptoms at age 12 years, a significant difference was found for 
participants assessed for psychotic symptoms at 18 years (see Chapter Six for full 
details). Hence, in an effort to maintain consistency across all studies, maternal 
marital status and socio-economic class were combined and controlled for as a 
latent continuous variable (see Chapter Five for full details).  
7.2.2 Measures 
7.2.2.1 Outcome variables: Psychotic symptoms at ages 12 and 18 years. 
The two primary outcome variables in the current study are again 
psychotic symptoms at ages 12 and 18 years both of which are explored as 
dichotomous variables (see Chapter Five for full details).  
7.2.2.2 Predictor variable: DNAm of individual CpG sites across the 
epigenome. 
The primary predictor variable in this study is DNAm data from umbilical 
cord blood. This data was obtained using the HM450 arrayarray technology 
(Illumina, Inc. CA, USA) which provides information about methylation status of 
CpG sites as a beta-value ranging from 0 (no methylation) to 1 (complete 
methylation). Refer to Chapter 2 for full details regarding the HM450 arrayarray 
technology and its applicability.  
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7.2.2.2.1 Data Cleaning: Filtering out data associated with problematic 
HM450 arrayarray probes. 
According to Naeem and colleagues (2014), the HM450 arrayarray is 
vulnerable to several genomic factors which may compromise its ability to 
accurately evaluate DNAm at an epigenome-wide level (i.e., increase the 
likelihood of false positive results). These factors include single nucleotide 
polymorphisms (SNPs), small insertions and deletions (INDELs), repetitive DNA, 
and areas with reduced genomic complexity. As a result, the authors investigated 
the effect of these influences on the performance of the HM450 arrayand 
identified subsets of both high quality probes, which provided reliable and 
unadulterated measurements of DNAm, and low quality probes which resulted in 
noisy methylation signals. As a result, the authors recommend all low quality 
probes be removed from DNAm data sets prior to conducting epigenome-wide 
analyses using the HM450 arraytechnology in order to reduce the risk of 
erroneous (i.e., false positive) results.  
In line with these recommendations, all of the CpG sites associated with 
problematic array probes, as identified by Naeem et al. (2014), were excluded 
prior to conducting the epigenome-wide associations of DNAm in CB and 
psychotic symptoms at ages 12 and 18 years. For full details of the CpG sites 
omitted see Naaem et al. (2014). The process of removing unreliable CpG sites 
was undertaken using R version 2.13 (R Development Core Team, 2011). Of the 
485,577 CpG sites in the initial R file 294,840 (61%) remained after removal of 
the erroneous sites. This finding is consistent with those of Naeem et al. (2014). 
Epigenome-wide DNAm will be explored as a continuous measure in the 
current study.  
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7.3 Statistical Method  
7.3.1 DNAm of individual CpG sites across the epigenome  
To examine the role of epigenome-wide DNAm in psychotic symptoms at 
age 12 years, the R function CpGassoc (Barfield, Kilaru, Smith, & Conneely, 
2012), specifically created for analysing DNA methylation microarray data was 
used. To conduct the analysis, beta values representing DNAm at a unique CpG 
site level, were modelled as the predictor variable and psychotic symptoms at age 
12 were modelled as the outcome variable. No potential covariates or confounders 
were added to the model as these will be explored at a later stage of the analysis.  
 After running the CpGassoc function, the results were filtered to remove 
M values (i.e., logit-transformed beta values) which represented a difference in 
DNAm at birth between participants who report psychotic symptoms at 12 years 
and those who do not report psychotic symptoms that was close to zero (e.g., 
.001). This approach was adopted on advice from the creator of the CpGassoc 
statistical function, because when the difference in DNAm between disease and 
non-disease groups, and M values are small (i.e., less than .001) this can lead to 
rounding errors, resulting in false positive results (Richard Barfield, personal 
communication, January 1, 2014). 
 Despite the exploratory nature of the current study, Benjamini-Hochberg 
False Discovery Rate (FDR) adjusted p values, provided by the CpGassoc output 
were used to assess the significance of the relationship between the DNAm of 
unique CpG sites and psychotic symptoms at age 12 years (Benjamini and 
Hochberg, 1995). Increasingly studies of this kind use the Benjamini-Hochberg’s 
method when controlling for the family wise error rate which is preferred over the 
highly conservative Bonferroni’s correction (for examples of this approach see 
147 
 
 
 
Castillo-Fernandez, Spector, & Bell, 2014; Dedeurwaerder et al., 2011; Joubert et 
al., 2012; Kinoshita et al., 2014; Mill et al., 2008), as the latter method frequently 
results in a significant loss of statistical power that increases the likelihood of 
Type 1 error (Nakagawa, 2004). The FDR value was set to .05 so any association 
between an individual CpG site and psychotic symptoms at age 12 years was 
considered statistically significant if it was represented by an FDR adjusted p-
value of less than .05.  The same statistical approach and procedure was used to 
explore the role of epigenome-wide DNAm in psychotic symptoms at age 18 
years.   
7.3.1.1 Testing assumptions of normality. 
 The distribution of DNAm values derived from cord blood was examined 
to determine the extent to which the assumptions of normality were met. A Q-Q 
plot of the data (see Appendix D) suggests that the DNAm of unique CpG sites 
was not normally distributed. To address this, logit transformations of the beta 
values (β values) were performed which improved the normality of the data. 
Moreover, logit-transformed β values (i.e., M values) have been shown to possess 
greater statistical power compared to β values with respect to identifying 
differences in DNAm at highly methylated and unmethylated CpG sites (Du et al., 
2010; Lee et al., 2014). 
7.3.2 Association of DNAm of the top 50 ranked CpG sites and 
psychotic symptoms at age 12 and 18 years. 
To further explore the relationship between epigenome-wide DNAm and 
psychotic symptoms at age 12 years, a series of univariate hierarchical binary 
logistic regression models were performed with the DNAm of 50 unique CpG 
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sites, as continuous measures. These 50 CpG sites were selected a priori based 
upon the results of the epigenome-wide analysis exploring the association 
between DNAm and psychotic symptoms at age 12 years, which listed 
differentially-methylated CpG sites between disease and non-disease groups 
according to adjusted p-values. More specifically, the 50 CpG sites with the 
smallest p-values (i.e., sites strongly associated with psychotic symptoms at age 
12) were selected for further exploration. The focus on 50 was also chosen a 
priori in light of the following factors: (1) the exploratory nature of the research, 
and (2) the potential for the 50 top-ranked CpG site to mediate the action of 
adverse antenatal exposures and sex in the development of psychotic symptoms at 
ages 12 and 18 years.   
 The statistical models described above involved the implementation of a 
three-stage analysis plan. Firstly, all β values were multiplied by 100 to permit 
DNAm of unique CpG sites to be described in terms of a percentage rather than as 
a proportion. Secondly, a univariate binary logistic regression was applied to 
assess the unadjusted association between each unique CpG site and psychotic 
symptoms. Thirdly, a confounder latent variable representing the total combined 
variance of maternal marital status and socio-economic class was added in 
subsequent analyses, at the first step, to assess the association between the 
predictor and outcome variables after adjusting for the effects of these 
confounders.  
As the current research is exploratory in nature, any associations between unique 
CpG sites and psychotic symptoms found to be represented by a p value of < .05 
will be considered statistically significant.  
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 The same procedure was used to explore the role of epigenome-wide 
DNAm in psychotic symptoms at age 18 years. 
7.3.2.1 Testing assumptions of normality. 
The shape of the distribution of each unique CpG sites was examined to 
determine the extent to which assumptions of normality were met. Results of the 
Shapiro-Wilk test of normality suggest that none of the 50 CpG sites at age 12 
(see Appendix E) or 18 years (see Appendix F) were normally distributed. In 
addition, a series of sensitivity analyses were run to determine the impact of using 
parametric methods with non-linear data. This involved testing the associations 
between the DNAm of these unique CpG sites and psychotic symptoms at 12 and 
18 years using both parametric and non-parametric methods. The results revealed 
several discrepancies at each time-point in terms of the significance of the 
findings, depending on which statistical method was used (see Appendices E and 
F). Hence, differences in DNA methylation of unique CpG sites at birth between 
participants with and without psychotic symptoms at ages 12 and 18 years will be 
quantified in terms of the median instead of the mean (see Tables 7 and 8).  
7.3.3 Biological significance of genes associated with differentially-
methylated CpG sites identified by the 450K array at ages 12 and 18 years. 
Following identification of differentially-methylated CpG sites between 
participants with and without psychotic symptoms at ages 12 and 18 years, the 
Infinium Human Methylation450k annotation file (Price et al., 2013) was used to 
determine the genomic location of each site. More specifically, the annotation file 
was reviewed in order to gain information about the chromosomal location of all 
relevant sites, the CpG region in which they are found, the nearest gene 
transcription start site and any regulatory features associated with the site. 
150 
 
 
 
Additionally, the University of California Santa Cruz (UCSC) Genome 
Bioinformatics Genome Browser was used in order to determine the function of 
genes associated with disease-associated CpG sites and facilitate interpretation of 
the possible biological significance of altered expression of these genes in the 
aetiology of psychotic symptoms during early and late adolescence.  
7.3.4 Similarity of individual CpG sites identified by the 450K array at 
ages 12 and 18. 
  To test the third hypothesis, that CpG sites detected by the 450k array as 
differentially-methylated between participants with and without psychotic 
symptoms at 12 and 18 years would be similar across these two time points, visual 
inspection of the results of the CpGassoc EWAS analyses was undertaken. In 
addition, the genomic location of each of the top 50 CpG sites identified at 12 and 
18 years was identified using an annotation file (Slieker) and the NCBI (see 
http://www.ncbi.nlm.nih.gov/ for more information).  
 7.4 Results 
In order to test the first hypothesis, that epigenome-wide DNAm 
differences would exist between participants with and without psychotic 
symptoms at ages 12 and 18 years, association analyses were run using the 
CpGassoc function (Barfield et al., 2012) in R (R Core Development Team, 2010) 
separately for 12 and 18 years of age. 
7.4.1 DNAm of individual CpG sites across the epigenome and 
psychotic symptoms. 
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7.4.1.1 Psychotic symptoms at age 12 years.  
Of the 294 840 CpG sites analysed, 9655 (3%) were found to be 
significantly associated with psychotic symptoms at age 12 years according to the 
unadjusted p-values (see Table G1, Appendix G). Only five CpG sites remained 
statistically significant after controlling for multiple comparisons. These were 
ch.13.79675484F, cg19006060, cg10088890, cg17888259 and cg22772355.  
In terms of genomic location, sites ch.13.79675484F and cg10088890 are 
not located within known CpG regions nor are they close to the transcription start 
site (TSS) of any gene/s. In contrast, sites cg19006060 and cg22772355 are 
located within CpG south shore and CpG island regions, respectively. In addition, 
the former loci is situated within close proximity of the transcription start site 
(TSS) of gene RERG, while the latter loci is situated near the TSS of COX6B2 
(see Appendix H for full gene names). Finally, site cg17888259 is found in a CpG 
south shore region and like ch.13.79675484F is not located near the TSS of any 
gene/s. 
 With respect to beta methylation differences, CpG sites cg19006060 and 
cg22772355 showed significantly higher median DNAm levels in participants 
with psychotic symptoms at age 12 years than in participants without symptoms at 
this time-point. In contrast, site cg17888259 showed significantly lower median 
DNAm levels in participants with psychotic symptoms than in those without 
symptoms. 
7.4.1.2 Psychotic symptoms at age 18 years.  
At age 18 years, 17, 821 (6%) of the 294 840 CpG sites analysed were 
found to be significantly associated with the presence of psychotic symptoms at 
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this time-point (see Table H1, Appendix H). However, only five CpG sites 
remained statistically robust after adjusting for multiple comparisons using the 
FDR. These were cg24374738, cg21781157, cg12500956, cg10478199 and 
cg04420907. In terms of genomic location, site cg24374738 is located within a 
CpG island region and within close proximity to the TSS of gene CRYBA2. In 
contrast, loci cg21781157, cg12500956, cg10478199 are not located within a 
known CpG site region; however, they are situated near the TSSs of genes 
ZNFX1, TMEM163, ATP6VIBI and WDR/STX8, respectively (see Appendix I 
for full gene names). With respect to beta methylation differences, sites 
cg24374738, cg21781157, cg10478199 and cg04420907 showed significantly 
higher median DNAm levels in participants with psychotic symptoms at age 18 
years than in those without symptoms. Site cg12500956, on the other hand, 
exhibited significantly lower DNAm in psychotic participants than in their non-
psychotic counterparts. 
7.4.2 Association of DNAm of the top 50 ranked CpG sites and 
psychotic symptoms. 
7.4.2.1 Psychotic symptoms at age 12 years.  
To further explore an association between epigenome-wide DNAm and 
psychotic symptoms at age 12 years by individual CpG sites, a series of univariate 
hierarchal binary logistic regression analyses were undertaken.  Of the top 50 
ranked CpG sites listed at age 12 years, 43 were found to be significantly 
associated with psychotic symptoms (as presented in Table 9). However, of these, 
only 42 remained statistically significant after controlling for maternal marital 
status and socio-economic class. When these 42 CpG sites were classified into 
four categories (islands, shores, shelves and others), according to the CpG content 
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in the genes, 13 sites (31%) were located in islands, 11 sites (26%) were located 
in shores (8 of which were north shores and 3 were south shores), 6 sites (14%) 
were located in shelves (5 of which were north shelves and 1 a south shelf) and 12 
sites (29%) were located in other regions. 
In terms of beta methylation differences, 23 (55%) of these sites showed 
significantly higher median DNAm levels in participants with psychotic 
symptoms at age 12 years than in those without symptoms at this time-point. The 
two CpG sites with the highest odds ratios (ORs), describing the association 
between psychotic symptoms and methylation, were cg22772355 and 
cg03404102. 
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Table 9. Binary logistic regression of DNAm in cord blood of 50 CpG sites and psychotic symptoms at age 12 years 
    Median methylation by psychotic 
Symptoms 12 yearse 
CpG IDa UCSC RefGene Nameb  Unadjusted Modelc 
(Model 1) 
Adjusted Modeld 
(Model 2) 
None Suspected/ 
Definite 
  OR 95% CI OR 95% CI n = 748 n = 83 
ch.13.79675484F None .96** .93-.98 .95** .93-.98 82.05 81.98 
cg19006060 RERG 1.98*** 1.46-2.69 1.97*** 1.41-2.75 3.95 4.19 
cg10088890 None .93 .86-1.00 .93 .87-1.00 85.82 85.77 
cg17888259 None .95*** .93-.97 .96** .94-.99 76.05 70.73 
cg22772355 COX6B2 4.49*** 2.23-9.02 4.42*** 2.10-9.30 1.41 1.56 
cg13787987 OGDHL 1.53*** 1.26-1.84 1.57*** 1.28-1.93 2.23 2.61 
cg26129759 SELK 1.26*** 1.12-1.42 1.26*** 1.11-1.43 1.47 1.67 
cg18005928 None .96** .93-.99 .96* .93-.99 84.91 84.75 
cg19259127 None 1.16** 1.04-1.28 1.18** 1.05-1.32 8.83 9.57 
cg13143529 PDX1 1.08 .95-1.24 1.10 .92-1.31 6.20 6.18 
cg05192538 None .96*** .94-.98 .97** .95-.99 90.13 88.56 
cg22920700 OSR2 1.07 .97-1.18 1.07 .98-1.17 6.70 6.56 
cg07513662 None .87*** .81-.94 .86*** .80-.93 86.48 85.33 
cg26884581 PYGM 1.02** 1.01-1.03 1.02** 1.01-1.04 .82 .89 
cg00910419 BCL11A 1.03* 1.01-1.06 1.03* 1.01-1.06 1.47 1.64 
ch.5.1258129F MAST4 1.06 .98-1.15 1.06 .95-1.19 6.71 6.74 
ch.2.204909450R None .96** .93-.99 .96** .93-.99 83.34 82.98 
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cg07349890 RRP7A 1.11** 1.05-1.18 1.09** 1.02-1.16 91.07 92.73 
cg07941983 ARAP2 .72*** .60-.85 .70*** .58-.84 7.88 7.42 
cg09667226 KLF5 1.37 .84-2.24 1.37 .84-2.21 1.36 1.42 
cg06302533 PCDHB18 .97** .95-.99 .97** .95-.99 85.60 85.28 
h.11.104864706F None .96** .93-.99 .96* .94-.99 87.13 87.00 
cg13550401 NUDT1 1.04** 1.02-1.08 1.05** 1.02-1.08 6.60 6.89 
cg09063944 LOC388588 2.63** 1.46-4.74 3.14** 1.60-6.16 1.55 1.62 
cg16363985 RNASEH1 .95*** .93-.98 .95*** .92-.98 36.90 34.38 
cg22021597 ITPKB .93** .89-.98 .94* .89-.99 10.11 9.12 
cg13185972 SHROOM2 .98*** .97-.99 .98** .97-.99 50.10 38.83 
cg23676475 None .20*** .08-.49 .16*** .06-.42 2.02 1.96 
cg21131149 ORAOV1 .46*** .30-.71 .52** .33-.82 2.94 2.68 
cg09355027 None .97*** .95-.99 .96*** .95-.98 65.07 61.48 
cg21144158 MIR612 .97** .95-.99 .96** .94-.99 27.86 22.43 
cg09611064 None 1.46*** 1.20-1.78 1.37** 1.10-1.71 4.08 4.32 
cg08105378 HOMER3 .95** .92-.98 .94** .91-.98 91.58 90.37 
cg25134306 UBE2D2 1.02** 1.01-1.03 1.02* 1.00-1.03 19.23 20.28 
cg03404102f FAM162A; CCDC58 3.72*** 1.85-7.50 3.98*** 1.83-8.66 1.72 1.86 
cg16559243 EGFLAM 1.04** 1.02-1.07 1.04** 1.01-1.07 75.16 79.92 
cg24373253 LPPR5 1.16** 1.05-1.27 1.15* 1.03-1.27 6.29 7.12 
cg24095592 HOXB3 1.08* 1.01-1.14 1.07* 1.01-1.14 3.63 4.04 
cg18465133 JSRP1 1.20** 1.05-1.19 1.14*** 1.06-1.22 8.83 9.31 
cg18194887 BET1 1.02** 1.01-1.03 1.02* 1.00-1.03 30.30 35.40 
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cg00959635 None 1.06 1.00-1.20 1.05 .98-1.13 9.13 9.26 
ch.1.4385290F None .91* .84-1.00 .92 .84-1.01 88.97 88.97 
ch.4.2045280F OSTC .96* .93-.99 .96** .93-.99 84.30 84.28 
cg11360689 None .93*** .89-.97 .92*** .88-.96 61.65 59.64 
cg03315456 HOPX 1.05** 1.02-1.09 1.06** 1.02-1.10 82.78 86.58 
ch.5.3079640F None .91 .83-1.00 .92 .84-1.00 89.34 89.23 
cg04864807 None 1.05** 1.02-1.08 1.04* 1.01-1.08 9.24 10.23 
cg18816098 PDE4C 1.29** 1.11-1.49 1.30** 1.11-1.51 3.69 4.02 
cg24764861f CCDC152;CLCN7 1.04*** 1.02-1.06 1.04** 1.01-1.06 41.72 42.80 
cg04223420 PITX1 1.06** 1.03-1.10 1.07** 1.03-1.11 9.13 11.18 
aProbe ID (i.e., CpG site) assessed by the HM450 arrayarray. 
bGene with its transcription start site closest to the listed probe ID. 
cModel 1 shows the results for the univariate hierarchical binary logistic regression analysis. 
dModel 2 shows the results after adjustment for maternal marital status and socio-economic class. 
 eMedian methylation by Psychotic Symptoms at age 12. 
fProbe ID is annotated with more than one gene (Price et al., 2013). 
*p < .05 
**p <.01  
***p < .001 
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In terms of their genomic location, site cg22772355 is located on chromosome 19 
and within close proximity to the TSS of the COX6B2 gene. In contrast, site 
cg03404102 is situated on chromosome three and within a promoter-associated 
island region and close proximity to the TSS of genes FAM162A and CCDC58.  
The two CpG sites with the lowest ORs were cg21131149 and 
cg23676475. Site cg21131149 is located on chromosome 11 and within a 
promoter-associated island region and close proximity of the TSS of gene 
ORAOV. Site cg23676475, on the other hand, is located on chromosome two and 
is not near the TSS of any genes.  
7.4.2.2 Psychotic symptoms at age 18 years.  
As previously described, a series of univariate hierarchical binary logistic 
regression analyses were undertaken to explore the relationship between 
epigenome-wide DNAm, by individual CpG sites, and psychotic symptoms at age 
18 years.  Of the top 50 ranked CpG sites listed at 18 years, 48 were found to be 
significantly associated with psychotic symptoms (as presented in Table 10). Of 
these, 45 sites remained statistically robust after controlling for maternal marital 
status and socio-economic class. When these 45 CpG sites were classified into 
four categories (islands, shores, shelves and others), according to the CpG content 
in the genes, 12 sites (27%) were located in islands, 9 sites (20%) were located in 
shores (with 5 of these being north shores and 4 being south shores), 7 sites (16%) 
were located in shelves (with 3 being north shelves and 4 being south shelves) and 
17 sites (38%) were located in other regions. 
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Table 10. Binary logistic regression of DNAm in cord blood of 50 CpG sites and psychotic symptoms at age 18 years 
    Median methylation by psychotic 
symptoms 18 yearse 
CpG IDa UCSC RefGene Nameb Unadjusted Modelc 
(Model 1) 
Adjusted Modeld 
(Model 2) 
None Suspected/ 
Definite 
  OR 95% CI OR 95% CI n = 678 n = 57 
cg24374738 CRYBA2 1.57*** 1.27-1.94 1.56*** 1.24-1.96 1.76 1.89 
cg21781157 ZNFX1 1.06*** 1.03-1.08 1.06*** 1.03-1.10 46.12 47.32 
cg12500956 TMEM163 .96*** .94-.98 .97** .94-.99 57.53 52.96 
cg10478199 ATP6V1B1 3.63*** 1.95-6.76 4.25*** 2.08-8.70 1.58 1.75 
cg04420907f WDR16; STX8 1.43* 1.04-1.97 1.51* 1.07-2.12 3.27 3.54 
cg19689211 KIAA1244 .91*** .87-.95 .90*** .86-.95 86.30 82.40 
cg11335536 None .93*** .90-.96 .93*** .90-.97 72.18 68.50 
cg06808522 None 1.04*** 1.02-1.06 1.04*** 1.01-1.06 58.98 66.36 
cg18235000 PNMA2 1.40* 1.04-1.87 1.33 .96-1.85 1.65 1.85 
cg14009451 CCDC155 .94*** .91-.97 .95** .92-.99 84.60 80.06 
cg00279790 None 1.61*** 1.24-2.10 1.53** 1.15-2.04 2.79 3.05 
cg22504898 None .97*** .96-.99 .97*** .96-.99 82.98 68.15 
cg26189021 KCNC4 .95*** .93-.97 .94*** .92-.97 84.01 81.42 
cg03162823 USP44 .97** .95-.99 .96** .94-.98 66.35 66.23 
cg01969403 None 1.17*** 1.07-1.27 1.19*** 1.08-1.31 87.86 90.15 
cg11538307 None 1.11*** 1.05-1.17 1.12*** 1.05-1.19 81.19 83.44 
cg00614314 LOC80154 1.12* 1.00-1.24 1.14 1.01-1.28 10.70 11.11 
159 
 
 
cg10794473 MIR1468 .97*** .95-.98 .97** .95-.99 87.05 81.15 
cg04689654 TPD52L2 .26*** .13-.52 .21*** .10-.47 2.68 2.47 
cg22403266 IGFBP3 1.43** 1.14-1.79 1.45** 1.12-1.87 5.25 5.58 
cg22811030 TEX11 .98*** .96-.99 .98** .96-.99 81.71 76.35 
cg09825080 None .92*** .88-.97 .92** .88-.97 92.22 88.84 
cg27635135 None .94*** .91-.97 .94*** .91-.97 82.26 79.70 
cg19824833 None .92*** .88-.96 .92** .87-.97 90.96 88.77 
cg09139923 None 1.03** 1.01-1.04 1.02** 1.01-1.04 10.87 11.16 
cg01806151 None .95*** .93-.98 .95*** .92-.97 60.41 55.28 
cg05657581 PKN2 1.42 .96-2.09 1.57* 1.01-2.44 4.72 4.83 
cg18826274 None .95*** .92-.97 .94*** .92-.97 64.90 60.04 
cg26023709f MRPL43;SEMA4G .97*** .95-.98 .97** .95-.99 85.02 81.58 
cg17739428 None 1.52 .90-2.56 1.58 .87-2.86 3.18 3.35 
ch.6.37043690R None 1.64 .98-2.76 1.62 .91-2.88 2.43 2.55 
cg26537076 HECW2 1.70** 1.25-2.32 1.67** 1.20-2.33 4.65 5.03 
cg03447083 CES3 1.36* 1.07-1.73 1.13 .92-1.38 5.13 5.22 
cg22510943 LMNB2 .57*** .43-.77 .60** .43-.83 8.67 8.16 
cg26951763 None .96*** .94-.98 .96** .93-.98 59.16 55.97 
cg16531342f DKC1;SNORA36A .97*** .96-.99 .97*** .96-.99 85.67 80.99 
cg09606090 SNX11 1.61* 1.02-2.54 1.83* 1.11-3.00 2.27 2.45 
cg23789157f UBOX5;FASTKD5 .23*** .10-.52 .20** .08-.51 1.83 1.75 
cg03771878 PHKG2 .47*** .31-.71 .44** .28-.70 4.54 4.29 
cg07283582 CCDC46 .96*** .95-.98 .97** .95-.99 84.80 78.11 
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cg11740099 SECTM1 1.75*** 1.30-2.37 1.68** 1.21-2.34 2.78 3.03 
cg11270192 IPO8 .38*** .23-.64 .40** .22-.70 3.39 3.08 
cg01429391 MYH7 .93** .89-.97 .93** .89-.97 90.59 87.22 
cg03037974 None .95** .92-.99 .95** .92-.99 89.43 88.86 
cg25371564 None .93*** .90-.97 .93*** .89-.97 80.47 77.57 
cg11257906 JRK .95*** .92-.98 .95** .92-.98 86.06 82.23 
cg05133814 None .92*** .88-.96 .91*** .87-.95 88.25 84.82 
cg11798758 NPHP4 1.12*** 1.05-1.19 1.13** 1.06-1.21 88.28 91.17 
cg21681643 LOC440839 1.10** 1.04-1.16 1.07* 1.01-1.13 83.69 86.46 
cg01440841 RNF175 1.99*** 1.42-2.80 2.05*** 1.43-2.94 2.30 2.48 
aProbe ID (i.e., CpG site) assessed by the HM450 arrayarray. 
bGene with its transcription start site closest to the listed probe ID. 
cModel 1 shows the results for the univariate hierarchical binary logistic regression analysis. 
dModel 2 shows the results after adjustment for maternal marital status and socio-economic class. 
 eMedian methylation by Psychotic Symptoms at age 18. 
fProbe ID is annotated with more than one gene (Price et al., 2013). 
*p < .05 
**p <.01  
***p < .001 
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In terms of beta methylation differences, 28 (62%) of these sites showed 
significantly lower median DNAm levels in participants with psychotic symptoms 
at age 18 years than in those without symptoms at this time-point. The two CpG 
sites with the highest odds ratios ORs, were cg10478199 and cg0144084. In terms 
of genomic location, site cg10478199 is located on chromosome two and within 
close proximity of the TSS of gene ATP6V1B1. In contrast, site cg0144084 is 
located on chromosome four and within a CpG island region and near the TSS of 
gene RNF175.  
The two loci with the lowest ORs were cg23789157 and cg04689654, both 
of which are located on chromosome 20. Site cg23789157 is found within a 
promoter-associated CpG island and in close proximity to the TSS of genes 
UBOX5 and FASTKD5, while site cg04689654 is also located within a promoter-
associated CpG island and near the TSS of gene TPD52L2. 
7.4.3 Biological significance of genes associated with differentially-
methylated CpG sites identified by the 450K array at ages 12 and 18 years. 
7.4.3.1 Psychotic symptoms at ages 12 and 18 years.  
A number of the sites identified suggest plausible biological functions 
which relate to various aspects of fetal neurodevelopment. For example, in terms 
of the 12 year findings, RERG, a protein-coding gene and member of the RAS 
superfamily of GTPases, plays an important role in inhibiting cell proliferation 
and tumour formation (Finlin et al., 2001). COX6B2, also a protein-coding gene, 
belongs to the cytochrome subunit 6B family and is involved in the regulation of 
mitochondrial biogenesis (Duggan, Kocha, Monk, Bremer, & Moyes, 2011). 
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In terms of the 18 year findings, CRYBA2, a protein-coding gene, belongs to the 
beta crystalline family and along with other crystalline genes functions to 
maintain the transparency and refractive index of the human eye lens (Thanos et 
al., 2014). ZNFX1, also a protein-coding gene, plays an important role along with 
other zinc finger proteins in a diverse range of functions, including enhancing or 
inhibiting gene expression and stabilising alpha helices (Pavletich & Pabo, 1991; 
Segal, Dreier, Beerli, & Barbas, 1999). Gene ATP6VIB1 codes for a component 
of vacuolar ATPase (V-ATPase), is a multisubunit enzyme that mediates the 
acidification of eukaryotic cells’ organelles. This acidification facilitates 
important intracellular processes such as protein sorting, receptor-mediated 
endocytosis and synaptic vesicle proton transportation (Beyenbach & Wieczorek, 
2006). The protein-coding gene WDR16 plays a crucial role in a wide range of 
physiological functions, including signal transduction, RNA processing, 
remodeling the cytoskeleton, regulation of vesicular traffic, and cell division 
(Silva, Hamamoto, Nakamura, & Furukawa, 2005). Protein-coding genes, STX8 
and TMEM163 are involved in protein trafficking (Thoreau et al., 1999) and 
cellular zinc homeostasis (Cuajungco et al., 2014), respectively.  
The function and biological significance of genes RERG, COX6B2, 
ZNFX1, ATP6V1B1, TMEM163, WDR16 and STX8, associated with the 
observed disease-associated CpG sites at 12 and 18 years, will be explored in 
greater detail in the discussion (Chapter 9). However, to date, no empirical data is 
available on the possible role of these genes in the development of psychotic 
symptoms and/or schizophrenia. Consequently, it is not clear if some or all of the 
methylation differences discerned have a function significance, whether 
methylation differences in cord blood does reflect their altered expression in 
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earlier fetal development and, as a consequence of possible epigenetic 
modifications during the antenatal period and may be involved in the aetiology of 
either of these two psychotic phenomena.  
7.4.4 Similarity of CpG sites identified by the 450K array at ages 12 
and 18 years. 
To test the second hypothesis, that CpG sites detected by the 450k array as 
differentially-methylated between participants with and without psychotic 
symptoms at 12 and 18 years would be similar across these two time points, visual 
inspection of the results of the CpGassoc EWAS analyses was undertaken. No 
similarities were found across the two time-points with respect to CpG sites or 
genes located within close proximity of these sites. 
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7.5 Discussion 
The current study aimed to explore an association between the DNAm of 
individual CpG sites in umbilical cord blood across the genome and psychotic 
symptoms at ages 12 and 18 years. Consistent with the first hypothesis, 
participants who reported psychotic symptoms at either 12 or 18 years of age 
exhibited differential methylation of individual CpG sites at birth compared to 
participants who did not report symptoms. More specifically, of the 294, 840 sites 
explored in the association analyses, 9, 655 (3%) and 17, 821 (6%) were 
significantly associated with psychotic symptoms at12 and 18 years, respectively. 
However, after adjusting for multiple comparisons, only five sites remained 
statistically robust at each time-point.  
The second hypothesis, that CpG sites found to be differentially-
methylated in cord blood between participants with and without psychotic 
symptoms during early and late adolescence, would be similar across the two 
time-points was not confirmed. None of the CpG sites identified at age 12 years 
were identical to those identified at age 18, nor were any of these sites located 
within the TSSs of the same genes. These findings extend those of the previous 
study by providing support for the role of DNAm of individual CpG sites and the 
development of psychotic symptoms at ages 12 and 18 years.  
 Despite the fact that the eight genes, affiliated with CpG sites exhibiting 
differential methylation between participants with and without psychotic 
symptoms at ages 12 and 18 years were not known genetic variants known to be 
associated with schizophrenia, this does not preclude an influence of epigenetic 
variance at novel genomic locations. Future epigenetic research should seek to 
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replicate these sites and establish what function they may have. More specifically, 
their altered expression during the antenatal period may compromise the typical 
pattern of prenatal brain development, laying down a vulnerability for the later 
onset of psychotic phenomena.  
To date, no research has investigated the relationship between putative 
antenatal environmental risk factors for schizophrenia and DNA modifications in 
the peripheral blood of offspring at birth. Nor have any studies explored the link 
between observed environmentally-associated epimutations at birth and psychotic 
symptoms during adolescence. The next study will examine the role of epigenetic 
processes in mediating the action of adverse antenatal exposures and sex in the 
development of psychotic symptoms at ages 12 and 18 years. 
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Chapter 8 
Epigenetic Mediation of Antenatal Factors on Psychotic 
Symptoms 
This third study builds on the findings of the previous study to examine the role of 
epigenetic processes in mediating the action of adverse antenatal exposures and 
sex in the development of psychotic symptoms at ages 12 and 18 years.  The 
current study uses CpG sites identified in Study 2 as mediators of the relationship 
between psychotic symptoms at ages 12 and 18 years and exposure to influenza 
and diabetes/glycosuria in utero. Given the known sex differences in vulnerability 
to psychosis in adolescence, sex is also used as an ‘exposure’ variable in 
mediation analyses.  
8.1 Study Aims and Hypotheses 
The specific hypotheses to be tested are: 
(1) The 50 top-ranked CpG sites, identified from study 2, will mediate the 
relationship between child sex and psychotic symptoms at ages 12 and 18 
years. 
(2) The 50 top-ranked CpG sites, identified from study 2, will mediate the 
relationship between maternal influenza and psychotic symptoms at ages 
12 and 18 years. 
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(3) The 50 top-ranked CpG sites, identified from study 2, will mediate the 
relationship between maternal diabetes and/or glycosuria and psychotic 
symptoms at ages 12 and 18 years. 
8.2 Method 
8.2.1 Participants. 
The ALSPAC and ARIES subsamples have both been described in detail 
in Chapter Six. This study uses data from participants who had available CB gene 
DNAm data from the ARIES subsample and who had participated in the PLIKSi 
at either of the two time-points of interest (at age 12 and 18 years).The socio-
demographic characteristics for both samples, 831 participants at 12 years of age 
and 735 participants at 18 years are outlined in Table Six (Chapter Seven) and 
Table Three (Chapter Six), respectively.  
No participants were found who report psychotic symptoms at 18 years and were 
also exposed to diabetes/glycosuria in utero. As such, the possible mediating role 
on the relationship between this predictor and psychotic symptoms will only be 
explored at the 12 year time-point.  
8.3 Measures 
8.3.1 Outcome variable: Psychotic symptoms at ages 12 and 18 years. 
The two primary outcome variables in the current study are psychotic 
symptoms at ages 12 and 18 years both of which are explored as dichotomous 
variables (see Chapter Five for full details).  
8.3.2 Predictor variables: Sex and exposure to influenza and 
diabetes/glycosuria in utero. 
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  The prenatal exposure of maternal influenza refers to the presence or 
absence of influenza at any time-point during pregnancy (see Chapter Five for full 
details). Similarly, the prenatal exposure of maternal diabetes and/or glycosuria, 
in the current study, refers to the presence or absence of existing diabetes, 
gestational diabetes or glycosuria at any time-point during pregnancy (see Chapter 
Five for full details). Finally, the predictor variable of sex will be explored in the 
current study as a dichotomous measure (see Chapter Five for full details), with 
the following two categories where: 0 = male and 1 = female. No participants with 
psychotic symptoms at age 18 had been exposed to diabetes/glycosuria in utero. 
Consequently, the mediating action of DNAm on the relationship between 
diabetes/glycosuria and psychotic symptoms will only be explored at age 12 
years. 
8.3.3 Mediator variable: Individual CpG site DNAm across the 
epigenome. 
The primary mediator variable in this study is epigenome-wide DNAm 
data from the umbilical cord blood of 831 children assessed for the presence of 
psychotic symptoms at 12 years of age and 735 individuals with and without 
psychotic symptoms at ages 18 years (see Chapter Six for full details).    
8.3.3.1 Testing assumptions of normality. 
As mediation analyses with dichotomous outcomes do not require 
mediator variables to be normally distributed (Hayes & Preacher, 2010; Wang, 
Nelson, Albert, 2013), the non-transformed original beta values will be used in the 
current study even though the distribution of DNAm is not normally distributed 
(see Chapter Seven for  full details).  
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8.4 Statistical Method  
8.4.1 DNAm as a mediator of antenatal factors and psychotic 
symptom at ages 12 and 18 years. 
The role of epigenome-wide DNAm as a potential mediator of the 
relationship between sex and psychotic symptoms at age 12 years was explored 
using a computational SPSS function for path-based mediation analysis called 
PROCESS. Designed by Hayes (2013), PROCESS uses maximum likelihood 
logistic regression to estimate unstandardised model coefficients, standard errors, 
t and p-values, and confidence intervals in mediation models with dichotomous 
outcomes. This statistical function also generates direct and indirect (mediated) 
effects as well as bias-corrected bootstrap confidence intervals for indirect effects.  
  In the current study, sex and psychotic symptoms at age 12 years were 
entered as the independent (X) and dependent (Y) variables, respectively. 
Epigenome-wide DNAm was explored as a potential mediator of the relationship 
between the predictor and outcome variables. According to Hayes (2013), 
unstandardised coefficients are the preferred metric when conducting causal 
mediation models with dichotomous predictor and outcome variables, Hayes 
argues that standardised coefficients for dichotomous variables generally have no 
useful substantive interpretation. As a result, none of the aforementioned variables 
were standardised prior to being entered into the mediation model.  
In order to reduce the size of the DNAm data, 50 CpG sites were selected 
a priori based upon the results of the epigenome-wide analyses conducted in 
Chapter 7 for psychotic symptoms measured at the age of 12 years (see Chapter 7 
for full details). By employing this data reduction, 50 simple mediation models 
(i.e., a model with one mediator) were performed with each of the 50 unique CpG 
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sites entered independently as the potential mediator variable (M).  To estimate 
the indirect effects of the 50 mediation models, 95 percentile bootstrapped 
confidence intervals were used, with 1,000 samples taken. Confidence intervals 
that did not include zero were considered statistically significant indirect effects 
(for full details see Hayes, 2013).  
The same statistical process was used to test the possible mediating effect of 
epigenome-wide DNAm on the associations between psychotic symptoms at 18 
years and maternal influenza and maternal diabetes/glycosuria. Figure 13 depicts 
the simple mediation model and independent variables explored with respect to 
their association with psychotic symptoms, taking into account the possible 
mediating effect of DNAm on this relationship.  
 
 
 
 
 
 
171 
 
 
X = Sex; Maternal Influenza; Maternal Diabetes/Glycosuria 
Y = Psychotic Symptoms at at age 12; Psychotic Symptoms at 18 years 
M = DNAm of individual CpG sites 
α = coefficient of the relationship between X and M 
β = coefficient of the relationship between M and Y 
c = ‘total effect’ 
c’ = ‘direct effect’ 
 
Figure 14. Hypothesised mediation model for the effect of DNAm on the relationship between 
sex/adverse antenatal outcomes and psychotic symptoms at ages 12 and 18 year.  
 
8.5 Results 
8.5.1 Characteristics of the study population. 
The characteristic of the study populations as they relate to sex, maternal 
influenza and psychotic symptoms at ages 12 and 18 years are outlined in Table 8 
(Chapter 7) and Table 5 (Chapter 6). Details of the number of participants 
exposed to maternal diabetes and/or glycosuria in utero across participants with or 
without psychotic symptoms at age 12 is presented in Table 11. 
Independent 
variable (X) 
Dependent 
variable (Y) 
Potential 
Mediator (M) 
α path β path 
c’ 
Independent 
variable 
Dependent 
variable 
 c 
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Table 11. Characteristics of participants who were exposed to diabetes/glycosuria in utero and who 
completed the PLIKSi at age 12 years (n = 831) 
 Psychotic Symptoms at age 12   
 None Definite/Suspected   
Child Characteristic 
Categorical n (%) n (%) F2 p 
Diabetes/Glycosuria 
Yes 26 (76) 8 (24) 7.39 .01 
 
As shown in Table 11, participants with psychotic symptoms at age 12 years were 
significantly more likely than their non-psychotic counterparts to have been 
exposed to diabetes and/or glycosuria in utero.  
8.5.2 Individual CpG site DNAm as a mediator of sex and psychotic 
symptoms. 
To explore the potential mediating effect of DNAm on the relationship 
between sex and psychotic symptoms at ages 12 and 18 years, a series of simple 
mediation models were run using the PROCESS statistical function (Hayes, 2013) 
in SPSS. The results of these mediation models are documented in Tables 10 and 
11 and include: (1) the association between the independent variable and DNAm 
of individual CpG sites (i.e., α coefficient), (2) the association between DNAm of 
individual CpG sites and psychotic symptoms at 12 and 18 years (i.e., β 
coefficient) (3) the product of the α and β coefficients (αβ) known as the point 
estimate or indirect effect and (4) the 95 percentile confidence intervals for the αβ 
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coefficient based on bias-corrected bootstrapping methods (1000 samples were 
taken). 
8.5.2.1 Sex and psychotic symptoms at age 12 years. 
The DNAm of 11 of the 50 CpG sites analysed at age 12 years, was found 
to significantly mediate the relationship between sex and psychotic symptoms at 
this time-point (see Table 12). 
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Table 12. Results of mediation analyses of the 50 CpG sites identified from Study 2 as a mediator of sex and 
psychotic symptoms at age 12 years 
       95% CIe 
CpG IDa Gene αb (SE) βc (SE) Αβd 
 
LLCI ULCI 
ch.13.79675484F None .30 (.42) -.05 (.02)* -.01 -.07 .04 
cg19006060 RERG -.09 (.05) .68 (.16)** -.06e -.16 -.01 
cg10088890 None .24 (.31) -.08 (.04) -.02 -.13 .02 
cg17888259 None .79 (.63) -.05 (.01)** -.04 -.11 .02 
cg22772355 COX6B2 -.01 (.02) 1.50 (.36)** -.02 -.09 .04 
cg13787987 OGDHL .04 (.07) .42 (.10)** .02 -.04 .08 
cg26129759 SELK -.08 (.10) .23 (.06)** -.02 -.07 .02 
cg18005928 None -.31 (.38) -.04 (.02)* .02 -.06 .09 
cg19259127 None .21 (.25) -.19 (.23)* .03 -.02 .14 
cg13143529 PDX1 -.53 (.32) .08 (.07) -.04 -.22 .001 
cg05192538 None .81 (.54) -.04 (.01)** -.03 -.09 .001 
cg22920700 OSR2 -.26 (.32) .07 (.05) -.02 -.11 .03 
cg07513662 None -.33 (.21) -.14 (.04)** .05 -.01 .12 
cg26884581 PYGM .26 (.77) .02 (.01)* .02 -.03 .07 
cg00910419 BCL11A -.28 (.41) .03 (.01)* -.01 -.28 .18 
ch.5.1258129F MAST4 -.43 (.33) .06 (.04) -.03 -.12 .01 
ch.2.204909450R None -.10 (.38) -.04 (.02)* .004 -.04 .10 
cg07349890 RRP7A -.38 (.43) .11 (.03)** -.04 -.16 .05 
cg07941983 ARAP2 -.61 (.09)** -.36 (.09)** .22 .11 .37 
cg09667226 KLF5 -.20 (.42) -.32 (.25) -.06 -.40 .04 
cg06302533 PCDHB18 .56 (.53) -.03 (.01)* -.02 -.07 .01 
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ch11.104864706F None .17 (.39) -.04 (.02)* -.01 -.07 .04 
cg13550401 NUDT1 -.06 (.36) .04 (.01)* -.003 -.03 .03 
cg09063944 LOC388588 < .001 (.03) .96 (.30)* < -.001 -05 .07 
cg16363985 RNASEH1 .68 (.73) -.05 (.01)** -.03 -.13 .03 
cg22021597 ITPKB -.89 (.57) -.07 (.03)* .07 -.01 .21 
cg13185972 SHROOM2 25.29 (1.19)** -.03 (.01)** -.76 -1.17 -.42  
cg23676475 None .03 (.02) -1.61 (.46)** -.05 -.15 .01 
cg21131149 ORAOV1 -.09 (.04)* -.79 (.22)** .07 .01 .16 
cg09355027 None -1.15 (.81) -.03 (.01)** .04 -.01 .11 
cg21144158 MIR612 1.42 (.96) -.03 (.01)* -.04 -.14 0.001 
cg09611064 None -0.01 (.07) .38 (.10)** -.003 -.06 .04 
cg08105378 HOMER3 -.44 (.40) -.05 (.02)* .02 -.01 .08 
cg25134306 UBE2D2 -.52 (1.00) .02 (.01)* -.01 -.06 .03 
cg03404102 FAM162A; 
CCDC58 
-.03 (.02) 1.31 (.36)** -.04 -.11 .01 
cg16559243 EGFLAM -2.02 (.68)* .04 (.01)* -.08 -.19 -.02 
cg24373253 LPPR5 -.01 (.19) .14 (.05) -.001 -.06 .06 
cg24095592 HOXB3 -.29 (.17) .07 (.03)* -.02 -.09 <.001 
cg18465133 JSRP1 -.90 (.19)** .11 (.03)** -.10 -.22 -.03 
cg18194887 BET1 -2.06 (1.13) .02 (.01)* -.04 -.09 -.01 
cg00959635 None -.75 (.31)* .05 (.03) -.04 -.11 .04 
ch.1.4385290F None .09 (.25) .09 (.05)* -.01 -.13 .02 
ch.4.2045280F OSTC .10 (.37) -.04 (.02)* -.004 -.06 .04 
cg11360689 None -.86 (.42)* -.08 (.02)** .07 .01 .15 
cg03315456 HOPX -1.56 (.54)* .05 (.02)* -.08 -.20 -.01 
ch.5.3079640F None .02 (.24) -.09 (.05)* -.002 -.12 .04 
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cg04864807 None -2.17 (.36)** .05 (.02)* -.10 -.19 -.03 
cg18816098 PDE4C -.13 (.09) .25 (.08)** -.03 -.09 .01 
cg24764861 CCDC152; 
CLCN7 
-.12 (.59) -.13 (.23) -.004 -.06 .32 
cg04223420 PITX1 -1.79 (.34)** .06 (.02)* -.11 -.20 -.04 
Note. CpG sites in bold reflect significant indirect (mediation) effects (i.e., 95% bootstrapped CIs do not go through 
zero. 
aGene with its transcription start site (TSS) closest to the CpG site. 
bCoefficient of the relationship between the mediator and independent variable (i.e. sex, maternal influenza or maternal 
diabetes/glycosuria). 
cCoefficient of the relationship between the mediator and dependent variable (i.e. psychotic symptoms at 12 or 18 
years). 
dCoefficient of the indirect effect of the simple mediation analysis.  
e95% percentile bootstrapped confidence interval; Lower Level Confidence Interval (LLCI) and Upper Level 
Confidence Interval (ULCI). 
*p < .05 
**p < .001 
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More specifically, the largest significant mediation effect was found for site 
cg13185972. In terms of genomic location, this site is situated on the X 
chromosome and within a CpG north shelf region, within close proximity to the 
TSS of gene SHROOM2 (see Appendix H for full gene names).  
 SHROOM2 belongs to an actin binding family of proteins (SHROOM) 
which play an essential role in facilitating neural tube closure during fetal 
development (Haigo, Hildebrand, Harland, & Wallingford, 2003). More 
specifically, this gene facilitates the formation of a contractile network within 
endothelial cells (i.e., cells which line the interior surface of blood vessels and 
lymphatic vessels) during embryonic development (Farber, Rizaldy, & 
Hildebrand, 2011). 
Also significant, and of moderate effect, was the mediation finding for 
CpG cg07941983. Situated on chromosome four, this site can be found within a 
north shore region and in close proximity to the TSS of the ARAP2 gene. The 
nine other significant mediators of the association between sex and psychotic 
symptoms at age 12 years, of smaller effect, included cg19006060, cg21131149, 
cg16559243, cg18465133, cg18194887, cg11360689, cg03315456, cg04864807 
and cg04223420. 
8.5.2.2 Sex and psychotic symptoms at 18 years. 
As shown in Table 13, the DNAm of 13 of the 50 CpG sites explored at 18 
years was found to significantly mediate the relationship between sex and 
psychotic symptoms. Of these, the largest significant mediation effect was found 
for site cg22510943. This CpG is situated on chromosome 19 and within a 
promoter-associated island region and close proximity of the TSS of gene 
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LMNB2 (see Appendix I for full gene names). LMNB2 codes for a protein of the 
nuclear lamina that has been shown in animal models to be critical for neuronal 
migration during embryonic development. Building upon these findings, a more 
recent animal study by Coffinier et al. (2011) found that LMNB2 is critical for 
preventing elongation of the nuclei in neurons during this period.  
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Table 13. Results of mediation analyses of 50 CpG sites identified from Study 2 as a mediator of sex and 
psychotic symptoms at age 18 years 
       95% CIe 
CpG IDa Gene αb (SE) βc (SE) Αβd 
 
LLCI ULCI 
cg24374738 CRYBA2 -.05 (.09) .45 (.11)** -.02 -.13 .06 
cg21781157 ZNFX1 -.48 (.51) .05 (.01)** -.03 -.10 .02 
cg12500956 TMEM163 -.42 (.81) -.04 (.01)** .02 -.04 .10 
cg10478199 ATP6V1B1 -.02 (.03) 1.30 (.32)** -.02 -.10 .04 
cg04420907 WDR16; STX8 -.24 (.26) .37 (.16)* -.09 -.50 .03 
cg19689211 KIAA1244 .35 (.43) -.09 (.02)** -.03 -.13 .05 
cg11335536 None .89 (.61) -.08 (.02)** -.07 -.18 .02 
cg06808522 None 4.19 (1.01)** .04 (.01)** .17 .07 .34 
cg18235000 PNMA2 .31 (.27) .33 (.15)* .10 <.001 .49 
cg14009451 CCDC155 .41 (.53) -.06 (.02)** -.03 -.11 .04 
cg00279790 None -.001 (.06) .48 (.13)** -.001 -.06 .08 
cg22504898 None -.53 (1.32) -.03 (.01)** .01 -.05 .10 
cg26189021 KCNC4 .03 (.67) -.05 (.01)** -.001 -.08 .06 
cg03162823 USP44 -.12 (.67) -.03 (.01)** .003 -.04 .05 
cg01969403 None -.47 (.36) .15 (.04)** -.07 -.23 .03 
cg11538307 None -.44 (.47) .10 (.03)** -.05 -.17 .05 
cg00614314 LOC80154 -.80 (.28)* .11 (.10)* -.09 -.28 -.02 
cg10794473 MIR1468 -11.55 (.69)** -.04 (.01)** .46 .23 .89 
cg04689654 TPD52L2 -.10 (.04)* -1.34 (.35)** .01 .04 .28 
cg22403266 IGFBP3 -.37 (.10)** .38 (.12)* -.14 -.29 -.05 
cg22811030 TEX11 -9.10 (1.04)** -.02 (.01)** .23 .09 .39 
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cg09825080 None .04 (.36) -.08 (.02)** -.003 -.07 .05 
cg27635135 None .55 (.60) -.06 (.02)** -.03 -.12 .04 
cg19824833 None .81 (.40)* -.08 (.02)** -.07 -.18 -.004 
cg09139923 None -.61 (.79) .02 (.01)* -.01 -.07 .02 
cg01806151 None -1.32 (.97) -.05 (.01)** .06 -.03 .17 
cg05657581 PKN2 -.24 (.26) .35 (.20) -.08 -.61 .03 
cg18826274 None .45 (.78) -.06 (.01)** -.02 -.13 .06 
cg26023709 MRPL43; 
SEMA4G 
-.16 (.81) -.03 (.01)** .01 -.05 .07 
cg17739428 None -.45 (.26) .46 (.27) -.21 -.87 -.03 
ch.6.37043690R None -.23 (.27) .42 (.27) -.10 -.76 .05 
cg26537076 HECW2 -.22 (.06)** .55 (.16)** -.12 -.24 -.04 
cg03447083 CES3 -.17 (.13) .31 (.12)* -.05 -.22 .01 
cg22510943 LMNB2 -.99 (.07)** -.68 (.17)** .67 .36 1.05 
cg26951763 None 1.18 (.86) -.04 (.01)** -.05 -.14 .02 
cg16531342 DKC1; 
SNORA36A 
-10.54 (.90)** -.03 (.01)** .29 .11 .51 
cg09606090 SNX11 -.29 (.24) .49 (.23)* -.14 -.78 .003 
cg23789157 UBOX: 
FASTKD5 
.02 (.03) -1.49 (.42)** -.03 -.13 .04 
cg03771878 PHKG2 -.26 (.05)** -.76 (.21)** .20 .09 .35 
cg07283582 CCDC46 -.94 (.89) -.04 (.01)** .03 -.02 .12 
cg11740099 SECTM1 -.05 (.05) .56 (.15)** -.03 -.11 .03 
cg11270192 IPO8 -.004 (.05) -.96 (.26)** .004 -.09 .11 
cg01429391 MYH7 1.55 (.42)** -.08 (.02)** -.12 -.22 -.05 
cg03037974 None .64 (.44) -.05 (.02)* -.03 -.10 .01 
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cg25371564 None .94 (.52) -.07 (.02)** -.07 -.17 -.001 
cg11257906 JRK .60 (.60) -.05 (.01)** -.03 -.13 .02 
cg05133814 None .10 (.40) -.08 (.02)** -.01 -.08 .06 
cg11798758 NPHP4 .10 (.40) -.08 (.02)** -.01 -.08 .06 
cg21681643 LOC440839 .70 (.42) .09 (.03)** .07 -.004 .20 
cg01440841 RNF175 -.01 (.04) .69 (.17)** -.01 -.08 .05 
Note. CpG sites in bold reflect significant indirect (mediation) effects (i.e., 95% bootstrapped CIs do not 
go through zero. 
aGene with its transcription start site (TSS) closest to the CpG site. 
bCoefficient of the relationship between the mediator and independent variable (i.e. sex, maternal 
influenza or maternal diabetes/glycosuria). 
cCoefficient of the relationship between the mediator and dependent variable (i.e. psychotic symptoms at 
12 or 18 years). 
dCoefficient of the indirect effect of the simple mediation analysis.  
e95% percentile bootstrapped confidence interval; Lower Level Confidence Interval (LLCI) and Upper 
Level Confidence Interval (ULCI). 
*p < .05 
**p < .001 
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The second largest significant mediation finding was for CpG site cg01429391. 
Located on chromosome 14, this site can be found within a 1-kb segment of the 
MYH7 gene.  
The 11 other significant mediators of the association between sex and psychotic 
symptoms at 18 years, of smaller effect, include cg06808522, cg00614314, 
cg10794473, cg04689654, cg22403266, cg22811030, cg19824833, cg17739428, 
cg26537076, cg16531342 and cg25371564. 
8.5.3 Individual CpG site DNAm as a mediator of maternal influenza 
and psychotic symptoms. 
8.5.3.1 Maternal influenza and psychotic symptoms at age 12 years. 
The DNAm of five of the 50 CpG sites explored at age 12 years, was 
found to significantly mediate the relationship between maternal influenza and 
psychotic symptoms (see Table 14). Of these, the largest significant mediation 
effect was CpG cg21144158 which is located on chromosome 11 and within close 
proximity of the TSS of gene miR-612 (see Appendix H for full gene names). 
MiR-612, a microRNA (miRNA), plays a critical role in neurogenesis through its 
involvement in regulatory neurodevelopmental processes, including neuronal 
proliferation, differentiation, maturation and migration (Zhang, Shykind, & Sun, 
2012).  
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Table 14. Results of mediation analyses of 50 CpG sites identified from Study 2 as a mediator of maternal 
influenza and psychotic symptoms at age 12 years 
       95% CIe 
CpG IDa Gene αb (SE) βc (SE) Αβd 
 
LLCI ULCI 
ch.13.79675484F None -.16 (.61) -.05 (.02)* .01 -.12 .06 
cg19006060 RERG .03 (.07) .67 (.16)** .02 -.08 .14 
cg10088890 None .32 (.46) -.08 (.04)* -.02 -.10 .004 
cg17888259 None -.45 (.92) -.05 (.01)** .02 -.07 .12 
cg22772355 COX6B2 .02 (.03) 1.48 (.36)** .03 -.05 .13 
cg13787987 OGDHL -.09 (.10) .43 (.10)** -.04 -.11 .03 
cg26129759 SELK .32 (.15)* .22 (.06)** .07 .01 .20 
cg18005928 None -.63 (.55) -.04 (.02)* .03 -.04 .08 
cg19259127 None .75 (.36)* .15 (.05)* .11 -.02 .58 
cg13143529 PDX1 -.09 (.47) .08 (.06) -.01 -.07 .03 
cg05192538 None 1.11 (.79) -.04 (.01)** -.04 -.12 .02 
cg22920700 OSR2 -.28 (.47) .07 (.05) -.02 -.09 .01 
cg07513662 None .29 (.30) .52 (.40) -.04 -.13 .40 
cg26884581 PYGM 2.19 (1.13) .02 (.01)* .04 -.01 .15 
cg00910419 BCL11A -.31 (.59) .03 (.01)* -.01 -.11 .08 
ch.5.1258129F MAST4 -.32 (.48) .06 (.04) -.02 -.08 .01 
ch.2.204909450R None .45 (.55) -.04 (.02)* -.02 -.08 .02 
cg07349890 RRP7A .82 (.63) .11 (.03)** .09 -.01 .25 
cg07941983 ARAP2 .14 (.14) -.34 (.09)** -.05 -.17 .20 
cg09667226 KLF5 -.01 (.35) .32 (.27) -.002 -.17 .20 
cg06302533 PCDHB18 -1.42 (.77) -.03 (.01)* .04 -.02 .15 
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ch11.104864706F None .67 (.57) -.04 (.02)* -.03 -.09 .002 
cg13550401 NUDT1 -.45 (.52) .04 (.01)* -.02 -.06 .01 
cg09063944 LOC388588 -.06 (.04) .98 (.30)* -.06 -.15 .01 
cg16363985 RNASEH1 1.59 (1.07) -.05 (.01)** -.08 -.25 .03 
cg22021597 ITPKB .41 (.83) -.07 (.03)* -.03 -.21 .11 
cg13185972 SHROOM2 -2.32 (2.15) -.02 (.01)** .04 -.04 .14 
cg23676475 None -.02 (.03) -1.61 (.46)** .03 -.06 .14 
cg21131149 ORAOV1 -.09 (.06) -.78 (.22)** .07 -.003 .18 
cg09355027 None .58 (1.19) -.03 (.01)** -.02 -.10 .07 
cg21144158 MIR612 3.54 (1.39)* -.03 (.01)* -.12 -.29 -.03 
cg09611064 None  .01 (.10) .38 (.10) .002 -.07 .09 
cg08105378 HOMER3 -.95 (.58) -.05 (.02)* .05 -.01 .14 
cg25134306 UBE2D2 1.11 (.145) .02 (.01)* .02 -.03 .10 
cg03404102 FAM162A; 
CCDC58 
.08 (.03) 1.28 (.40)** .10 .01 .24 
cg16559243 EGFLAM .09 (1.00) .04 (.01)* .003 -.08 .10 
cg24373253 LPPR5 -.17 (.28) .15 (.05)* -.02 -.10 .03 
cg24095592 HOXB3 -.38 (.26) .08 (.03)* -.03 -.10 -.01 
cg18465133 JSRP1 .35 (.28) .11 (.03)** .04 -.02 .13 
cg18194887 BET1 .78 (1.66) .02 (.01)* .01 -.03 .03 
cg00959635 None .05 (.46) .05 (.03) .003 -.03 .03 
ch.1.4385290F None .28 (.36) -.09 (.05)* -.03 -.10 .004 
ch.4.2045280F OSTC .51 (.54) -.04 (.02)* -.02 -.07 .01 
cg11360689 None .17 (.61) -.08 (.02)** -.01 -.12 .10 
cg03315456 HOPX -.06 .79 .05 (.02)* -.003 -.12 .08 
ch.5.3079640F None .34 (.36) -.09 (.05) -.03 -.12 .002 
185 
 
cg04864807 None 1.43 (.53)* (.05) (.02)* .06 .01 .15 
cg18816098 PDE4C -.07 (.13) .05 (.02)* -.02 -.09 .06 
cg24764861 CCDC152; 
CLCN7 
-.39 (.87) .04 (.01)** -.02 -.08 .05 
cg04223420 PITX1 .57 (.50) .06 (.02)* .03 -.03 1.01 
Note. CpG sites in bold reflect significant indirect (mediation) effects (i.e., 95% bootstrapped CIs do not 
go through zero. 
aGene with its transcription start site (TSS) closest to the CpG site. 
bCoefficient of the relationship between the mediator and independent variable (i.e. sex, maternal 
influenza or maternal diabetes/glycosuria). 
cCoefficient of the relationship between the mediator and dependent variable (i.e. psychotic symptoms at 
12 or 18 years). 
dCoefficient of the indirect effect of the simple mediation analysis.  
e95% percentile bootstrapped confidence interval; Lower Level Confidence Interval (LLCI) and Upper 
Level Confidence Interval (ULCI). 
*p < .05 
**p < .001 
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The four other significant mediators of the association between maternal influenza 
and psychotic symptoms at age 12 years, of smaller effect, included cg26129759, 
cg03404102, cg24095592 and cg04864807. 
8.5.3.2 Maternal influenza and psychotic symptoms at age 18. 
  As shown in Table 15, the DNAm of three CpG sites of the 50 analysed at 
age 18 significantly mediated the relationship between maternal influenza and 
psychotic symptoms at this time-point. Of these, the largest significant mediation 
effect was found for site cg18235000. This CpG is located on chromosome 20 and 
within a promoter-associated island region and close proximity of the TSS of gene 
PNMA2 (see Appendix I for full gene names).  
PNMA2 belongs to a family of proteins which are implicated in the 
development of paraneoplastic neurological syndromes, a group of rare disorders 
caused by an autoimmune response to specific antigens expressed in the brain as a 
result of cancerous tumours in other parts of the body (Albert & Darnell, 2004). 
These syndromes result in neurological dysfunction characterised by cerebellar 
degeneration, limbic or brainstem encephalitis, neuromyotonia, and sensory 
neuropathy (Voltz, 2002).  
The two other significant mediators of the association between maternal 
influenza and psychotic symptoms at age 18, of smaller effect, were cg01969403 
and cg23789157. 
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Table 15. Result of mediation analyses of 50 CpG sites identified from Study 2 as a mediator of maternal 
influenza and psychotic symptoms at age 18 years. 
       95% CIe 
CpG IDa Gene αb (SE) βc (SE) Αβd 
 
LLCI ULCI 
cg24374738 CRYBA2 .25 (.13) .45 (.11)** .11 -.40 .45 
cg21781157 ZNFX1 .54 (.73) .05 (.01)** .03 -.03 .17 
cg12500956 TMEM163 .50 (.16) -.04 (.01)** -.02 -.01 .06 
cg10478199 ATP6V1B1 .002 (.04) 1.29 (.32)** .003 -.11 .10 
cg04420907 WDR16; STX8 -.06 (.38) .35 (.17)** -.02 -.28 .06 
cg19689211 KIAA1244 .03 (.60) -.09 (.02)** -.003 -.11 .11 
cg11335536 None 1.42 (.86) -.08 (.02)** -.11 -.28 .02 
cg06808522 None -.40 (1.45) .04 (.01)** -.02 -.14 .09 
cg18235000 PNMA2 -.27 (.39) .36 (.15)* -.10 -.36 -.02 
cg14009451 CCDC155 -1.14 (.75) -.06 (.02)** .07 -.03 .19 
cg00279790 None -.11 (.08) .49 (.14)** -.06 -.16 .01 
cg22504898 None -.25 (.18) -.03 (.01)** .01 -.10 .12 
cg26189021 KCNC4 .27 (.95) -.05 (.01)** -.01 -.12 .08 
cg03162823 USP44 -1.11 (.95) -.03 (.01)** .04 -.02 .15 
cg01969403 None -.69 (.51) .16 (.04)** -.11 .35 .04 
cg11538307 None .37 (.66) .10 (.03)** .04 -.08 .18 
cg00614314 LOC80154 -.31 .40 .11 (.06)* -.03 -.13 .01 
cg10794473 MIR1468 .85 (1.15) -.04 (.01)** -.03 -.13 .07 
cg04689654 TPD52L2 -.01 (.05) -1.34 (.35)** -.01 -.11 .17 
cg22403266 IGFBP3 -.03 (.14) .35 (.12)* -.01 -.10 .06 
cg22811030 TEX11 .48 (1.55) -.03 (.01)** -.01 -.09 .06 
cg09825080 None .244 (.52) -.08 (.02)** -.02 -.10 .07 
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cg27635135 None .63 (.86) .38 (.37) -.04 -.16 .09 
cg19824833 None -.74 (.57) -.08 (.02)** .06 -.06 .25 
cg09139923 None -.78 (1.12) .02 (.01)* -.02 -.08 .03 
cg01806151 None -1.15 (1.38) -.05 (.01)** .05 -.07 .22 
cg05657581 PKN2 .82 (.37)* .35 (.20) .29 -.05 1.64 
cg18826274 None 1.65 (1.10) -.06 (.01)** -.09 -.27 .02 
cg26023709 MRPL43; 
SEMA4G 
-.69 (1.15) -.03 (.01)** .02 -.01 .14 
cg17739428 None -.11 (.37) .40 (.27) -.04 -.39 .04 
ch.6.37043690R None .99 (.38) .40 (.27) .39 .002 2.14 
cg26537076 HECW2 -.06 (.08) .54 (.16)** -.03 -.14 .05 
cg03447083 CES3 -.07 (.19) .31 (.12)* -.02 -.13 .04 
cg22510943 LMNB2 .09 (.11) -.56 (.15)** -.05 -.22 .07 
cg26951763 None -.18 (1.23) -.04 (.01)** .01 -.10 .12 
cg16531342 DKC1; 
SNORA36A 
.36 (1.36) -.03 (.01)** -.01 -.08 .09 
cg09606090 SNX11 -.09 (.34) -.03 (.23)* -.04 -.32 .06 
cg23789157 UBOX; 
FASTKD5 
.06 (.04) -1.57 (.43)** -.09 -.25 -.01 
cg03771878 PHKG2 .02 (.08) -.75 (.21)** -.01 -.17 .10 
cg07283582 CCDC46 -.52 (1.26) -.04 (.01)** .02 -.05 .12 
cg11740099 SECTM1 .01 (1.26) .56 (.15)** .01 -.08 .09 
cg11270192 IPO8 .05 (.07) -.97 (.26)** -.05 -.27 .09 
cg01429391 MYH7 -.89 (.60) -.07 (.02)** .07 -.02 .19 
cg03037974 None -1.08 (.62) -.05 (.02)* .05 -.01 .15 
cg25371564 None 1.28 (.74) -.07 (.02)** -.10 -.25 -.01 
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cg11257906 JRK .17 (.86) -.05 (.01)** -.01 -.10 .07 
cg05133814 None .56 (.56) -.09 (.02)** -.05 -.16 .05 
cg11798758 NPHP4 -.98 (.79) .12 (.03)** -.11 -.37 .06 
cg21681643 LOC440839 -.26 (.60) .09 (.03)** .02 -.08 .15 
cg01440841 RNF175 -.04 (.06) .69 (.17)** -.03 -.13 .06 
Note. CpG sites in bold reflect significant indirect (mediation) effects (i.e., 95% bootstrapped CIs do not 
go through zero. 
aGene with its transcription start site (TSS) closest to the CpG site. 
bCoefficient of the relationship between the mediator and independent variable (i.e. sex, maternal 
influenza or maternal diabetes/glycosuria). 
cCoefficient of the relationship between the mediator and dependent variable (i.e. psychotic symptoms at 
12 or 18 years). 
dCoefficient of the indirect effect of the simple mediation analysis.  
e95% percentile bootstrapped confidence interval; Lower Level Confidence Interval (LLCI) and Upper 
Level Confidence Interval (ULCI). 
*p < .05 
**p < .001 
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8.5.4 Individual CpG site DNAm as a mediator of maternal 
diabetes/glycosuria and psychotic symptoms at age 12 years. 
As shown in Table 16, DNAm of 2 sites out of the 50 explored at this 
time-point, were found to significantly mediate the relationship between maternal 
diabetes/glycosuria and psychotic symptoms at age 12 years. Of these, the largest 
significant mediation effect was found for site cg07941983. Also a significant 
mediator of sex and psychotic symptoms at age 12 years, this CpG is located on 
chromosome four within a north shore region and within close proximity of the 
TSS of gene ARAP2. ARAP2 belongs to a family of proteins that regulate 
membrane trafficking and actin remodelling (Yoon et al., 2006). However, the 
influence of alterations in ARAP2 gene expression on neurodevelopment 
following exposure to diabetes/glycosuria and the subsequent development of 
psychotic symptoms or schizophrenia has not been explored.  
The other significant mediator of the association between maternal 
diabetes/glycosuria and psychotic symptoms at age 12, of smaller effect, was 
cg10088890. 
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Table 16. Results of mediation analyses of 50 CpG sites identified from Study 2 as a mediator of maternal 
diabetes/glycosuria and psychotic symptoms at age 12 years 
       95% CIe 
CpG IDa Gene αb (SE) βc (SE) Αβd 
 
LLCI ULCI 
ch.13.79675484F None .43 (1.06) -.05 (.02)* -.02 -.13 .03 
cg19006060 RERG .07 (.12) .66 (.16)** .04 -.08 .20 
cg10088890 None .55 (.79) -.11 (.06) -.06 -.16 -.01 
cg17888259 None -2.78 (1.59) -.04 (.01)** .12 .02 .31 
cg22772355 COX6B2 -.03 (.05) 1.50 (.36)** -.05 -.19 .08 
cg13787987 OGDHL .23 (.17) .44 (.10)** .10 -.04 .30 
cg26129759 SELK -.19 (.26) .24 (.06)** -.05 -.15 .09 
cg18005928 None .35 (.95) -.05 (.02)* -.02 -.14 .05 
cg19259127 None .25 (.63) .12 (.06)* .03 -.03 .13  
cg13143529 PDX1 -.07 (.83) .08 (.07) -.01 -.08 .05 
cg05192538 None -.10 (1.38) -.04 (.01)** .004 -.08 .14 
cg22920700 OSR2 -.09 (.82) .07 (.05) -.01 -.06 .04 
cg07513662 None .32 (.52) -14 (.04)** -.05 -.19 .07 
cg26884581 PYGM 4.55 (1.97)* .02 (.01)* .09 -.02 .39  
cg00910419 BCL11A 2.61 (1.03)* .03 (.01)* .08 -.08 2.93 
ch.5.1258129F MAST4 -.20 (.83) .06 (.03) -.01 -.06 .02 
ch.2.204909450R None .15 (.95) -.04 (.02)* -.01 -.13 .06 
cg07349890 RRP7A .74 (1.09) .10 (.03)* .08 -.05 .30 
cg07941983 ARAP2 .53 (.24)* -.36 (.09)** -.19 -.51 -.01 
cg09667226 KLF5 2.90 (.61)** .31 .24 .87 -.05 5.17 
cg06302533 PCDHB18 -1.50 1.34 -.03 (.01)* .04 -.05 .46 
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ch11.104864706F None .66 .98 -.04 (.02)* -.03 -.13 .004 
cg13550401 NUDT1 .86 (.90) .04 (.01)* .04 -.03 .20 
cg09063944 LOC388588 .02 (.07) .95 (.31)* .02 -.07 .11 
cg16363985 RNASEH1 -1.71 (1.84) -.05 (.02)** .08 -.07 .27 
cg22021597 ITPKB -.42 (1.44) -.07 (.03) .03 -.32 .27 
cg13185972 SHROOM2 4.98 (3.73) -.02 (.01)** -.10 -.29 .02 
cg23676475 None -.09 (.05) -1.69 (.47)** .15 -.03 .40 
cg21131149 ORAOV1 .09 (.10) -.86 (.23)** -.08 -.27 .05 
cg09355027 None -.38 (2.07) -.03 (.09)** .01 -.11 .15 
cg21144158 MIR612 -.08 (2.42) -.03 (.01)* .002 -.18 .15 
cg09611064 None .06 (.18) .38 (.10)** .02 -.07 .15 
cg08105378 HOMER3 .29 (.99) -.05 (.02)** -.02 -.10 .08 
cg25134306 UBE2D2 -.61 (2.52) .02 (.01)* -.01 -.12 .07 
cg03404102 FAM162A; 
CCDC58 
-.06 (.06) 1.32  (.37)** -.08 -.26 .05 
cg16559243 EGFLAM -1.85 (1.72) .05 (.01)** -.08 -.37 .06 
cg24373253 LPPR5 -.21 (.48) .15 (.05)* -.03 -.17 .20 
cg24095592 HOXB3 .36 (.45) .07 (.03)* .03 -.03 .19 
cg18465133 JSRP1 -.44 (.48) .11 (.03)** -.05 -.15 .04 
cg18194887 BET1 .03 (2.87) .02 (.01)* .001 -.10 .13 
cg00959635 None -.40 (.81) .05 (.03) -.02 -.06 .03 
ch.1.4385290F None .29 *.61) -.16 (.08) -.05 -.20 .02 
ch.4.2045280F OSTC .29 (.94) -.04 (.02)* -.01 -.08 .02 
cg11360689 None 1.12 (1.04) -.08 (.02)** -.08 -.35 .09 
cg03315456 HOPX -.14 (1.38) .05 (.02)* -.06 -.26 .06 
ch.5.3079640F None .31 (.61) -.15 (.08) -.05 -.18 .01 
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cg04864807 None .08 (.88) .06 (.02)* .005 -.06 .10 
cg18816098 PDE4C -.10 (.23) .26 (.08)** -.03 -.13 .07 
cg24764861 CCDC152; 
CLCN7 
1.68 (1.51) .04 (.01)** .07 -.03 .26 
cg04223420 PITX1 -.52 (.88) .06 (.02)** -.03 -.13 .05 
Note. CpG sites in bold reflect significant indirect (mediation) effects (i.e., 95% bootstrapped CIs do not 
go through zero. 
aGene with its transcription start site (TSS) closest to the CpG site. 
bCoefficient of the relationship between the mediator and independent variable (i.e. sex, maternal 
influenza or maternal diabetes/glycosuria). 
cCoefficient of the relationship between the mediator and dependent variable (i.e. psychotic symptoms at 
12 or 18 years). 
dCoefficient of the indirect effect of the simple mediation analysis.  
e95% percentile bootstrapped confidence interval; Lower Level Confidence Interval (LLCI) and Upper 
Level Confidence Interval (ULCI). 
*p < .05 
**p < .001 
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 8.6 Discussion 
The current study aimed to explore the mediating action of epigenetic processes, 
observed in umbilical cord blood at birth, on the associations between sex and 
adverse antenatal exposures and psychotic symptoms at ages 12 and 18 years. 
The hypothesis that the 50 top-ranked CpG sites most strongly associated 
with psychotic symptoms at ages 12 and 18 years, identified from study 2, would 
mediate the relationship between sex and psychotic phenomena at these two time-
points was partially supported. More specifically, at age 12 years, 11 of the top-
ranked 50 CpG sites were found to significantly mediate the relationship between 
sex and psychotic symptoms. During later adolescence, DNAm of 13 of the top-
ranked CpG sites mediated the relationship between the exposure variable and the 
outcome of interest.  
The second hypothesis that the 50 top-ranked CpG sites identified in study 
2 as being most strongly associated with psychotic symptoms during early and 
late adolescence would mediate the relationship between maternal influenza and 
psychotic phenomena at 12 and 18 years of age was also partially supported. 
Simple mediation analysis showed that the DNAm of five and three of the top 50-
ranked CpG sites mediated the relationship between maternal influenza and 
psychotic symptoms at ages 12 and 18 years, respectively. 
 Finally, the third hypothesis that the 50 top-ranked CpG sites most 
strongly associated with psychotic symptoms at age 12 years, identified from 
study 2, would mediate the relationship between maternal diabetes/glycosuria and 
psychotic symptoms at this time point was partially found. More specifically, four 
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of the top 50-ranked CpG sites mediated the relationship between the exposure 
variable and outcome of interest.  
 These findings provide preliminary evidence for the role of putative 
environmental risk factors for schizophrenia in the development of epigenetic 
marks during the fetal period which are later associated with the onset of 
psychotic phenomena during adolescence. Importantly, the precise molecular 
mechanisms which underlie the pathway from participants’ initial exposure to 
influenza and diabetes/glycosuria in utero, to epigenetic alterations at birth, to 
their transition to psychosis at ages 12 and 18 years, remain to be elucidated. 
However, these findings provide early support for the role of aberrant methylomic 
profiles in umbilical cord blood tissue as peripheral biomarkers for the later 
development of psychotic symptoms and/or schizophrenia. 
  While these findings present exciting opportunities and ideas for future 
research, their exploratory and preliminary nature cannot be overstated. The next 
chapter will provide an overview of the key findings of three empirical papers of 
the thesis in the context of existing empirical data. It will also discuss the 
strengths and limitations of the research, along with recommendations for future 
directions in this area. Chapter 9 will then conclude with a brief summary 
outlining the theoretical and clinical implications of the research findings.  
196 
 
Chapter 9 
Discussion and Conclusions 
9.1 Overall Aim of the Current Research 
The overall aim of the current research was two-fold. Firstly, it sought to 
examine the differences in levels of DNA methylation at both global (i.e., 
average) and individual CpG site levels in umbilical cord blood, taken at birth, for 
those with psychotic symptoms during adolescence, as compared to normal 
controls. Secondly, it sought to explore the role of epigenetic marks, found to be 
differentially methylated in affected participants at ages 12 and 18 years, in 
mediating the relationship between antenatal exposures and psychotic symptoms 
at these two time-points, and to examine the influence of child sex on this 
relationship. 
 This discussion chapter will initially provide a detailed summary of the 
results of each of the three empirical studies presented in Chapters 6 through to 8 
and compare these results to previous studies. Overall strengths and limitations of 
the current research, along with recommendations for further studies within the 
field of epigenetic epidemiology, will also be provided. The chapter will conclude 
with a brief overview of the theoretical and clinical implications of the current 
research findings in the context of the aetiology of schizophrenia 
9.2 Summary of the Empirical Studies 
9.2.1 Study 1: Global DNAm and psychotic symptoms at age 18 years. 
Study 1, presented in Chapter 6, sought to explore the role of global DNAm in the 
development of psychotic symptoms in ALSPAC participants at age 18 years. The 
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study also aimed to investigate this association across specific CpG site regions 
(islands, north shores, north shelves, south shores and south shelves).  
Consistent with the first hypothesis, participants who reported psychotic 
symptoms at age 18 years were found to exhibit higher global DNA methylation 
(DNAm) levels in umbilical cord blood than did those who did not report 
psychotic symptoms, and this effect was statistically robust to control for the 
covariation of child sex, birth weight, gestational age, and maternal influenza and 
diabetes. Despite high odds ratios (ORs) for the unadjusted and adjusted models, 
the association between global DNAm and psychotic symptoms at age 18 years 
did not reach statistical significance at or below the five percent level of 
probability. The imprecise estimates observed for these relationships (i.e., high 
standard errors and extremely wide confidence intervals) may be attributed to the 
small number of participants in the psychotic group (n = 57) compared to the non-
psychotic group (n = 678) at age 18 years, as well as to the non-normal 
distribution of the data.  
 Further exploratory analyses revealed moderating effects of sex on the 
relationship between psychotic symptoms and global DNAm which remained 
robust after adjusting for the effects of all covariate and confounding variables. 
Female participants who reported psychotic symptoms at age 18 years were 
significantly more likely to show higher global DNAm levels in cord blood at 
birth than were females who did not report psychotic symptoms at this time-point. 
Although not statistically significant, participants exposed to influenza in utero 
who reported psychotic symptoms at age 18 years were more likely to exhibit 
higher global DNAm at birth than were their exposed, non-psychotic counterparts.   
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 The current finding of higher global DNA methylation (DNAm) in cord 
blood taken at birth in participants with psychotic symptoms during late 
adolescence differs from the results of recent research exploring the global 
DNAm patterns in whole blood leukocytes. Using different assay technologies 
and statistical methods to quantify global methylation, two recent studies (Melas 
et al., 2012; Nishioka et al., 2013) both found significantly lower levels of global 
DNA methylation in participants with the disorder. Moreover, an earlier study by 
Shimabukuro et al. (2007) reported a pattern of global hypomethylation in the 
peripheral blood tissue of male cases with schizophrenia, an effect that was found 
to be more pronounced in younger male cases. However, the findings of the 
current study are not directly comparable to those of Melas et al. (2012), Nishioka 
et al. (2013) and Shimabukuro et al. (2007) for a number of reasons. Firstly, 
unlike these studies which were all cross-sectional in nature, the current research 
employed a longitudinal research design in which global DNAm was measured at 
birth, and well prior to the onset of psychotic symptoms in adolescence. Secondly, 
the majority of affected cases in these studies had been exposed to anti-psychotic 
medication. Thirdly, these older studies used peripheral blood leukocyte cells as a 
marker of brain-based epimutations and these may differ from the epigenetic 
signatures and cell-type proportions that are unique to umbilical cord blood. 
Hence, the inconsistency in findings between those of the current study and prior 
research may, in fact, be a consequence of the disease process of schizophrenia, 
exposure to prophylactic treatment used to treat the disorder and/or the tissue-
specific nature of epigenetic mechanisms (Armstrong, Lesseur, Conradt, Lester, & 
Marsit, 2014). 
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Not supporting the second hypothesis, global DNAm of CpG island 
regions in cord blood did not significantly differ between participants with and 
without psychotic symptoms, at age 18 years. Rather, the findings showed that 
only global DNAm of north shelf regions was significantly higher in participants 
with psychotic symptoms than in those without symptoms at this time-point.  
Further exploratory analyses revealed moderating effects of sex on the 
relationship between psychotic symptoms, whereby female participants who 
reported psychotic symptoms at age 18 years were significantly more likely to 
show higher global DNAm of north shore, north shelf and south shelf regions at 
birth than their non-psychotic, female counterparts. Although not statistically 
significant, interaction effect was indicated for maternal influenza, characterised 
by a high OR (adjusted model, OR = 458), whereby participants who were 
exposed to the virus in utero and who reported psychotic symptoms during late 
adolescence were more likely to show higher global DNAm of CpG south shore 
regions than were exposed participants who did not report psychotic symptoms. 
Further investigation is needed using a larger number of cases with psychotic 
symptoms during late adolescence in order to verify this finding.  
Very few studies have investigated global DNAm differences in peripheral 
blood tissue across specific CpG site regions between people with and without 
schizophrenia. Recent research by Nishioka et al. (2013) which explored 
differential global DNA methylation in the peripheral blood leukocytes of first-
episode schizophrenia (FESZ) cases and healthy controls found that affected cases 
showed significantly lower levels of global DNA methylation across sites located 
in CpG island regions than did their non-affected counterparts. However, unlike 
the current study, Nishioka and colleagues did not explore global methylation 
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differences across CpG north shelf regions between disease and non-disease 
groups. 
 9.2.1.1 Significance of Study 1. 
The current study is the first empirical investigation to examine global 
DNAm in umbilical cord blood as a prospective predictor of the development of 
psychotic symptoms in adolescence. To date, all global DNAm studies have been 
cross-sectional in nature, comprising patients with schizophrenia (and healthy 
controls) who had typically been exposed to antipsychotic medication. DNA 
methylation data in the current study was collected at birth, which afforded the 
advantage of controlling for possible confounding effects associated with anti-
psychotic medication and/or disease-associated factors such as poor nutrition 
and/or substance use and for the impact of the disorder itself. Moreover, it 
allowed the temporal sequence of DNA methylation changes and the presence of 
psychotic symptoms at age 18 years to be determined. 
Although preliminary in nature, the results of the current study suggest 
that higher levels of global DNAm in umbilical cord blood at birth may predict 
the later development of schizophrenia. Moreover, they provide support for the 
neurodevelopmental model of schizophrenia and suggest that epigenetic 
mechanisms may play an important role in the functional and structural cortical 
anomalies witnessed in people with the disorder, or that epigenetic changes may 
point to the biological processes in fetal development which are at the origin of 
the psychotic disorder. The epigenome appears to be most vulnerable to disruption 
during prenatal growth, when embryonic stem cells are undergoing differentiation 
and complex DNA methylation patterns essential for normal brain development 
are being established (Dolinoy, Huang, & Jirtle, 2007). As previously described 
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(Section 2.4.2), several genes that are critical for the formation of functional 
synaptic connections and normal neuronal maturation, such as glutamate, gamma-
Aminobutyric acid (GABA) and reelin (RELN), have been found to be down-
regulated in the post-mortem brain tissue of individuals with schizophrenia owing 
to hypermethylation of their gene promoters, particularly in the prefrontal cortex 
(Roth et al., 2009). The findings of the current study show hypermethylation of 
CpG sites, on average, across the genome at birth in participants with psychotic 
symptoms at age 18 years. Therefore, consistent with the neurodevelopmental 
model of schizophrenia, the findings support the notion that the initial 
vulnerability in those who go on to develop the disorder may be laid down during 
gestation as a consequence of reduced expression of genes that are required for 
the development of healthy neurotransmitter and cortical network systems.  
Interestingly, for participants with higher global DNAm at birth, the 
likelihood that they would report psychotic symptoms at age 18 years was greater 
for females and those who were exposed to influenza in utero. There has been 
very little investigation into possible mechanisms by which sex-specific 
epigenetic permutations may confer vulnerability to schizophrenia. This may be 
because early investigations that explored aberrant methylation profiles in the 
post-mortem brain tissue and peripheral blood of individuals with schizophrenia 
identified differentially expressed genes that are located on autosomes and so 
were not thought to exhibit sex-specific regulation (Mill et al., 2008). It is possible 
that sex-specific hormonal imprinting could play a role. It is well known that sex-
specific steroid hormones released during fetal development have major roles 
sexual dimorphism. Recent research indicates that the sex-steroid hormone 
estrogen is critically important in regulating frontal lobe function in females 
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(Morrison, Rodgers, Morgan, & Bale, 2014). Moreover, considerable evidence 
suggests that estrogen is involved in the modulation of chromatin structures, 
including DNA and histone methylation, at a number of gene promoters 
(Kaminsky, Wang, & Petronis, 2006). A study by Huang et al. (2007) investigated 
epigenetic patterns in human prefrontal cortical post-mortem tissue taken from 
fetal, neonatal and child samples as well as from adult cases with schizophrenia 
and age-matched healthy controls. The researchers reported reduced GABA 
expression in the prefrontal cortex of female schizophrenia cases, which was 
associated with histone modifications of GABAergic gene promoters, including 
glutamate decarboxylase1 (GAD1). Interestingly, this effect was not found in 
male participants, leading Huang et al. (2007) to conclude that promoter-
associated histone methylation changes at select GABAergic gene loci may be 
more pronounced in affected female cases than in their affected male counterparts. 
Hence, although this thesis is concerned with DNA methylation (as opposed to 
histone modifications), similar mechanisms may be underlying the interaction 
effect observed for sex and higher global DNAm in the current study. More 
specifically, aberrations in the levels of sex-specific hormones such as estrogen 
during gestation may subsequently alter DNA methylation patterns, 
compromising the expression of genes that are critical for healthy neuronal 
development. Clearly, further research regarding this possibility is needed.  
 The interactive effect for exposure to influenza in utero and higher global 
DNAm in cord blood at birth is consistent with the neurodevelopmental model of 
schizophrenia. When first proposed, the neurodevelopmental model was largely 
agnostic about the specific factors which altered early neurodevelopment and led 
down a pathway towards schizophrenia. However, subsequent work reviewing 
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epidemiological studies has focussed attention on specific pregnancy exposures 
such as infections and viruses. Viral exposure during gestation may have 
programming effects on fetal brain development in particular, influencing the 
proliferation, migration and connectivity of neurons (Kofink, Boks, Timmers, & 
Kas, 2013). Maternal influenza may initiate the production and release of 
cytokines in the fetal environment (described in detail in section 2.3.2.2), which 
may result in alteration of DNA methylation within the fetus’s brain, resulting in a 
neurodevelopmental vulnerability for the later development of the psychotic 
disorder (i.e., schizophrenia).  
Finally, the results of the present study suggest that the risk of psychotic 
symptoms at age 18 years for participants with higher global DNAm appears to be 
restricted to regions outside CpG islands, namely CpG shelves and shores, which 
traditionally have not been explored with respect to differential methylation 
between disease and non-disease groups. To date, research investigating 
epimutations in diseases other than schizophrenia (e.g., cancer) has typically 
found global DNAm of CpG island regions to significantly differ between 
affected cases and healthy controls (Feinberg & Tycko, 2004). In contrast, the 
current findings suggest that, the risk of schizophrenia, unlike other diseases, may, 
in fact be conferred in the fetal brain via aberrant methylation of genomic regions 
that surround CpG island regions, rather than by way of epimutations of CpG 
islands themselves.  
In summary, the molecular mechanisms by which global hypermethylation 
may confer susceptibility to psychotic symptoms in late adolescence may lie in 
the decreased expression of genes that are necessary for the establishment of 
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healthy neuronal and synaptic connections within the brain during embryonic 
development.  
9.2.2 Study 2: Epigenome-wide association analysis of individual CpG 
site DNAm and psychotic symptoms at ages 12 and 18 years. 
The second study, presented in Chapter 7, sought to examine associations 
between DNAm in umbilical cord blood of individual CpG sites across the 
genome and psychotic symptoms at ages 12 and 18 years. The hypothesis that 
individual CpG sites could be identified that were differentially methylated at 
birth between participants with and without psychotic symptoms at ages 12 and 18 
years was supported. Specifically, of the 294 840 CpG sites analysed, after 
adjustment of significance values for multiple testing, five (ch.13.79675484F, 
cg19006060, cg10088890, cg22772355 and cg17888259) were found to be 
significantly associated with psychotic symptoms at age 12 years. Of these, two 
sites showed significantly higher levels of DNAm and three sites showed 
significantly lower levels of DNAm in participants with psychotic symptoms at 
this time-point. 
At age 18 years, five (cg24374738, cg21781157, cg10478199, 
cg04420907 and cg12500956) of the 294, 840 CpG sites analysed were found to 
be differentially methylated between participants with and without psychotic 
symptoms. Four of these sites showed significantly higher levels of DNAm and 
one site showed significantly lower levels of DNAm in participants with 
psychotic symptoms at this time-point.  
These findings are not consistent with four recent studies (Aberg et al., 
2014; Kinoshita et al., 2012; Liu et al., 2013; Nishioka et al., 2013) that explored 
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the role of epigenome-wide DNAm of individual CpG sites in the peripheral 
blood of cases with schizophrenia (full details of these studies were presented in 
Chapter 3). Specifically, none of the CpG sites identified as being differentially 
methylated between participants with and without psychotic symptoms at ages 12 
or 18 years were the same as those found to be differentially methylated between 
cases with schizophrenia and healthy controls in these previous studies.  
However, some similarities were noted across the current and previous 
research in terms of the percentage and direction of beta methylation differences 
between affected and non-affected participants. For example, in the same way 
Kinoshita et al. (2013) observed significantly higher DNAm in 92.4% (234 sites) 
of loci differentially methylated between schizophrenia cases and controls, in the 
current study 80% (four sites) of the differentially methylated sites in umbilical 
cord blood at birth also showed hypermethylation.  
Similar to the results found for participants with psychotic symptoms at 
age 18 years, two sites exhibited significantly higher levels of DNAm in cord 
blood in participants with psychotic symptoms at age 12 years than in those 
without symptoms. This finding is consistent with the results of Kinoshita et al. 
(2014) who reported observing hypermethylation in 45.5% (2, 552) of loci 
identified to be differentially methylated between cases with schizophrenia and 
their healthy counterparts.  
As in the case of Study 1, the findings for Study 2 are not directly 
comparable to those of previous research since the methodology of previous 
studies was very different. All of the cases in studies by Aberg et al. (2014), 
Kinoshita et al (2012), Liu et al. (2013) and Nishioka et al. (2013) had an existing 
clinical diagnosis of schizophrenia and the large majority had been exposed to 
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anti-psychotic medication. In this respect, they differed from the cases in the 
current study who were medication-naïve and were defined by the presence of 
psychotic symptoms at ages 12 or 18 years. Consequently, the observed 
inconsistencies in findings between prior research and the current study with 
respect to the nature and quantity of disease-associated CpG sites may, in fact, be 
attributable to the additive effects of disease-status and psychotropic medication 
on the epigenome. Further, the current findings are based upon epimutations 
found in the umbilical cord blood of participants with psychotic symptoms during 
adolescence and so may differ from peripheral blood leukocyte tissue that was 
used in these previous studies in terms of its unique epigenetic signatures and cell-
type proportions.    
Following the procedure of Naeem and colleagues (2014), the current 
study removed a large number of CpG sites prior to conducting EWAS analyses 
for individuals with and without psychotic symptoms at ages 12 and 18 years. 
According to Naeem et al. (2014), the HM450 arrayarray is vulnerable to several 
genomic factors, including single nucleotide polymorphisms (SNPs), small 
insertions and deletions (INDELs), repetitive DNA, and areas with reduced 
genomic complexity, which they assert may compromise its ability to accurately 
evaluate DNAm at an epigenome-wide level (i.e., may increase the likelihood of 
false positive results). Hence, the authors recommend the exclusion of low quality 
probes from EWAS analyses in order to reduce the risk of false discoveries when 
using the 450k array platform, while at the same time maximising the power of 
the array to detect methylation differences between participants (see Section 
7.2.2.2.1 for full details of this procedure). This approach has not previously been 
adopted by researchers exploring aberrant methylomic profiles in schizophrenia.  
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Not supporting the second hypothesis, none of the five sites identified at 
age 12 years were identical to those identified at age 18 years, nor were any of 
these sites located within the transcription start sites (TSSs) of the same genes. 
This observation suggests that there may be a wide range of epigenetic 
mechanisms that occur during fetal development which confer risk of psychotic 
symptoms during adolescence. The outcome measure used in the current study 
refers to the presence or absence of psychotic symptoms at each time-point as 
determined using the PLIKSi (see section 5.7.1). However, as noted in Chapter 1 
(Section 1.1.3), psychotic symptoms that comprise schizophrenia are largely 
heterogeneous in nature. Hence, the lack of consistency with respect to 
epimutations identified in affected cases at ages 12 and 18 years may also suggest 
the presence of different symptom profiles of psychotic participants at these time-
points (e.g., a positive symptom profile characterised by hallucinations versus a 
negative symptom profile characterised by poor motivation, energy and mood). 
9.2.2.1 Significance of Study 2. 
The current empirical investigation is the first known exploration of an 
association between DNAm of individual CpG sites at an epigenome-wide level, 
in umbilical cord blood at birth, and psychotic symptoms at ages 12 and 18 years. 
To date, no research has explored the possible role played by genes RERG, 
COX6B2, CRYBA2, ZNFX1, ATP6VIB1, TMEM163, WDR16 and STX8, 
linked to differentially methylated CpG sites at these two time-points, in psychotic 
symptoms or schizophrenia. Consequently, it is not clear how their up- or down-
regulation, as a consequence of altered DNA methylation, may be involved in the 
aetiology of either of these two clinical phenotypes.  
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 However, in line with the neurodevelopmental model of schizophrenia, a 
number of the sites identified do play important roles in fetal neurodevelopment. 
For example, alterations in cytochrome c oxidase subunit VIb polypeptide 2 
(COX6B2; located on chromosome 19) expression during the embryonic period 
may compromise healthy neuronal development, survival, activity, connectivity 
and plasticity  due to the role played by this gene in the regulation of 
mitochondrial biogenesis (i.e., aerobic energy) within the human body 
(Hüttemann, Lee, Grossman, Doan, & Sanderson, 2012).  
Additionally, syntaxin 8 (STX8; located on chromosome 19) is a member 
of the syntaxin family which encodes nervous system-specific proteins, implicated 
in the docking of synaptic vesicles in presynaptic plasma membrane within the 
central nervous system (Lai, Lou, Diao, & Shin, 2015). Syntaxin genes possess 
Soluble N-ethylmaleimide sensitive factor (NSF) attachment-protein receptor 
(SNARE) proteins which form a complex that is critical for effective 
neurogenesis, neural migration and synaptic transmission (Lai et al., 2015). A 
number of human genetic studies have found associations between components of 
the SNARE complex and its interacting proteins (e.g., Syntaxin 1a, 
Synaptosomal-Associated Protein 25) and schizophrenia (Lewis et al., 2003; 
Wong et al., 2004). Moreover, alterations in the expression of SNARE proteins 
have been found in relevant brain regions of schizophrenic patients, namely the 
hippocampus, the thalamus and the dorsolateral prefrontal cortex (Harrison and 
Weinberger, 2005). Results of the present study showed hypermethylation of CpG 
site cg04420907 in participants with psychotic symptoms at age 18 years, 
suggesting reduced expression of STX in fetal brain regions during embryonic 
development. Given its pivotal role in the development of cortical microcircuitry, 
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aberrant STX expression may be a plausible molecular mechanism contributing to 
the manifestation of psychotic symptoms at age 18 years in the current study. 
Belonging to the WD repeat domain containing family, the gene 
WD repeat domain 16 (WDR16; located on chromosome 17) modules essential 
biological functions relating to signal transduction, transcription regulation and 
apoptosis (Li and Roberts, 2001). Recent research by Hirschner et al. (2007) 
reports an association between decreased expression of WDR16 and 
hydrocephalus in zebra fish embryos (zebra fish are a widely accepted biomedical 
model for understanding human embryonic brain development; Selderslaghs, 
Blust, & Witters, 2012). A study which prospectively collected 
neurodevelopmental data on 38 children who had pre-natal hydrocephalus found 
that one child was assessed as having borderline intellectual functioning, seven 
children were assessed as having a mild intellectual disability and 27 children 
exhibited motor deficits, commonly seen in neurodevelopmental disorders 
(Futagi, Suzuki, Toribe, & Morimoto, 2002). Interestingly, the differentially 
methylated CpG site associated with gene WDR16 (cg04420907)  was found, in 
the current study, to be significantly more methylated in participants with 
psychotic symptoms at age 18 years than in participants without symptoms. 
Hence, the hypermethylation of site cg04420907 may have altered the expression 
of WDR16, subsequently impacting on brain maturational processes.  
 Further research is needed to replicate the results of the current study. 
Nonetheless, they provide preliminary support for the differential methylation of 
specific CpG sites being a risk  factor for the later expression of psychotic 
phenomena at ages 12 (e.g., ch.13.79675484F, cg19006060, cg10088890, 
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cg17888259 and cg22772355) and 18 (e.g., cg24374738, cg21781157, 
cg12500956, cg10478199 and cg04420907) years.  
9.2.3 Study 3: Role of epigenetic processes in mediating the relationship 
between sex and adverse antenatal exposures and psychotic symptoms at ages 
12 and 18 years. 
In the third study, presented in Chapter 8, we sought to build on the 
findings of Study 2 in order to explore the mediating action of epigenetic 
processes on the associations between sex and adverse antenatal exposures and 
psychotic symptoms at ages 12 and 18 years. This line of research sought to 
extend epidemiological findings summarised in Chapter 2 (Section 2.2), which 
show robust associations between exposure to influenza (Brown et al., 2004) and 
diabetes/glycosuria (Cannon et al., 2003; Zammit et al., 2009) in utero and the 
subsequent development of schizophrenia. Our line of thinking here was that 
epigenetic changes might act as a mediator of these established associations. 
 The hypothesis that the 50 top-ranked CpG sites identified in study 2 as 
being most strongly associated with psychotic symptoms at ages 12 and 18 years 
would mediate the relationship between sex and psychotic symptoms was partially 
supported. Specifically, 11 of the top 50-ranked CpG sites were found to 
significantly mediate the relationship between sex and psychotic symptoms at age 
12 years (cg19006060, cg07941983, cg13185972, cg21131149, cg16559243, 
cg18465133, cg1894887, cg11360689, cg03315456, cg04864807 and 
cg04223420).  
At age 18 years, the DNAm of 13 of the top 50-ranked CpG sites 
significantly mediated the relationship between sex and psychotic symptoms at 
211 
 
this time-point (cg22510943, cg06808522, cg00614314, cg10794473, 
cg04689654, cg22403266, cg22811030, cg19824833, cg17739428, cg26537076, 
cg16531342, cg01429391 and cg25371564). 
 The second hypothesis, that the 50 top-ranked CpG sites identified in 
study 2 as most strongly associated with psychotic symptoms at ages 12 and 18 
years would mediate the relationship between maternal influenza and psychotic 
symptoms, was also partially supported. The DNAm of five of the top 50-ranked 
CpG sites for those with psychotic symptoms at age 12 years (cg26129759, 
cg21144158, cg03404102, cg24095592 and cg04864807) was observed to 
significantly mediate the association between influenza exposure in utero and 
psychotic symptoms.  
During later adolescence, the DNAm of three of the top 50-ranked CpG 
sites (cg18235000, cg23789157 and cg25371564) was found to significantly 
mediate the relationship between maternal influenza and psychotic symptoms at 
age 18 years.  
Finally, the third hypothesis in Study 3, that the 50 top-ranked CpG sites 
identified from Study 2 would mediate the relationship between maternal 
diabetes/glycosuria and psychotic symptoms at age 12 years, was partially 
supported. More specifically, the DNAm of two of the top 50-ranked CpG sites 
(cg07941983 and cg10088890) was found to significantly mediate the relationship 
between the antenatal exposure and the outcome of interest.  
No previous research within the field of epigenetic epidemiology has 
explored the mediation of sex and adverse antenatal exposures on psychotic 
symptoms during adolescence via epigenetic effects. However, in a step in this 
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direction, Pidsley et al. (2014) investigated the role of developmentally regulated 
epigenetic variation in schizophrenia. Using the Infinium HumanMethylation450 
BeadChip platform, the authors quantified and compared methylation profiles in 
brain tissue from the prefrontal cortex and cerebellum of 20 cases with 
schizophrenia and 23 healthy controls matched in terms of age, sex and brain 
sample quality markers (e.g., pH levels of brain tissue). In prefrontal cortical 
areas, a number of differentially methylated CpG sites were observed between 
cases and controls, with four sites reaching genome-wide significance at FDR-
adjusted p values of < .05, a result which remained statistically robust after 
controlling for cell heterogeneity. The differentially methylated CpG sites were 
cg26173173, cg24803255, cg00903099 and cg08171022; these CpG site 
identifiers refer to findings from the HM450 arrayarray and so may vary 
depending on the DNA methylation assay method that is used. In terms of 
genomic location, these sites can be found in close proximity to the TSS of genes 
GSDMD, RASA3, HTR5A and PPFIA1, respectively (see Abbreviations list for 
full gene names). Interestingly, very few differentially methylated sites (none at 
FDR ≤ .05) were identified in the cerebellum, indicating that disease-associated 
epigenetic alterations are likely to be specific to certain brain regions.  
  Pidsley et al. (2014) then went on to explore brain tissue taken from the 
cortex of 179 human fetal samples in order to investigate whether schizophrenia-
associated CpG loci underwent dynamic DNAm changes during fetal brain 
development. Remarkably, the DNA methylation of 44% of the previously 
identified differentially methylated sites was found to be significantly associated 
with post-conception age in fetal brain tissue (at FDR-adjusted p values of < .05). 
These results indicate that certain CpG loci undergo dynamic DNA methylation 
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changes during fetal development. Such changes may possibly be associated with 
exposure to adverse environmental events and may later play a role in 
predisposing an individual to developing schizophrenia.  
 9.2.3.1 Significance of Study 3. 
The first of its kind, the current study showed that several differentially 
methylated CpG sites in umbilical cord blood, associated with psychotic 
symptoms at ages 12 and 18, mediated the relationship between schizophrenia and 
child sex and exposure to maternal influenza and diabetes/glycosuria in utero.    
Consistent with the neurodevelopmental model, several of the disease-
associated CpG loci found to mediate the aforementioned relationships appear to 
be involved in critical brain maturation processes. For example, the shroom 
family member 2 (SHROOM2) gene, linked to the CpG site which exhibited the 
largest mediating effect on relationship between sex and psychotic symptoms at 
age 12 years (cg13185972), is an X-linked gene belonging to a family of proteins 
that facilitate neural tube formation essential for healthy central nervous system 
(CNS) development. Findings from a large number of animal studies consistently 
report abnormalities in neural tube formation and closure following dysregulation 
of SHROOM expression, resulting in a variety of cognitive and motor deficits in 
the offspring, including spina bifida, encephalocele and anencephaly (Harris & 
Juriloff, 2007; Yamaguchi & Miura, 2013). Moreover, a prospective birth-cohort 
study by Sutton, Daly, & Kirke (2008), which explored the developmental 
outcomes of 623 children born with neural tube defects, found that of the 255 
children who were alive at five years, 130 had mobility limitations and 43 had 
intellectual and cognitive deficits that were similar in nature to those observed in 
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pre-schizophrenia children. Further, as SHROOM2 is an X-linked gene, males 
may be particularly vulnerable to the neurodevelopmental impacts of altered 
expression of this gene.  
Another example is the RAS-like, estrogen-regulated, growth inhibitor 
(RERG) gene, linked to CpG site cg19006060, which also mediated the 
association between sex and psychotic symptoms at age 12 years. RERG has been 
shown to play a critical role in inhibiting abnormal cell proliferation, 
differentiation and migration within the mammalian brain (Finlan et al., 2001). In 
women with breast cancer, for example, lower RERG expression was associated 
with a faster rate of tumour cell growth and propagation, and subsequently poorer 
prognosis, than was higher RERG expression. (Finlan et al., 2001). The current 
study showed significant hypermethylation of the CpG site cg19006060 in 
participants with psychotic symptoms at age 12 years, suggesting lower levels of 
RERG expression in the central nervous system during gestation. Given RERG’s 
important role in regulating normal cell development, reduced expression of this 
gene in utero may increase the risk of the abnormal growth, distribution and 
positioning of neurons within the fetal brain. Moreover, as this gene is modulated 
by the sex-specific hormone estrogen, the risk of aberrant RERG expression may 
be higher for females.  
The gene micro612 (miR-612), linked to the site which showed the largest 
mediating effect on the relationship between maternal influenza during pregnancy 
and psychotic symptoms at age 12 years (cg21144158), constitutes a class of non-
coding molecules which dynamically regulate genes responsible for neuronal 
proliferation, cell differentiation/cycling, neurite outgrowth and synaptic plasticity 
during CNS development (Pham, & Gallicano, 2012; Siegel et al., 2009; Rogaev, 
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2005). A recent review by Trammel and Toth (2008) that summarised research 
investigating genetic susceptibility to influenza found that miRNA also played a 
critical role in the development and regulation of the human immune system, 
particularly the inflammatory response, following exposure to the pathogen. 
While the precise impact of pre-natal influenza on miR-612 expression is not 
known, it is hypothesised that it may compromise the regulation of genes that are 
critical for neurogenesis and morphology, which, in turn, may lay down a 
vulnerability for the development of psychotic symptoms at age 12 years. 
 Given the unique prospective approach in this study of gene methylation, 
replication of these findings in independent studies is required. However, they do 
provide preliminary evidence for altered DNA methylation being a molecular 
mechanism which may bring about aberrant brain development, following 
exposure to influenza and diabetes/glycosuria in utero. The current findings also 
suggest that sex differences, observed in many aspects of schizophrenia, including 
its onset, course and prognosis, may be also be mediated by aberrant DNA 
methylation.   
9.3 Strengths of the Current Research 
A major strength of the current research is the use of a transgenerational, 
longitudinal birth-cohort sample to explore the role played by DNA methylation 
in the umbilical cord blood in the development of psychotic symptoms at ages 12 
and 18 years. Previously, all studies investigating differential epigenetic marks in 
the peripheral blood of participants with and without schizophrenia have 
employed cross-sectional designs. Although methodologicallyrobust cross-
sectional studies (i.e., careful matching of cases and controls) can produce 
findings that are suggestive of a causal relationship between aberrant DNA 
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methylation and schizophrenia, the inferences are still based on correlational 
analyses. It is impossible, therefore, to determine the direction of effect, especially 
given the many confounding factors previously discussed. In contrast, the current 
research used data on maternal exposure to adverse environmental factors 
collected during the prenatal period to explore DNA methylation change, taken at 
birth, and the subsequent development of psychotic symptoms during early and 
late adolescence. These data form important elements of a developmental pathway 
and are a more robust test of a neurodevelopmental model involving epigenetic 
changes than has previously been undertaken. In the current study, DNA 
methylation was measured prior to disease onset, thus enabling the temporal 
relationship between disease-associated epimutations and psychotic symptoms to 
be determined. In addition, given the dynamic nature of epigenetic patterns, the 
measurement of DNA methylation prior to the onset of schizophrenia allows for 
methylation changes to be identified independently of the secondary effects of the 
disease process or the medications used in treatment (Guidotti et al., 2012). For 
example, clozapine and sulpiride (atypical anti-psychotics) have both been found 
to result in dose-dependent increases in RELN and GAD67 (see Abbreviations list 
for full gene names), via hypomethylation of their promoters, in striatum and 
cortical regions of the mouse brain (Dong, Nelson, Grayson, Costa, & Guidotti, 
2008). Down-regulation of RELN and GAD67 has consistently been found in 
post-mortem prefrontal brain tissue taken from individuals diagnosed with 
schizophrenia (Guidotti et al., 2000; Guidotti et al., 2011; Mitchell, Jiang, Peter, 
& Akbarian, 2014), leading empiricists to propose that the therapeutic action of 
prophylactic treatment may occur via epigenetic mechanisms (Guidotti & 
Grayson, 2014).   
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Finally, the epigenome appears especially vulnerable during fetal 
development, a time when rapid cell replication is taking place and when the 
standard DNA methylation indicators driving development are being formed 
(Dolinoy, Weidman, & Jirtle, 2007; Nafee, Farrell, Carroll, Fryer, & Ismail, 
2008). Consequently, the measurement of antenatal exposures (e.g., maternal 
influenza and diabetes/glycosuria) during and shortly after pregnancy, and the 
quantification of participants’ methylomic profiles upon delivery provided 
preliminary information about how these environmental influences may bring 
about DNA methylation changes, which subsequently affect the gene expression 
necessary for healthy brain development and may predispose an individual to the 
later development of psychotic symptoms and/or schizophrenia. 
9.4 Limitations of the Current Research 
While the exploration of the impact of maternal influenza on the 
epigenomes of child participants is a considerable strength of the current research, 
it is limited by the manner in which this variable was measured. ALSPAC 
mothers were asked via a self-report postal questionnaire at three time-points (i.e., 
18 and 32 weeks of gestation and two months post-natal) about the presence or 
absence of influenza during the preceding trimester. This methodological design 
presents two limitations. Firstly, the questionnaires were asking mothers to 
retrospectively report influenza across a period of several months. As such, the 
reporting of the illness for the purposes of the current thesis was dependent upon 
the participant’s accurate recollection. However, it should be noted that only 
short-term recall of maternal participants was required, with individuals asked to 
comment on, at most, the previous four months. Secondly, the determination of 
the presence (or absence) of influenza during pregnancy was based solely on 
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mothers’ subjective assessment and did not require medical confirmation. The 
absence of medical verification of influenza during pregnancy may have increased 
the likelihood of diagnostic misclassification of this variable in the current 
research. Consequently, caution is recommended in drawing definitive and 
interpretative conclusions from the current findings that involve exploration of the 
maternal influenza variable. It is also difficult for many members of the public to 
differentiate between influenza as a viral infection and the ‘common cold’ which 
often has similar, but less severe, symptoms. These comments point to a need for 
greater methodological rigor in the measurement of exposure to influenza in utero 
in future epigenetic epidemiological research. As a minimum,  Brown and Susser 
(2002) recommend that exposure to the virus should be confirmed serologically 
(i.e., by testing for viral antibodies in blood serum) in individual pregnancies 
whose offspring comprise a carefully diagnosed sample of cases who later 
develop the phenotype of interest, in this case psychotic symptoms, from a 
prospectively followed, well-characterised birth-cohort. 
A second (potential) limitation of the current research, and of epigenetic 
studies in general that explore DNA methylation in peripheral tissue, is the fact 
that epigenetic perturbations are tissue-specific (Kirkbride et al., 2012). As 
psychotic symptoms (and schizophrenia) are brain-based phenomena with 
hypothesised neurodevelopmental origins, epimutations observed in the umbilical 
cord blood of participants affected during adolescence may not mirror those that 
occurred within the brains of participants during fetal development. To date, 
umbilical cord blood samples have not been used for DNA methylation analyses 
in association with schizophrenia. Consequently, there is no empirical data 
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available regarding the validity of cord blood as a surrogate for brain tissue when 
exploring epigenetic marks linked with the disorder.  
Nevertheless, there is increasing evidence to suggest that peripheral tissue 
may be a viable way of identifying aberrant DNA methylation profiles in affected 
individuals. For example, Dempster et al. (2011) investigated epimutations in the 
peripheral blood leukocytes of monozygotic twins (MZ) discordant for 
schizophrenia, using the Infinium 27k platform and reported hypomethylation of 
the top-ranked disease-associated probe in both blood and post-mortem brain 
tissue of an independent sample of cases with schizophrenia. Furthermore, 
Ingenuity Pathway Analysis conducted on the differentially methylated sites 
between affected and non-affected MZ twins showed clear epigenetic changes to 
schizophrenia-relevant pathways.  
As the cell composition of whole blood leukocytes differs considerably 
from that of umbilical cord blood (e.g., lymphocyte subsets), future research is 
needed to clarify the role of the latter tissue as a biomarker of brain-based diseases 
like schizophrenia. Indeed, if found to be a plausible indicator of schizophrenia 
risk, umbilical cord blood may, in fact, confer some benefits over cortical tissue in 
that it is not subject to the following potential confounders: ante-mortem events, 
including hospitalization, coma, respiratory illness and the use of artificial 
ventilation, duration of post-mortem delay and brain pH levels.  
 Thirdly, a number of participants with psychotic symptoms at age 12 years 
had missing responses on the PLIKSi at age 18 years. This may have biased 
findings on the consistency of differentially methylated CpG sites between 
participants with and without psychotic symptoms at ages 12 and 18 years, 
limiting the generalizability of the findings. Additionally, missing data was also 
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identified for several of the confounding factors resulting in reduced sample sizes 
for the adjusted analyses; however, previous exploration of this cohort has shown 
that selective dropout has only a minimal impact on associations between 
predictors and outcomes (Sidebotham, Heron & Teamc, 2003).  
  Although the HM450K array offers a relatively inexpensive, high-
throughput solution to epigenome-wide profiling, it only covers around 1.7% of 
all CpG sites in the genome (Clark et al., 2012) Hence, there may have been a 
number of genes and other genomic features (e.g., repetitive elements) that were 
not identified by the HM450K array which may have been of functional 
significance.  
Finally, validation and replication of the top-ranked differentially 
methylated CpG sites at ages 12 and 18 years was not undertaken, limiting the 
interpretation of results for the five sites identified as significantly associated with 
psychotic symptoms at each of these time-points. Given these limitations, further 
study of the association between these loci and psychotic symptoms in 
adolescence is warranted and will be undertaken with the new release of ARIES data 
which is has been subjected to rigorous cleaning and curation procedures. A 
number of other birth cohort studies, including The Japan Environment and 
Children’s Study (JCES), Life Study and Mercy Pregnancy and Emotional 
Wellbeing Study (MPEWS) may offer further research opportunities for 
replication of the results of this thesis.  
9.5 Future Directions  
Empirical findings suggest that the molecular mechanisms that underpin 
epigenetic regulation may be comparable across both brain and peripheral blood 
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tissue and so may result in parallel disease-associated aberrations that can be seen 
in both these tissues.  
However, several recent studies (Kinoshita et al., 2014; Liu et al., 2013; Reinius et 
al., 2012) have reported biologically significant variations in DNA methylation 
profiles among different types of peripheral blood monocular cells (e.g., 
monocytes, B cells). Consequently, future researchers exploring methylomic 
variation in the peripheral blood of participants with schizophrenia or a 
predisposition to developing the disorder would be wise to adjust for the potential 
confounding effect of blood tissue heterogeneity (see Kinoshita et al., 2014 for 
full details). Additionally, future research which focuses on exploring cross-tissue 
comparisons of DNA methylation and other epigenetic marks within the same 
individual, across the life span, would enable the creation of a record of 
epimutations at discrete genomic regions for which quantifications in blood are 
informative for one or more inaccessible tissues (Mill & Heijmans, 2013). 
Further, the inclusion of pathophysiological measures (e.g., functional magnetic 
resonance imaging/positron emission tomography) in lymphocyte epigenetic 
research may allow for a greater understanding of the relationship between 
epigenetic marks occurring in the brain and those in the peripheral blood of 
people with schizophrenia (Guidotti et al., 2014). 
 Of equal importance is the need for further explorations in this area to 
adopt an integrative research paradigm in which epigenetic and genomic factors 
are considered in concert, rather than in isolation. According to Mill & Heijmans 
(2013), the addition of transcriptomic data to epigenomic findings would greatly 
improve the interpretation of epigenome-wide analyses, as “differential gene 
expression, including long range effects, remains the primary readouts of 
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functionality (p. 592).” More specifically, as DNA sequence variation can directly 
impact upon epigenetic processes across the genome and as recent empirical 
findings already provide evidence for the enrichment of methylation quantitative 
loci (mQTLs) for schizophrenia susceptibility alleles (van Eijk et al., 2014), it is 
probable that the interpretation of genetic data would be improved by the 
incorporation of allele-specific epigenetic data into analyses (Meaburn, 
Schalkwyk, & Mill, 2010). On the other hand, certain epimutations (e.g., genomic 
imprinting) may mask direct associations between putative schizophrenia-
candidate genes and the disorder or, as investigated in this thesis, may mediate the 
relationship between environmental exposures and gene expression at a molecular 
level. With these considerations in mind, Kirkbride et al. (2012) have proposed a 
model using a novel two-step Mendelian Randomisation (MR) approach to test 
the role of environmental exposures in schizophrenia-risk via epigenetic effects. 
This approach in the context of epigenetic epidemiological research refers to 
using a genetic proxy for DNA methylation (i.e., an mQTL) to determine a causal 
relationship between an exposure and a phenotype of interest (e.g., psychotic 
symptoms or schizophrenia). The MR model has a number of advantages for 
epigenetic epidemiological research. Firstly, it incorporates both genetic and 
epigenetic information. Secondly, it tests the temporal relationship between 
environmental influences in modulating the risk to schizophrenia via epigenetic 
mechanism. This enables causal inferences to be drawn about the direction of any 
observed effects. And thirdly, it aids statistical robustness by reducing the 
likelihood of retrieving spurious findings associated with measurement error (Mill 
& Heijmans, 2013) and confounding factors known to influence the methylome 
(e.g., age, sex, nicotine use, cellular heterogeneity). 
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Finally, the current research only explores covalent modifications of DNA 
occurring at cytosine residues, in the context of CG dinucleotides. However, this 
is not the only form of genomic methylation which can occur. Indeed, the role 
played by several other sources of epigenetic regulation, including 
posttranslational histone modifications, 5-hydroxymethlcytosine, 5-
formylcytosine and 5-carboxylcytosine, in the aetiology of schizophrenia have 
recently been investigated. With respect to abnormalities in histone modifications, 
for example, two post-mortem studies found significantly higher levels of histone 
deacetylase 1 (HDAC1) in the brain tissue of cases with schizophrenia than in 
healthy controls (Benes, Lim, Matzilevich, Subburaju, & Walsh, 2008; Sharma, 
Grayson, & Gavin, 2008). A link between elevated levels of HDAC1 expression 
and reduced glutamate decarboxylase (GAD67) has consistently been reported 
(Sharma et al., 2008), with decreased levels of GAD67 regularly found in the 
hippocampus and prefrontal cortical regions of cases with schizophrenia (Benes et 
al., 2007; Kimoto, Bazmi, & Lewis, 2014). Findings such as these point to the 
importance of exploring the role of other epigenetic marks in the development of 
psychotic symptoms and/or schizophrenia and, in particular, their role in 
mediating the relationship between adverse antenatal exposures and these 
psychotic phenomena.  
As with its precursors in genetic research, an overarching difficulty of epigenetic 
research is that no single study is likely to be able to include all the components 
that are necessary in order to draw causal and valid inferences about epigenetic 
associations (Mill and Heijmans, 2013). Nevertheless, a powerful strategy for 
potentially overcoming many of the previously mentioned methodological issues 
would involve the longitudinal evaluation of MZ twins discordant for 
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schizophrenia. As MZ twins share identical genomes, parents, birth-date and sex 
and are likely to have been exposed to  highly comparable fetal and post-natal 
environments, they represent an ideal paradigm for exploring the influence of 
environmentally driven epigenetic features of the disease (Dempster et al., 2011).  
9.6 Theoretical and Clinical Implications of the Current Research 
As our knowledge about the epigenome is still in its early stages 
scientifically, it is difficult to make causal inferences about the nature and location 
of disease-relevant variation in the development of psychotic symptoms and 
schizophrenia.  
Remarkably, up until now, the idea that epigenetic marks may mediate the 
relationship between environmental exposures and psychotic phenomena has been 
largely speculative and based on very limited evidence from animal and human 
models. The specific innovation in the current research is to have investigated the 
role of adverse antenatal factors and sex in aberrant methylomic profiles in 
umbilical cord blood and their subsequent contribution to the development of 
psychotic symptoms during adolescence. Despite its exploratory nature, the 
research and its findings provide preliminary support for the notion that epigenetic 
processes are the molecular mechanisms which underlie the transition from early 
neurodevelopmental disruptions, associated with adverse antenatal exposures, to 
the later onset of schizophrenia.  
Future research is required in order to replicate these findings. However, if 
epigenetic marks in umbilical cord blood are found to be valid and reliable 
biomarkers of disease-associated abnormalities occurring in the cortical tissue of 
participants at high risk of schizophrenia, they may prove invaluable in the 
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development of new clinical interventions aimed at early identification and 
psychotropic treatment of the disorder. More specifically, as epigenetic 
modifications are dynamic and potentially reversible processes occurring 
throughout the lifetime, future research exploring whether epigenetic drugs and 
psychotherapy can alleviate the cognitive and social deficits associated with 
schizophrenia, respectively. A wealth of empirical data supports a robust 
association between longer duration of untreated psychosis and poorer outcomes 
in terms of treatment response, remission of both positive and negative symptoms, 
overall functioning and quality of life (Marshall et al., 2005; Perkins, Gu, Boteva, 
& Lieberman, 2005, Tang et al., 2014; Ziermans et al., 2011). These findings have 
consistently been found using both cross-sectional and prospective longitudinal 
cohort samples, and remain robust even after adjusting for the effects of 
premorbid status. Early diagnosis and specialised intervention targeting specific 
aberrant epigenetic marks may have the potential, therefore, to prevent the long-
term deterioration in functioning and the reduced life expectancy typically 
witnessed in the course of schizophrenia.   
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APPENDIX A 
 
Copy of the email granting access to the ALSPAC phenotype and ARIES DNA 
cord blood methylation data. 
 
Dear Alicia, 
 
The Executive Committee met yesterday and are pleased to approve your proposal, 
subject to the variables requested.  The reference number is B2042 (please quote this on 
all correspondence). 
 
Please note that due to the Wellcome Trust's open access policy, you will be responsible 
for making any publications open access.  For further clarification, please visit the below 
link:- 
 
<http://www.wellcome.ac.uk/About-us/Policy/Spotlight-issues/Open-
access/index.htm> 
 
I have copied in Jackie Slack who will be in touch regarding costings.  I have also copied 
in Kate Northstone who, if necessary, will be in touch to assign a data buddy to help with 
the data. 
 
Please also note that I will be monitoring the proposals process and I would therefore 
appreciate any updates regarding the project. 
 
The approved project will be listed on ALSPAC's website. 
 
Best wishes 
 
Barb. 
 
-----------------------------------------  
Miss Barbara Johnstone 
Research Secretary 
ALSPAC (Children of the 90s) 
University of Bristol 
Oakfield House 
Oakfield Grove 
Bristol BS8 2BN 
UK 
Tel: +44 (0)117 3310167 
http://www.bristol.ac.uk/alspac 
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APPENDIX E 
 
Results of a sensitivity analysis which investigated and compared the relationship between global DNAm of specific CpG site regions and 
psychotic symptoms at age 18 years using non-parametric and parametric statistical tests. 
Table E1 
     Psychotic Symptoms 18  
Mdn values 
  Psychotic Symptoms 18  
M (Std dev.) values 
Regiona nb % Uc p None 
(n = 678) 
Definite/Suspected 
(n = 57) 
t (df)d p None 
(n = 678) 
Definite/Suspected 
(n = 57) 
Islands 16 648 46.32 18 937.00 .80 17.43 17.43  -.89 (1, 733) .38 17.42 (.07) 17.43 (.05) 
North Shore 9 619 26.76 17 893.00 .35 43.36 43.39 -1.16 (1, 733) .25 43.25 (.38) 43.31 (.34) 
North Shelf 2 467 6.86 15 240.00 .01 70.30 70.40 -2.16 (1, 733) .03 70.21 (.37) 70.32 (.29) 
South Shore 5 066 14.09 16 943.00 .12 41.62 41.66 -1.46  (1, 733) .14 41.56 (.25) 41.61 (.20) 
South Shelf 2 145 5.97 16 546.00 .07 69.44 69.52 -1.57 (1, 733) .12 69.36 (.33) 69.43 (.33) 
aRefers to a specific CpG site region 
bRefers to the number of CpG sites in the corresponding region 
cRefers to the result of a non-parametric Mann-Whitney U test 
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dRefers to the result of a parametric  Independent T-test 
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APPENDIX F 
 
Normal Q-Q plot of the distribution of umbilical cord blood DNAm beta values. 
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APPENDIX G 
 
Descriptives for top 50-ranked differentially methylated CpG sites: 
 DNAm and PS at age 12 years. 
 
Table G1 
 Shapiro-Wilk  
S-W 
Mann-Whitney  
U   
Independent  
t-test 
CpG IDa S-Wb p Uc p t d (df) p 
ch.13.79675484F  .22 <.001 -1.38 .17 1.95  (1, 82.94) .05 
cg19006060 .66 <.001 -3.69 <.001 -3.49  (1, 90.20) .001 
cg10088890 .16 <.001 -.36 .72 1.59 (1, 82.20) .12 
cg17888259 .95 <.001 -4.42 <.001 4.50 (1, 829) <.001 
cg22772355 .96 <.001 -4.24 <.001 -4.54 (1, 829) <.001 
cg13787987 .87 <.001 -3.67 <.001 -3.49 (1, 90.77) .001 
cg26129759 .63 <.001 -3.72 <.001 -3.01 (1, 90.91) .003 
cg18005928e .21 <.001 -2.02 .04 1.76 (1, 83.30) .08 
cg19259127e .35 <.001 -3.27 .001 -1.51 (1, 82.61) .14 
cg13143529 .16 <.001 -.65 .52 -1.48 (1, 82.12) .14 
cg05192538 .56 <.001 -2.94 .003 2.50 (1, 87.13) .02 
cg22920700 .14 <.001 -.58 .57 -1.43 (1, 82.09) .16 
cg07513662 .98 <.001 -3.90 <.001 3.80 (1, 829) <.001 
cg26884581e .10 <.001 -3.70 <.001 -1.92 (1, 84.93) .06 
cg00910419e .06 <.001 -2.80 .01 -1.41 (1, 83.05) .16 
ch.5.1258129F .15 <.001 -.20 .85 -1.42 (1, 82.12) .16 
ch.2.204909450R .23 <.001 -1.92 .06 1.75 (1, 83.41) .09 
cg07349890 .74 <.001 -3.60 <.001 -3.11 (1, 829) .002 
cg07941983 .98 <.001 -3.54 <.001 3.73 (1, 829) <.001 
cg09667226 .05 <.001 -1.33 .19 -1.22 (1, 82.02) .23 
cg06302533 .25 <.001 -1.87 .06 1.89 (1, 84.36) .11 
ch11.104864706F .21 <.001 -1.11 .27 1.63 (1, 83.33) .11 
cg13550401e .30 <.001 -2.64 .01 -2.02 (1, 86.80) .05 
cg09063944 .66 <.001 -2.41 .02 -2.09 (1, 84.10) .04 
cg16363985 .94 <.001 -3.33 .001 4.31 (1, 111.93) <.001 
cg22021597 .69 <.001 -2.87 .004 4.17 (1, 141.64) <.001 
cg13185972 .98 <.001 -3.46 .001 3.60 (1, 829) <.001 
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cg23676475 .97 <.001 -3.21 .001 3.56 (1, 829) <.001 
cg21131149 .99 <.001 -3.33 .001 3.59 (1, 829) <.001 
cg09355027 .95 <.001 -3.60 <.001 3.71 (1, 829) <.001 
cg21144158 .96 <.001 -3.04 .002 3.15 (1, 829) .002 
cg09611064 .94 <.001 -3.37 .001 -3.31 (1, 94.74) .001 
cg08105378 .74 <.001 -3.60 <.001 2.77 (1, 93.30) .01 
cg25134306 .82 <.001 -2.40 .02 -3.16 (1, 829) .002 
cg03404102 .99 <.001 -3.77 <.001 -3.72 (1, 829) <.001 
cg16559243 .97 <.001 -3.57 <.001 -3.16 (1, 829) .002 
cg24373253e .65 <.001 -3.24 .001 -2.01 (1, 84.04) .05 
cg24095592e .40 <.001 -3.33 .001 -1.89 (1, 88.28) .06 
cg18465133 .73 <.001 -2.64 .01 -2.67 (1, 88.98) .01 
cg18194887 .92 <.001 -2.12 .03 -2.89 (1, 829) .004 
cg00959635 .17 <.001 -.27 .79 -1.36 (1, 82.13) .18 
ch.1.4385290F .21 <.001 -.93 .35 1.35 (1, 82.37) .18 
ch.4.2045280F 20 <.001 -1.06 .29 1.58 (1, 83.24) .12 
cg11360689 .98 <.001 -3.92 <.001 3.75 (1, 829) <.001 
cg03315456 .98 <.001 -3.63 <.001 -3.10 (1, 829) .002 
ch.5.3079640F .18 <.001 -1.68 .09 1.34 (1, 82.31) .19 
cg04864807 .68 <.001 -3.69 <.001 -2.76 (1, 96.61) .01 
cg18816098 .92 <.001 -3.19 .001 -3.49 (1, 829) .001 
cg24764861 .81 <.001 -2.48 .01 -2.64 (1, 90.18) .01 
cg04223420 .83 <.001 -3.75 <.001 -3.47 (1, 829) .01 
aID of CpG site assessed by the HM450 arrayarray. 
bValue of the Shapiro-Wilk (S-W) test statistic. 
 Value of the Mann-Whitney (U) test statistic. 
dValue of the Independent t-test (t) statistic  
eCpG sites which show different results across non-parametric and parametric methods. 
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APPENDIX H 
 
Descriptives for top 50-ranked differentially methylated CpG sites: 
 DNAm and PS at age 18 years. 
 
Table H1 
 Shapiro-Wilk  
S-W 
Mann-Whitney  
U   
Independent  
t-test 
CpG IDa S-Wb p Uc p t d (df) p 
cg24374738 .34 <.001 -2.45 .01 -2.10 (1, 56.27) .04 
cg21781157 .73 <.001 -2.26 .02 -2.35 (1, 58.00) .02 
cg12500956 .92 <.001 -3.54 <.001 3.95 (1, 733) <.001 
cg10478199 .88 <.001 -4.33 <.001 -3.49 (1, 61.31) .001 
cg04420907e .10 <.001 -3.03 .002 -1.13 (1, 56.03) .26 
cg19689211 .92 <.001 -3.81 <.001 3.29 (1, 59.58) .002 
cg11335536 .99 <.001 -3.92 <.001 4.51 (1, 733) <.001 
cg06808522 .98 <.001 -3.58 <.001 -3.75 (1, 733) <.001 
cg18235000e .09 <.001 -2.70 .01 -1.14 (1, 56.03) .26 
cg14009451 .94 <.001 -4.60 <.001 3.94 (1, 733) <.001 
cg00279790 .83 <.001 -3.30 .001 -3.15 (1, 60.90) .003 
cg22504898 .88 <.001 -3.57 <.001 3.65 (1, 62.26) .001 
cg26189021 .90 <.001 -3.04 .002 2.88 (1, 59.33) .01 
cg03162823 .53 <.001 -1.23 .22 2.09 (1, 58.00) .04 
cg01969403 .90 <.001 -4.19 <.001 -4.77 (1, 74.56) <.001 
cg11538307 .96 <.001 -3.78 <.001 -4.72 (1, 72.95) <.001 
cg00614314e .35 <.001 -2.06 .04 -1.33 (56.26) .19 
cg10794473 .81 <.001 -3.22 .001 2.69 (59.08) .01 
cg04689654 .92 <.001 -3.68 <.001 3.65 (1, 733) <.001 
cg22403266e .72 <.001 -3.31 .001 -4.61 (1, 56.98) .05 
cg22811030 .81 <.001 -2.91 .004 2.64 (1, 59.77) .01 
cg09825080 .85 <.001 -4.02 <.001 3.85 (1, 733) <.001 
cg27635135 .95 <.001 -3.14 .002 3.05 (1, 59.85) .003 
cg19824833 .75 <.001 -3.05 .002 2.49 (1, 57.85) .02 
cg09139923 .30 <.001 1.36 .18 -1.85 (1, 57.43) .07 
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cg01806151 .99 <.001 -3.91 <.001 4.05 (1, 733) <.001 
cg05657581 .11 <.001 -1.67 .10 -1.11 (1, 56.03) .27 
cg18826274 .99 <.001 -3.59 <.001 4.04 (1, 733) <.001 
cg26023709 .82 <.001 -2.97 .003 2.56 (1, 58.93) .01 
cg17739428 .07 <.001 -1.99 .05 -1.06 (1, 56.01) .29 
ch.6.37043690R .07 <.001 -1.88 .06 -1.08 (1, 56.02) .29 
cg26537076 .92 <.001 -3.58 <.001 -3.89 (1, 733)  <.001 
cg03447083 .26 <.001 -2.07 .04 -1.45 (1, 56.24) .15 
cg22510943 .99 <.001 -3.70 <.001 3.74 (1, 733) <.001 
cg26951763 .90 <.001 -3.12 .002 3.85 (1, 733) <.001 
cg16531342 .76 <.001 -2.22 .03 2.36 (1, 58.52) .02 
cg09606090 .09 <.001 -2.18 .03 -1.10 (1, 56.02) .28 
cg23789157 .98 <.001 -3.24 .001 3.51 (1, 733) <.001 
cg03771878 .99 <.001 -3.45 .001 3.67 (1, 733) <.001 
cg07283582 .90 <.001 -3.26 .001 3.07 (1, 60.34) .003 
cg11740099 .87 <.001 -3.38 .001 -3.86 (1, 733) <.001 
cg11270192 .93 <.001 -4.04 <.001 4.51 (1, 72.75) <.001 
cg01429391 .93 <.001 -3.78 <.001 3.57 (1, 733) <.001 
cg03037974 .68 <.001 -2.24 .03 1.69 (1, 57.36) .10 
cg25371564 .99 <.001 -3.75 <.001 3.90 (1, 733) <.001 
cg11257906 .87 <.001 -3.45 .001 3.09 (1, 59.86) .003 
cg05133814 .92 <.001 -3.53 <.001 3.83 (1, 733) <.001 
cg11798758 .83 <.001 -3.90 <.001 -5.85 (1, 94.23) <.001 
cg21681643 .97 <.001 -3.10 .002 -3.46 (1, 733) .001 
cg01440841 .85 <.001 -2.62 .01 -2.65 (1, 58.86) .01  
aID of CpG site assessed by the HM450 arrayarray. 
bValue of the Shapiro-Wilk (S-W) test statistic. 
 Value of the Mann-Whitney (U) test statistic. 
dValue of the Independent t-test (t) statistic  
eCpG sites which show different results across non-parametric and parametric methods. 
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APPENDIX I 
 
Genomic information for top 50-ranked differentially methylated CpG sites: 
 DNAm and PS at age 12 years. 
Table I1 
Rank 
 
Probe IDa UCSC RefGene Nameb Gene Abb. Chrc Positiond UCSC Reference 
Gene Group 
UCSC 
Regulatory 
Feature Group 
Relation to 
UCSC CpG 
island 
FDR 
Corrected 
p-valuee 
1 ch.13.79675484F None None 13 80777483 
 
Unclassified Unclassified Others 0.01 
2 cg19006060 RAS-like, estrogen-regulated, 
growth inhibitor 
RERG  12 15374609 
 
TSS1500 
 
Unclassified S_Shore 0.03 
3 cg10088890 None None 8 16637442 
 
Unclassified Unclassified Others 0.04 
4 cg17888259 None None 1 179557662 
 
Unclassified Unclassified S_Shore 0.05 
5 cg22772355 Cytochrome c oxidase subunit 
VIb polypeptide 2 (testis) 
COX6B2 19 55865356 
 
Gene Body Unclassified Island 0.05 
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6 cg13787987 Oxoglutarate dehydrogenase-like OGDHL  10 50970591 
 
TSS200 Unclassified Island 0.08 
7 cg26129759 Selenoprotein K SELK  3 53926056 
 
TSS200 Promoter 
Associated 
Island 0.15 
8 cg18005928 None None 4 72050086 
 
Unclassified Unclassified N_Shelf 0.18 
9 cg19259127 None None 9 72908 Unclassified Unclassified N_Shore 0.19 
10 cg13143529 Pancreatic and duodenal 
homeobox 1 
PDX1 13 28492971 Unclassified Unclassified N_Shore 0.22 
11 cg05192538 None None 10 134804447 
 
Unclassified Unclassified Island  0.26 
12 cg22920700 Odd-skipped related transciption 
factor 2 
OSR2 8 99955610 
 
TSS1500 Unclassified N_Shore 0.30 
13 cg07513662 None None 7 88315867 
 
Unclassified Unclassified Others 0.31 
14 cg26884581 Phosphorylase, glycogen, muscle PYGM 11 64527414 
 
1stExon;5'UTR Unclassified  Others 0.32 
15 cg00910419 B-cell CLL/lymphoma 11A (zinc 
finger protein) 
BCL11A 2 60780754 TSS200 Unclassified N_Shore 0.36 
16 ch.5.1258129F Microtubule associated 
serine/Threonine kinase family 
member 4 
MAST4 5 65930883 
 
Gene body Unclassified Others 0.38 
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17 ch.2.204909450R None None 2 205201205 
 
Unclassified Unclassified Others 0.39 
18 cg07349890 Ribosomal RNA processing 7 
homolog A (S. cerevisiae) 
RRP7A 22 42913926 
 
Gene body Unclassified N_Shore 0.43 
19 cg07941983 ArfGAP with RhoGAP domain, 
ankyrin repeat and PH domain 2 
ARAP2 4 36245138 
 
5'UTR 
 
Unclassified N_Shore 0.44 
20 cg09667226 Kruppel-like factor 5 (intestinal) KLF5  13 73632762 
 
TS1500 Promoter 
Associated 
N_Shore 0.44 
21 cg06302533 Protocadherin beta 18 
pseudogene 
PCDHB18  5 140613740 
 
TS200 Unclassified N_Shore 0.49 
22 ch.11.104603277F 
 
None None 11 105098067 
 
Unclassified Unclassified Others 0.51 
23 cg13550401 Nudix (nucleoside diphosphate 
linked moiety X)-type motif 1 
NUDT1 7 2288716 
 
Gene body Unclassified Others 0.54 
24 cg09063944 Small integral membrane protein 
1 (Vel blood group) 
LOC388588 1 3688921 
 
TS1500 Unclassified Island 0.57 
25 cg16363985  Ibonuclease H1 
 
RNASEH1 2 3604987 
 
Gene body Unclassified N_Shore 0.58 
26 cg22021597 Inositol-trisphosphate 3-kinase B ITPKB  1 226841240 
 
Gene body Promoter 
Associated 
Others 0.60 
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27 cg13185972 Shroom family member 2 SHROOM2 X 9908641 
 
Gene body Unclassified N_Shelf 0.60 
28 cg23676475 None None 2 64455515 
 
Unclassified Promoter 
Associated 
Others 0.60 
29 cg21131149  Oral cancer overexpressed 1 
 
ORAOV1 11 69490108 
 
1stExon;5'UTR Promoter 
Associated 
Island 0.60 
30 cg09355027 None None 2 2581353 
 
Unclassified Unclassified Others 0.60 
31 cg21144158  MicroRNA 612 
 
MIR612 11 65211084 
 
Unclassified Unclassified Others 0.60 
32 cg09611064 None None  17 48043063 
 
Unclassified Unclassified Island 0.62 
33 cg08105378 Homer homolog 3 (Drosophila) HOMER3 19 19040175 
 
Gene body;3'UTR Unclassified N_Shore 0.62 
34 cg25134306 Ubiquitin-conjugating enzyme 
E2D 2 
UBE2D2 5 138945277 
 
5'UTR;Gene body Unclassified S_Shelf 0.65 
35 cg03404102f Family with sequence similarity 
162, member A; Coiled-coil 
domain containing 58 
FAM162A; 
CCDC58 
3  122103036 
 
1stExon; 5'UTR Promoter 
Associated 
Island 0.67 
36 cg16559243 EGF-like, fibronectin type III and 
laminin G domains 
EGFLAM 5 38445612 
 
Gene body Unclassified Others 0.67 
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37 cg24373253 Lipid phosphate phosphatase-
related protein type 5 
LPPR5  1 99469634 
 
Gene body Unclassified N_Shore 0.67 
38 cg24095592 Homeobox B3 HOXB3 17 46633202 
 
5’UTR Unclassified S_Shore 0.67 
39 cg18465133 Junctional sarcoplasmic reticulum 
protein 1 
JSRP1 19 2252282 
 
3’UTR Unclassified Island 0.68 
40 cg18194887 Bet1 golgi vesicular membrane 
trafficking protein 
BET1 7 93629937 
 
Gene body Unclassified N_Shelf 0.68 
41 cg00959635 None None  7 113724153 
 
Unclassified Unclassified N_Shore 0.68 
42 ch.1.4385290F None None 1 224974190 
 
Unclassified Unclassified Others 0.71 
43 ch.4.2045280F Oligosaccharyltransferase 
complex subunit (non-catalytic) 
OSTC 4 109577036 
 
Gene body Unclassified Others 0.71 
44 cg11360689 None None 3 52229467 
 
Unclassified Unclassified N_Shelf 0.73 
45 cg03315456 HOP homeobox HOPX 4 57525626 
 
5’UTR Unclassified S_Shelf 0.73 
46 ch.5.3079640F None None 5 163067975 
 
Unclassified Unclassified Others 0.74 
293 
 
47 cg04864807 None None 2 121412139 
 
Unclassified Unclassified Island 0.75 
48 cg18816098  Phosphodiesterase 4C, cAMP-specific  
 
PDE4C  19 18335182 
 
5'UTR;Body; 
1stExon 
Promoter 
Associated 
Island 0.77 
49 cg24764861f Coiled-coil domain containing 
152; chloride channel, voltage-
sensitive 7 
CCDC152; 
CLCN7 
16 1495122 
 
TS1500; 3’UTR; 
3’UTR 
Unclassified Island 0.77 
50 cg04223420  Paired-like homeodomain 1  
 
PITX1  5 134363877 
 
3’UTR Unclassified Island 0.78 
aProbe lD (i.e., CpG site) assessed by the HM450 arrayarray. 
bGene with its transcription start site closest to the listed probe ID. 
cChromosome on which CpG site is located. 
dPositions refer to Genome Research Consortium human genome build 37 (GRCh37)/ UCSC hg19 
eFalse Discovery Rate (FDR) adjustment. 
fProbe ID is annotated with more than one gene (Price et al., 2013). 
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APPENDIX J 
 
Genomic information for top 50-ranked differentially methylated CpG sites: 
 DNAm and PS at age 18 years. 
Table J1 
Rank 
 
Probe ID UCSC RefGene name Gene Abb. Chr Position UCSC 
RefGene group 
UCSC 
Regulatory 
Feature Group 
Relation to 
UCSC CpG 
island 
FDR 
corrected 
p value 
1 cg24374738 Crystallin, beta A2 CRYBA2 2 219858146 Unclassified  Unclassified Island <.001 
2 cg21781157 Zinc finger, NFX1-type 
containing 1 
ZNFX1 20 47874111 Gene body Unclassified Others <.001 
3 cg12500956 Transmembrane protein 163 TMEM163 2 135428796 Gene body Unclassified Others 0.02 
4 cg10478199 ATPase, H+ transporting, 
lysosomal 56/58kDa, V1 subunit 
B1 
ATP6V1B1 2 71175792 Gene body Unclassified Others 0.04 
5 cg04420907f WD repeat domain 16; Syntaxin 8 WDR16; STX8 17 9480215 Gene body; 
Gene body 
Promoter 
Associated 
S_Shore 0.05 
6 cg19689211 KIAA1244 KIAA1244 6 138655905 Gene body Unclassified Others 0.06 
7 cg11335536 None None 3 14668377 Unclassified  Unclassified Others 0.08 
295 
 
8 cg06808522 None None 1 149153931 Unclassified  Unclassified N_Shelf 0.09 
9 cg18235000 Paraneoplastic Ma antigen 2 PNMA2 8 26372829 Unclassified  Unclassified Island 0.09 
10 cg14009451 Coiled-coil domain containing 
155 
CCDC155 19 49893460 5’UTR Unclassified S_Shore 0.10 
11 cg00279790 None None 1 46914033 Unclassified Unclassified Island 0.15 
12 cg22504898 None None 12 52294622 Unclassified Unclassified Island 0.18 
13 cg26189021 Potassium voltage-gated channel, 
Shaw-related subfamily, member 
4 
KCNC4 1 110757770 
 
Gene body Unclassified S_Shelf 0.20 
14 cg03162823 Ubiquitin specific peptidase 44 USP44 12 95941571 5’UTR Promoter 
Associated 
N_Shore 0.21 
15 cg01969403 None None 2 12480395 Unclassified Unclassified Others 0.21 
16 cg11538307 None None 5 40984654 Unclassified Unclassified Others 0.21 
17 cg00614314 Golgin A2 pseudogene LOC80154 15 82944287 Unclassified Unclassified N_Shore 0.21 
18 cg10794473 MicroRNA 1468 MIR1468 X 63006350 Unclassified Unclassified Others 0.22 
19 cg04689654 Tumor protein D52-like 2 TPD52L2 20 62496444 
 
Unclassified Promoter 
Associated 
Island 0.22 
20 cg22403266 Insulin-like growth factor binding 
protein 3 
IGFBP3 7 45962090 Unclassified Unclassified S_Shore 0.24 
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21 cg22811030 Testis expressed 11 TEX11 X 70128262 5’UTR Unclassified Others 0.25 
22 cg09825080 None None 16 86940337 Unclassified Unclassified Others 0.26 
23 cg27635135 None None 7 145395986 Unclassified Unclassified Others 0.27 
24 cg19824833 None None 8 1041264 Unclassified Unclassified Others 0.28 
25 cg09139923 None None 1 149162462 Unclassified Unclassified Island 0.31 
26 cg01806151 None None 1 2470965 Unclassified Unclassified N_Shore 0.32 
27 cg05657581 Protein kinase N2 PKN2 1 89149443 Unclassified Unclassified N_Shore 0.36 
28 cg18826274 None None 17 76335184 Unclassified Unclassified N_Shelf 0.37 
29 cg26023709f Mitochondrial ribosomal protein 
L43; Sema domain, 
immunoglobulin domain (Ig), 
transmembrane domain (TM) and 
short cytoplasmic domain, 
(semaphorin) 4G 
MRPL43; 
SEMA4G 
10 102745343 
 
Gene body; 
3’UTR 
Unclassified N_Shore 0.37 
30 cg17739428 None None 19 23598854 Unclassified Unclassified Others 0.37 
31 ch.6.37043690R None None 6 36935712 Unclassified Unclassified Others 0.38 
32 cg26537076 
 
HECT, C2 and WW domain 
containing E3 ubiquitin protein 
ligase 2  
 
HECW2 2 197458548 
 
Unclassified Unclassified S_Shore 0.38 
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33 cg03447083 Carboxylesterase 3 CES3 16 66993711 Unclassified Unclassified Others 0.39 
34 cg22510943 Lamin B2 LMNB2 19 2456368 Gene Gene 
body 
Promoter 
Associated 
Island 0.40 
35 cg26951763 None None 9 47182923 Unclassified Unclassified N_Shore 0.40 
36 cg16531342f Dyskeratosis congenita 1, 
dyskerin; small nucleolar RNA, 
H/ACA box 36A 
DKC1; 
SNORA36A 
X 153995564 
 
Gene body; 
Unclassified 
Unclassified S_Shelf 0.41 
37 cg09606090 Sorting nexin 11 SNX11 17 46184889 
 
Unclassified Promoter 
Associated  
Island 0.41 
38 cg23789157f U-box domain containing 5; 
FAST kinase domains 5 
UBOX5;FASTKD5 20 3140490 
 
5'UTR;1stExon Promoter 
Associated 
Island 0.41 
39 cg03771878 Phosphorylase kinase, gamma 2 
(testis) 
PHKG2 16 30760186 Gene body Promoter 
Associated 
Island 0.41 
40 cg07283582 Centrosomal protein 112kDa CCDC46 17 63770753 Gene body Unclassified Others 0.41 
41 cg11740099 Secreted and transmembrane 1 SECTM1 17 80279430 3’UTR Unclassified Island 0.42 
42 cg11270192 Importin 8 IPO8 12 30849015 Unclassified Unclassified Island 0.42 
43 cg01429391 Myosin, heavy chain 7, cardiac 
muscle, beta 
MYH7 14 23904930 
 
Unclassified Unclassified Others 0.42 
44 cg03037974 None None 15 76606532 Unclassified Unclassified S_Shelf 0.42 
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45 cg25371564 None None 1 43993236 Unclassified Unclassified N_Shelf 0.42 
46 cg11257906 Jrk homolog JRK 8 143743446 Gene 
body;3'UTR 
Unclassified Others 0.43 
47 cg05133814 None None 3 112135991 Unclassified Unclassified Others 0.44 
48 cg11798758 Nephronophthisis 4 NPHP4 1 5957004 Gene body Unclassified Others 0.44 
49 cg21681643 LOC440839 LOC440839 2 114039512 Gene body Unclassified S_Shelf 0.44 
50 cg01440841 Ring finger protein 175 RNF175 4 154681066 5'UTR;1stExon Unclassified Island 0.45 
aProbe lD (i.e., CpG site) assessed by the HM450 arrayarray. 
bGene with its transcription start site (TSS) closest to the listed CpG site. 
cChromosome on which CpG site is located. 
dPositions refer to Genome Research Consortium human genome build 37 (GRCh37)/ UCSC hg19 
eFalse Discovery Rate (FDR) adjustment. 
fProbe ID is annotated with more than one gene (Price et al., 2013). 
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